Projecting Individualized Probabilities of Developing Br Who Are Being Examined Annually

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 363.	0.6	12
2	Estimating the Long-Term Probability of Developing Breast Cancer. Journal of the National Cancer Institute, 1989, 81, 1854-1855.	3.0	10
5	Design issues for a breast cancer chemoprevention trial. Preventive Medicine, 1991, 20, 101-108.	1.6	5
6	Cancer risk notification: psychosocial and ethical implications.. Journal of Clinical Oncology, 1991, 9, 1275-1282.	0.8	120
7	A bibliography and comments on the use of statistical models in epidemiology in the 1980s. Statistics in Medicine, 1991, 10, 1819-1885.	0.8	30
8	Racial differences in the risk of invasive squamous-cell cervical cancer. Cancer Causes and Control, 1991, 2, 283-290.	0.8	19
9	Breast Cancer. New England Journal of Medicine, 1992, 327, 319-328.	13.9	593
10	Heuristics for Determining the Optimal Interval between Checkups. Psychological Science, 1992, 3, 279-285.	1.8	7
11	The Genetic Epidemiology of Second Primary Breast Cancer*. American Journal of Epidemiology, 1992, 136, 937-948.	1.6	84
12	How Much of the Recent Rise in Breast Cancer Incidence Can Be Explained by Increases in Mammography Utilization?. American Journal of Epidemiology, 1992, 136, 1423-1436.	1.6	131
13	A quantitatively scored cancer-risk assessment tool: Its development and use. Journal of Cancer Education, 1992, 7, 15-36.	0.6	9
14	Tamoxifen: disease prevention or disease substitution?. Lancet, The, 1992, 340, 1143-1145.	6.3	77
16	Pre-cancerous breast lesions: Implications for breast cancer prevention trials. International Journal of Radiation Oncology Biology Physics, 1992, 23, 1071-1078.	0.4	29
17	The relationship between age and incidence of breast cancer population and screening program data. Cancer, 1992, 69, 1896-1903.	2.0	34
18	Breast cancer chemoprevention tamoxifen: Current issues and future prospective. Cancer, 1993, 72, 1032-1037.	2.0	34
19	Cancer chemoprevention. Cancer, 1993, 72, 3374-3380.	2.0	3
20	Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. Journal of Cellular Biochemistry, 1993, 53, 153-160.	1.2	26
21	Selection criteria for breast cancer chemoprevention subjects. Journal of Cellular Biochemistry, 1993, 53, 234-241.	1.2	18

#	ARTICLE	IF	CITATIONS
22	Subjects and recruitment strategies for a short-term phase II chemoprevention trial of breast cancer using surrogate endpoint biomarkers. Journal of Cellular Biochemistry, 1993, 53, 257-258.	1.2	1
23	Reporting bilaterality status in first-degree relatives with breast Cancer: A validity study. Genetic Epidemiology, 1993, 10, 245-256.	0.6	8
24	Breast cancer risk: weaving facts into fabric. Breast Cancer Research and Treatment, 1993, 28, 91-96.	1.1	2
25	The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment, 1993, 28, 115-120.	1.1	177
26	Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Research and Treatment, 1993, 28, 145-155.	1.1	230
27	Clinical management of women at increased risk for breast cancer. Breast Cancer Research and Treatment, 1993, 28, 195-210.	1.1	33
28	Breast cancer: Incidence, risks, and primary and adjuvant therapy. Seminars in Roentgenology, 1993, 28, 182-192.	0.2	0
29	A current view of tamoxifen for the treatment and prevention of breast cancer. British Journal of Pharmacology, 1993, 110, 507-517.	2.7	252
30	Initiators and Promoters of Lung Cancer. Chest, 1993, 103, 4S-11S.	0.4	31
31	Tamoxifen for the Primary Prevention of Breast Cancer: A Review and Critique of the Concept and Trial. Epidemiologic Reviews, 1993, 15, 233-243.	1.3	65
32	The Influence of Family History on the Risk of Breast Cancer. Surgical Oncology Clinics of North America, 1993, 2, 125-134.	0.6	0
33	Cancer in Women: Trends in Care. Journal of Pharmacy Practice, 1993, 6, 216-221.	0.5	0
34	Tamoxifen Chemoprevention—Are We Throwing Out the Baby with the Bathwater?. Cancer Investigation, 1994, 12, 671-675.	0.6	1
35	Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk. Journal of the National Cancer Institute, 1994, 86, 600-607.	3.0	208
36	Epidemiology and Biostatistics Program of the National Cancer Institute. Journal of the National Cancer Institute, 1994, 86, 573-575.	3.0	84
37	Re: Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk. Journal of the National Cancer Institute, 1994, 86, 1350-1350.	3.0	6
38	Responses to Atkins. Journal of the National Cancer Institute, 1994, 86, 1350-1352.	3.0	0
39	Re: Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk. Journal of the National Cancer Institute, 1994, 86, 1350-1350.	3.0	0

#	ARTICLE	IF	CITATIONS
40	A comparison of three approaches to estimate exposure-specific incidence rates from population-based case-control data. Statistics in Medicine, 1994, 13, 651-661.	0.8	29
41	Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer. Breast Cancer Research and Treatment, 1994, 30, 263-274.	1.1	27
42	Identification and management of the woman at increased risk for breast cancer development. Breast Cancer Research and Treatment, 1994, 31, 53-60.	1.1	25
43	Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 1994, 73, 643-651.	2.0	902
44	The effect of dietary fat and fiber on serum estrogen concentrations in premenopausal women under controlled dietary conditions. Cancer, 1994, 74, 1125-1131.	2.0	123
45	Clinical development plan: Tamoxifen. Journal of Cellular Biochemistry, 1994, 56, 252-267.	1.2	2
46	Chemoprevention of cancer. Current Problems in Cancer, 1994, 18, 6-79.	1.0	44
47	The potential for hormonal prevention trials. Cancer, 1994, 74, 2726-2733.	2.0	22
48	Attributable Risk Estimation in Case-Control Studies. Epidemiologic Reviews, 1994, 16, 51-64.	1.3	148
49	Genetics of breast and ovarian cancer. British Medical Bulletin, 1994, 50, 656-676.	2.7	24
50	Cohort-Specific Risks of Developing Breast Cancer to Age 85 in Connecticut. Epidemiology, 1994, 5, 290-296.	1.2	11
51	Potential Impact of Genetic Testing on Cancer Prevention Trials, Using Breast Cancer as an Example. Journal of the National Cancer Institute, 1995, 87, 1137-1145.	3.0	15
52	Predictors of adoption of mammography in women under age 50.. Health Psychology, 1995, 14, 274-278.	1.3	65
53	Dave Byar's contribution to epidemiology. Contemporary Clinical Trials, 1995, 16, 230-248.	2.0	0
54	The woman at increased risk for breast cancer: evaluation and management strategies. Ca-A Cancer Journal for Clinicians, 1995, 45, 263-278.	157.7	79
55	Interest in genetic testing among first-degree relatives of breast cancer patients. American Journal of Medical Genetics Part A, 1995, 57, 385-392.	2.4	304
56	Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer, 1995, 76, 46-56.	2.0	60
57	A Complete Analysis of Variability for Estimates of Absolute Risk from a Population-Based Case-Control Study on Breast Cancer. Biometrical Journal, 1995, 37, 1-24.	0.6	6

#	Article	IF	Citations
58	Using loss of heterozygosity data in affected pedigree member linkage tests. Genetic Epidemiology, 1995, 12, 339-350.	0.6	7
59	?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancer. Breast Cancer Research and Treatment, 1995, 36, 267-285.	1.1	140
60	Are increases in mammographic screening still a valid explanation for trends in breast cancer incidence in the United States?. Cancer Causes and Control, 1995, 6, 135-144.	0.8	47
61	Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. Breast Journal, 1995, 1, 128-154.	0.4	1
62	Potential Use of Biomarkers in Breast Cancer Risk Assessment and Chemoprevention Trials. Breast Journal, 1995, 1, 236-242.	0.4	10
63	Cytology Patterns in Random Aspirates from Women at High and Low Risk for Breast Cancer. Breast Journal, 1995, 1, 343-349.	0.4	35
64	Design of the Prostate Cancer Prevention Trial (PCPT). Contemporary Clinical Trials, 1995, 16, 150-163.	2.0	125
65	Thymidine kinase: the future in breast cancer prognosis. Breast, 1995, 4, 79-83.	0.9	6
66	Breast Cancer Genetics: Relevance to Oncology Practice. Cancer Control, 1995, 2, 107327489500200.	0.7	2
67	p53 mutations in benign breast tissue.. Journal of Clinical Oncology, 1995, 13, 2293-2300.	0.8	75
68	The practice of prophylactic mastectomy: a survey of Maryland surgeons.. American Journal of Public Health, 1995, 85, 801-805.	1.5	47
69	Accuracy of Health Research Reported in the Popular Press: Breast Cancer and Mammography. Health Communication, 1995, 7, 147-161.	1.8	53
70	Proportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors. Journal of the National Cancer Institute, 1995, 87, 1681-1685.	3.0	549
71	Breast Cancer Genetic Screening and Critical Bioethics' Gaze. Journal of Medicine and Philosophy, 1995, 20, 313-337.	0.4	17
72	Adherence to Mammography Among Subgroups of Women at High Risk for Breast Cancer. Journal of Women's Health, 1995, 4, 645-654.	0.9	2
73	Methods of Inference for Estimates of Absolute Risk Derived from Population-Based Case-Control Studies. Biometrics, 1995, 51, 182.	0.8	57
74	Assessment and Counseling for Women With a Family History of Breast Cancer. JAMA - Journal of the American Medical Association, 1995, 273, 577.	3.8	220
75	Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. Journal of the National Cancer Institute, 1995, 87, 1372-1382.	3.0	193

#	ARTICLE	IF	CITATIONS
76	Statistical Analysis of Passive Surveillance Disease Registry Data. Biometrics, 1995, 51, 831.	0.8	11
77	Breast cancerâ€"Can we prevent it?. Primary Care Update for Ob/Gyns, 1995, 2, 45-52.	0.1	0
78	Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer. Annual Review of Pharmacology and Toxicology, 1995, 35, 195-211.	4.2	111
79	The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs. American Journal of Medicine, 1995, 99, 180-189.	0.6	19
80	An Overview of Considerations for the Testing of Tamoxifen as a Preventive for Breast Cancer. Annals of the New York Academy of Sciences, 1995, 768, 141-147.	1.8	14
81	Breast Cancer in African-American Families. Annals of the New York Academy of Sciences, 1995, 768, 281-285.	1.8	30
82	A Clinician-friendly Computer Program for Calculating Breast Cancer Risk Using the Gail and Claus Modelsa. Annals of the New York Academy of Sciences, 1995, 768, 301-307.	1.8	4
83	Object Class Networks (OCNs) for Interface-independent Calculation with Gail and Claus Modelsa. Annals of the New York Academy of Sciences, 1995, 768, 308-311.	1.8	2
84	INHERITED BREAST CANCER. Surgical Clinics of North America, 1996, 76, 205-220.	0.5	24
85	Breast Cancer in the Nineties. AORN Journal, 1996, 64, 64-72.	0.2	6
86	Perception of breast cancer risk among women in breast center and primary care settings: Correlation with age and family history of breast cancer. Surgery, 1996, 120, 297-303.	1.0	80
87	THE CURRENT ROLE OF PROPHYLACTIC MASTECTOMY. Surgical Clinics of North America, 1996, 76, 231-242.	0.5	41
88	Graphs to estimate an individualized risk of breast cancer.. Journal of Clinical Oncology, 1996, 14, 103-110.	0.8	81
89	The Case-Control Study as Data Missing by Design. Epidemiology, 1996, 7, 144-150.	1.2	33
90	The effect of an educational intervention on the perceived risk of breast cancer. Journal of General Internal Medicine, 1996, 11, 92-97.	1.3	83
91	Ethnic differences in risk perception among women at increased risk for breast cancer. Breast Cancer Research and Treatment, 1996, 40, 25-35.	1.1	127
92	Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Research and Treatment, 1996, 41, 59-70.	1.1	69
93	Addressing women's breast cancer risk and perceptions of control in medical settings. Journal of Clinical Psychology in Medical Settings, 1996, 3, 185-199.	0.8	10

#	Article	IF	Citations
94	Development of molecular approaches to early lung cancer detection. Seminars in Radiation Oncology, 1996, 6, 72-75.	1.0	7
95	Understanding the relationship between relative and absolute risk. , 1996, 77, 2193-2199.		32
96	Participation in a women's breast cancer risk counseling trial: Who participates? Who declines?. Cancer, 1996, 77, 2348-2355.	2.0	71
97	Hereditary cancer susceptibility. Cancer, 1996, 78, 553-557.	2.0	7
98	Risk biomarkers and current strategies for cancer chemoprevention. Journal of Cellular Biochemistry, 1996, 63, 1-14.	1.2	138
99	Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. Journal of Cellular Biochemistry, 1996, 63, 112-122.	1.2	32
100	Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer. Journal of Cellular Biochemistry, 1996, 63, 123-130.	1.2	4
101	Estimating disease risks for individuals with a given family history in different populations with an application to breast cancer. , 1996, 13, 229-242.		9
102	A Hospitalwide Integrated Database Infrastructure to Support a Research Program for a Multidisciplinary Breast Center. Breast Journal, 1996, 2, 289-298.	0.4	0
103	Some public health issues in the current state of genetic testing for breast cancer in Australia. Australian and New Zealand Journal of Public Health, 1996, 20, 467-472.	0.8	9
104	Agreement Between Breast Cancer Risk Estimation Methods. Journal of the National Cancer Institute, 1996, 88, 1315-1317.	3.0	36
105	Awareness of and Responses to Changes in the National Cancer Institute's Guidelines for Mammography in Women Aged 35â€"49. Journal of Women's Health, 1996, 5, 33-41.	0.9	3
106	Chemoprevention of Breast Cancer. JAMA - Journal of the American Medical Association, 1996, 275, 1349.	3.8	23
107	Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1997, 277, 1140.	3.8	176
108	Clinical and ethical issues in the diagnosis of hereditary breast cancer (review). International Journal of Oncology, 1997, 10, 323-8.	1.4	0
109	Breast Cancer Clusters in the Northeast United States: A Geographic Analysis. American Journal of Epidemiology, 1997, 146, 161-170.	1.6	350
110	BRCA1Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer. New England Journal of Medicine, 1997, 336, 1409-1415.	13.9	660
111	Construction of Composite Scales for Risk Assessment in Epidemiology: An Application to Ectopic Pregnancy. American Journal of Epidemiology, 1997, 145, 278-289.	1.6	32

#	ARTICLE	IF	CITATIONS
112	Estimation of Absolute Risk from Nested Case-Control Data. Biometrics, 1997, 53, 767.	0.8	78
113	The oncology nurse's role in cancer risk assessment and counseling. Seminars in Oncology Nursing, 1997, 13, 123-128.	0.7	19
114	Assessing individual risk for breast cancer: Risky business. Journal of Clinical Epidemiology, 1997, 50, 547-556.	2.4	36
115	Common cancersâ€"Genetics, origin, prevention, screening: Parts I and II. Disease-a-Month, 1997, 43, 681-742.	0.4	4
116	Excessive Breast Self-Examination Among First-Degree Relatives of Newly Diagnosed Breast Cancer Patients. Psychosomatics, 1997, 38, 253-261.	2.5	62
117	Humbug Breast Cancer Follies: Odds Ratios for the Relative Risk of the Truth; Unsolicited Reportage From a Board Certified Non-Epidemiologist. Perspectives in Biology and Medicine, 1997, 40, 536-542.	0.3	2
118	Estimation of Breast Cancer Risk by Women Aged 40 and Over: A Population-based Study. Canadian Journal of Public Health, 1997, 88, 392-396.	1.1	20
119	Special Report: Highlights of the NSABP Breast Cancer Prevention Trial. Cancer Control, 1997, 4, 78-86.	0.7	24
120	Biomarkers Predictive of Short-Interval Breast Cancer Development in High-Risk Women. Breast Journal, 1997, 3, 42-48.	0.4	3
121	Genetic Object Class Networks: Transformational Object Modeling of Breast Cancer Risk and Family History Data. Annals of the New York Academy of Sciences, 1997, 833, 164-166.	1.8	0
122	The Breast Cancer Prevention Trial: Evaluating Tamoxifenâ€™s Efficacy in Preventing Breast Cancer. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 1997, 26, 79-90.	0.2	8
123	The Breast Cancer Detection Demonstration Project 25 years later. Ca-A Cancer Journal for Clinicians, 1997, 47, 131-133.	157.7	9
124	The Familial Cancer Program of the Vermont Cancer Center: Development of a Cancer Genetics Program in a Rural Area. Journal of Genetic Counseling, 1997, 6, 131-145.	0.9	7
125	Complexities in Cancer Risk Counseling: Presentation of Three Cases. Journal of Genetic Counseling, 1997, 6, 147-167.	0.9	2
126	Cancer Risk Counseling: How Is It Different?. Journal of Genetic Counseling, 1997, 6, 97-109.	0.9	16
127	Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer. Annals of Behavioral Medicine, 1997, 19, 362-369.	1.7	131
128	Psychological issues in cancer genetics: current research and future priorities. Patient Education and Counseling, 1997, 32, 19-31.	1.0	50
129	A review on family history of breast cancer: screening and counseling proposals for women with familial (non-hereditary) breast cancer. Patient Education and Counseling, 1997, 32, 117-127.	1.0	9

#	ARTICLE	IF	CITATIONS
130	Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials. Journal of Cellular Biochemistry, 1997, 67, 101-110.	1.2	25
131	Automated analysis of mammographic densities and breast carcinoma risk. Cancer, 1997, 80, 66-74.	2.0	103
132	Genetic counseling and hereditary cancer. Cancer, 1997, 80, 576-586.	2.0	26
133	Breast carcinoma genetics from a primary care perspective. Cancer, 1997, 80, 621-626.	2.0	3
134	Age-related differences in breast carcinoma knowledge, beliefs, and perceived risk among women visiting an academic general medicine practice. Cancer, 1997, 80, 413-420.	2.0	64
135	AN APPROACH TO ESTIMATING EXPOSURE-SPECIFIC RATES OF BREAST CANCER FROM A TWO-STAGE CASE-CONTROL STUDY WITHIN A COHORT. , 1997, 16, 133-151.		11
136	Construction of a Bayesian network for mammographic diagnosis of breast cancer. Computers in Biology and Medicine, 1997, 27, 19-29.	3.9	141
137	Estimating lifetime and age-conditional probabilities of developing cancer. Lifetime Data Analysis, 1998, 4, 169-186.	0.4	70
138	Screening and clinical implications for BRCA1 and BRCA2 mutation carriers. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 377-387.	1.0	0
139	ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Research and Treatment, 1998, 49, 261-270.	1.1	27
140	Cancer Risk Assessment and Genetic Counseling in an Academic Medical Center: Consultands' Satisfaction, Knowledge, and Behavior in the First Year. Journal of Genetic Counseling, 1998, 7, 279-297.	0.9	29
141	Title is missing!. Journal of Clinical Psychology in Medical Settings, 1998, 5, 365-379.	0.8	32
142	Should Women at Risk Take Tamoxifen?. Nursing for Women's Health, 1998, 2, 20-25.	0.2	0
143	Involvement of tyrosine phosphorylation of p185c-erbB2/neu in tumorigenicity induced by x-rays and theneu oncogene in human breast epithelial cells. Molecular Carcinogenesis, 1998, 21, 225-233.	1.3	37
144	Random Fine Needle Aspiration of the Breast of Women at Increased Breast Cancer Risk and Standard Risk Controls. Breast Journal, 1998, 4, 420-425.	0.4	18
145	Communicating cancer risk information: the challenges of uncertainty. Patient Education and Counseling, 1998, 33, 67-81.	1.0	109
146	Cancer genetic clinics: why do women who already have cancer attend?. European Journal of Cancer, 1998, 34, 1549-1553.	1.3	40
147	Women at high risk for breast cancer: a primary care perspective. Primary Care Update for Ob/Gyns, 1998, 5, 268-275.	0.1	1

#	Article	IF	Citations
148	A review of breast cancer chemoprevention. Biomedicine and Pharmacotherapy, 1998, 52, 133-136.	2.5	15
149	PHASE III, LARGE-SCALE CHEMOPREVENTION TRIALS. Hematology/Oncology Clinics of North America, 1998, 12, 1019-1036.	0.9	13
150	A New Strategy for Evaluating the Impact of Epidemiologic Risk Factors for Cancer with Application to Melanoma. Journal of the American Statistical Association, 1998, 93, 415-426.	1.8	10
151	Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 1998, 90, 1371-1388.	3.0	5,238
152	The Effect of Physician Recommendation on Enrollment in the Breast Cancer Chemoprevention Trial. Preventive Medicine, 1998, 27, 713-719.	1.6	90
153	Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2. American Journal of Human Genetics, 1998, 62, 145-158.	2.6	690
154	Scheduling Periodic Examinations for the Early Detection of Disease: Applications to Breast Cancer. Journal of the American Statistical Association, 1998, 93, 1271-1281.	1.8	55
156	Perceived and Actual Breast Cancer Risk. Journal of Health Psychology, 1998, 3, 181-193.	1.3	46
157	Cancer Chemoprevention: Progress and Promise. Journal of the National Cancer Institute, 1998, 90, 1514-1528.	3.0	145
158	Breast Cancer Susceptibility Genes: BRCA1 and BRCA2. Medicine (United States), 1998, 77, 208-226.	0.4	126
159	Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives.. International Journal of Oncology, 1998, 13, 275-9.	1.4	1
160	A Group Therapy Approach to Facilitate Integration of Risk Information for Women at Risk for Breast Cancer. Canadian Journal of Psychiatry, 1998, 43, 375-380.	0.9	20
161	Breast Cancer Care: Developments in 1998. Cancer Control, 1998, 5, 338-345.	0.7	0
162	Assessing the Benefits of Testing for Breast Cancer Susceptibility Genes: A Decision Analysis. Breast Disease, 1998, 10, 115-125.	0.4	6
163	Risk-based recommendations for mammographic screening for women in their forties.. Journal of Clinical Oncology, 1998, 16, 3105-3114.	0.8	78
164	MOPP Versus ABVD and Low-Dose Versus High-Dose Irradiation in Hodgkin's Disease at Intermediate and Advanced Stages: Analysis of a Meta-Analysis by Clinicians. Journal of Clinical Oncology, 1999, 17, 730a-730a.	0.8	8
165	Coming Together to Conquer Cancer. Journal of Clinical Oncology, 1999, 17, 730-730.	0.8	11
166	American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. Journal of Clinical Oncology, 1999, 17, 1939-1939.	0.8	160

#	ARTICLE	IF	CITATIONS
167	Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women. Archives of Internal Medicine, 1999, 159, 1458.	4.3	56
168	The Role of the Primary Care Physician in Cancer Care. Oncology Issues, 1999, 14, 27-29.	0.0	5
169	Program Development in a Community Setting. Oncology Issues, 1999, 14, 16-20.	0.0	3
170	Efficacy of Controlled-Release Oxycodone. Journal of Clinical Oncology, 1999, 17, 730d-730d.	0.8	5
171	Chemotherapy of Advanced Non–Small-Cell Lung Cancer: "Those Who Cannot Remember the Past Are Condemned to Repeat It". Journal of Clinical Oncology, 1999, 17, 730b-730b.	0.8	0
172	Wherefore Global Quality-of-Life Assessment?. Journal of Clinical Oncology, 1999, 17, 730e-730e.	0.8	3
173	Strategies for Individualizing Patient Decisions About Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1799-1802.	1.8	2
174	Risk of Risk-Based Mammography Screening, Ages 40 to 49. Journal of Clinical Oncology, 1999, 17, 730c-730c.	0.8	3
175	Risk Communication in Genetic Testing for Cancer Susceptibility. Journal of the National Cancer Institute Monographs, 1999, 1999, 59-66.	0.9	138
176	Selective Estrogen Receptor Modulators: Clinical Spectrum*. Endocrine Reviews, 1999, 20, 418-434.	8.9	176
177	Where Are We Going?. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1798-1799.	1.8	52
178	Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*. Endocrine Reviews, 1999, 20, 253-278.	8.9	206
179	Prosthetic-Valve Endocarditis Caused by Penicillin-ResistantStreptococcus mitis. New England Journal of Medicine, 1999, 340, 1843-1844.	13.9	30
181	Prophylactic Mastectomy in Women with a High Risk of Breast Cancer. New England Journal of Medicine, 1999, 340, 1837-1839.	13.9	16
182	The One-In-Nine Risk of Breast Cancer. New England Journal of Medicine, 1999, 340, 1839-1840.	13.9	5
183	Infected Dog and Cat Bites. New England Journal of Medicine, 1999, 340, 1841-1842.	13.9	16
184	Treatment of Cat Scratch Disease. New England Journal of Medicine, 1999, 340, 1842-1843.	13.9	2
185	Breast Tumor Characteristics as Predictors of Mammographic Detection: Comparison of Interval- and Screen-Detected Cancers. Journal of the National Cancer Institute, 1999, 91, 2020-2028.	3.0	239

#	Article	IF	Citations
186	Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 1999, 91, 730-730.	3.0	18
187	Hypovitaminosis D in a Sunny Country. New England Journal of Medicine, 1999, 340, 1840-1841.	13.9	83
188	Does This Patient Have Breast Cancer?. JAMA - Journal of the American Medical Association, 1999, 282, 1270.	3.8	306
189	A 40-Year-Old Woman With a Strong Family History of Breast Cancer. JAMA - Journal of the American Medical Association, 1999, 282, 1953.	3.8	14
190	Women's Perceptions of Breast Cancer Risk. Medical Decision Making, 1999, 19, 221-229.	1.2	164
191	Refining Breast Cancer Risk Assessment With Molecular Markers: the Next Step?. Journal of the National Cancer Institute, 1999, 91, 2067-2068.	3.0	7
192	Development of a Statistical Model for Prediction of Acute Myocardial Infarction by Biochemical Markers. Drug Information Journal, 1999, 33, 141-148.	0.5	3
193	Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. Journal of the National Cancer Institute, 1999, 91, 1829-1846.	3.0	641
194	Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence. Journal of the National Cancer Institute, 1999, 91, 1541-1548.	3.0	671
195	Psychosocial factors in the etiology of breast cancer: review of a popular link. Patient Education and Counseling, 1999, 37, 201-214.	1.0	44
196	Relationship Between Relative Risk of Developing Breast Cancer and Absolute Risk in a Population of Rural, Older African American Women. Breast Journal, 1999, 5, 364-368.	0.4	1
197	A Reconsideration of the Benefits of Cancer Screening in Dialysis Patients. Seminars in Dialysis, 1999, 12, 140-143.	0.7	1
198	A Bayesian Hierarchical Approach for Combining Case-Control and Prospective Studies. Biometrics, 1999, 55, 858-866.	0.8	20
199	Diagnostic Work-Up of Breast Cancer in Females. Journal of the American Academy of Nurse Practitioners, 1999, 11, 71-79.	1.4	0
200	Attitudes toward Prophylactic Oophorectomy and Screening Utilization in Women at Increased Risk of Developing Hereditary Breast/Ovarian Cancer. Gynecologic Oncology, 1999, 75, 122-129.	0.6	68
201	Decision Making about Prophylactic Oophorectomy among At-Risk Women: Psychological Influences and Implications. Gynecologic Oncology, 1999, 75, 406-412.	0.6	58
202	The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. Journal of Mammary Gland Biology and Neoplasia, 1999, 4, 401-413.	1.0	8
203	Current controversies in breast cancer management. Current Problems in Surgery, 1999, 36, 153-216.	0.6	9

#	ARTICLE	IF	CITATIONS
204	The Genetic Revolution. Journal of the American Dietetic Association, 1999, 99, 1412-1420.	1.3	35
205	Genetic cancer risk assessment. Cancer, 1999, 86, 2483-2492.	2.0	47
206	Integrated approach to prediction of cervical intra-epithelial neoplasia status through a case-control study. , 1999, 84, 69-73.		7
207	Current status of tamoxifen use: An update for the surgical oncologist. , 1999, 72, 42-49.		13
208	Tumor suppressor genes and breast cancer. Radiation Oncology Investigations, 1999, 7, 55-65.	1.3	28
209	Breast cancer prevention. Breast Cancer Research, 1999, 2, 10-2.	2.2	0
210	Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer. New England Journal of Medicine, 1999, 340, 77-84.	13.9	1,343
211	A critical evaluation of the process of cancer genetic counselling: From research-based investigation to clinical diagnosis. European Journal of Oncology Nursing, 1999, 3, 96-101.	0.9	1
212	Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet, The, 1999, 354, 1846-1850.	6.3	202
213	Perspectives on Cancer Chemoprevention Research and Drug Development. Advances in Cancer Research, 1999, 78, 199-334.	1.9	234
214	Breast cancer screening, diagnosis, and treatment. Disease-a-Month, 1999, 45, 333-405.	0.4	6
215	CLINICAL OPTIONS FOR WOMEN AT HIGH RISK FOR BREAST CANCER. Surgical Clinics of North America, 1999, 79, 1189-1206.	0.5	19
216	HORMONAL THERAPY FOR BREAST CANCER. Hematology/Oncology Clinics of North America, 1999, 13, 435-455.	0.9	16
217	Estimating Adverse Selection Costs from Genetic Testing for Breast and Ovarian Cancer: The Case of Life Insurance. Journal of Risk and Insurance, 1999, 66, 531.	1.0	58
218	CHEMOPREVENTION OF BREAST CANCER. Surgical Clinics of North America, 1999, 79, 1207-1221.	0.5	28
219	Patterns of Breast Cancer Screening Among Lesbians at Increased Risk for Breast Cancer. Women and Health, 1999, 29, 35-55.	0.4	29
220	Effect of SERMs on breast tissue. Journal of Endocrinological Investigation, 1999, 22, 636-640.	1.8	7
221	Comparison of Risk Estimates for Selected Diseases and Causes of Death. Preventive Medicine, 1999, 28, 179-193.	1.6	35

#	Article	IF	Citations
222	Bilateral Prophylactic Mastectomy Decision Making: A Vignette Study. Preventive Medicine, 1999, 29, 216-221.	1.6	32
223	Tailored Risk Notification for Women with a Family History of Breast Cancer. Preventive Medicine, 1999, 29, 355-364.	1.6	95
224	The Epidemiology of Cardiovascular Disease in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1803-1806.	1.8	19
225	Individually randomized intervention trials for disease prevention and control. Statistical Methods in Medical Research, 1999, 8, 287-309.	0.7	14
226	Risk Perception and Risk Communication for Cancer Screening Behaviors: a Review. Journal of the National Cancer Institute Monographs, 1999, 1999, 101-119.	0.9	180
227	Assessing risk of breast cancer. Postgraduate Medicine, 1999, 105, 49-58.	0.9	6
228	When should tamoxifen be offered for breast cancer prevention?. Postgraduate Medicine, 1999, 105, 61-78.	0.9	0
229	A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use.. American Journal of Public Health, 1999, 89, 924-926.	1.5	61
230	On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility. Genetics in Medicine, 2000, 2, 186-192.	1.1	16
231	Psychological adjustment of women at increased risk of developing hereditary breast cancer. Psychology, Health and Medicine, 2000, 5, 377-388.	1.3	29
232	Comparative optimism in breast cancer risk perception: Effects of experience and risk factor knowledge. Psychology, Health and Medicine, 2000, 5, 367-376.	1.3	31
233	Management of women at risk for malignancy. Current Opinion in Oncology, 2000, 12, 508-513.	1.1	0
234	Evaluation and Treatment of BRCA-Positive Patients. Plastic and Reconstructive Surgery, 2000, 105, 714-719.	0.7	7
235	A comparison of methods currently used in clinical practice to estimate familial breast cancer risks. Annals of Oncology, 2000, 11, 451-454.	0.6	16
236	Genetic counseling for women with an intermediate family history of breast cancer. , 2000, 90, 361-368.		75
237	Assessing changes in ages at onset over successive generation: An application to breast cancer. , 2000, 18, 17-32.		15
238	Clinical management of BRCA1- and BRCA2-associated breast cancer. , 2000, 18, 296-304.		9
239	Genetic counseling and clinical cancer genetics services. , 2000, 18, 347-357.		50

#	ARTICLE	IF	CITATIONS
240	Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer, 2000, 89, 2046-2052.	2.0	40
241	Designing cancer prevention trials: a stochastic model approach. Statistics in Medicine, 2000, 19, 1983-1995.	0.8	14
242	Magnetic resonance imaging of breast cancer: Clinical indications and breast MRI reporting system. Journal of Magnetic Resonance Imaging, 2000, 12, 975-983.	1.9	60
243	Genetic epidemiology with a capital ?E?. Genetic Epidemiology, 2000, 19, 289-300.	0.6	45
244	A supportive-expressive group intervention for women with a family history of breast cancer: results of a phase II study. Psycho-Oncology, 2000, 9, 243-252.	1.0	37
245	Benign Breast Tissue Sampling for Prevention Studies. Breast Journal, 2000, 6, 215-219.	0.4	7
246	Quality of Life Across the Continuum of Breast Cancer Care. Breast Journal, 2000, 6, 324-330.	0.4	49
247	Absolute Risk of Breast Cancer for Australian Women with a Family History. ANZ Journal of Surgery, 2000, 70, 725-731.	0.3	12
248	A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics, 2000, 58, 299-308.	1.0	95
249	Prevention of breast cancer. Critical Reviews in Oncology/Hematology, 2000, 33, 221-238.	2.0	7
250	The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 943-949.	0.4	35
251	Tomatoes, Pap Smears, and Tea? Adopting Behaviors That May Prevent Reproductive Cancers and Improve Health. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2000, 29, 641-652.	0.2	1
252	CE Forum. Breast Cancer Genetics and the Role of Tamoxifen in Prevention. Journal of the American Academy of Nurse Practitioners, 2000, 12, 21-28.	1.4	1
253	Prophylactic mastectomy. Journal of the American College of Surgeons, 2000, 191, 322-330.	0.2	34
254	Drugs for the gynecologist to prescribe in the prevention of breast cancer: Current status and future trends. American Journal of Obstetrics and Gynecology, 2000, 182, 1121-1126.	0.7	15
255	Breast cancer prevention: a review of current evidence. Ca-A Cancer Journal for Clinicians, 2000, 50, 156-170.	157.7	54
256	Psychological distress, health beliefs, and frequency of breast self-examination. Journal of Behavioral Medicine, 2000, 23, 277-292.	1.1	55
257	Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Research and Treatment, 2000, 59, 101-111.	1.1	48

#	ARTICLE	IF	CITATIONS
258	Management of familial breast cancer risk. Breast Cancer Research and Treatment, 2000, 62, 19-33.	1.1	12
259	Cancer control research 2001. , 2000, 11, 257-270.		9
260	Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes and Control, 2000, 11, 477-488.	0.8	273
261	Reproductive and hormonal factors associated with mammographic breast density by age (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	99
262	chemoprevention of breast and colon cancer. Current Oncology Reports, 2000, 2, 223-224.	1.8	1
263	Fenretinide and cancer prevention. Current Oncology Reports, 2000, 2, 263-270.	1.8	25
264	Breast cancer prevention trials. Current Oncology Reports, 2000, 2, 558-565.	1.8	12
265	Looking forward and back: Distress among women at familial risk for breast cancer. Annals of Behavioral Medicine, 2000, 22, 53-59.	1.7	114
266	Underutilizers of mammography screening today: Characteristics of women planning, undecided about, and not planning a mammogram. Annals of Behavioral Medicine, 2000, 22, 80-88.	1.7	66
267	Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman. Annals of Surgical Oncology, 2000, 7, 67-71.	0.7	6
268	Insurance Policies for Prophylactic Surgery: To cover or Not to Cover?. Annals of Surgical Oncology, 2000, 7, 321-322.	0.7	3
269	Practical Issues in Counseling Healthy Women About Their Breast Cancer Risk and Use of Tamoxifen Citrate. Archives of Internal Medicine, 2000, 160, 3034.	4.3	13
271	Intention to Undergo Prophylactic Bilateral Mastectomy in Women at Increased Risk of Developing Hereditary Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2250-2257.	0.8	112
272	Safety and efficacy of antiestrogens for prevention of breast cancer. American Journal of Health-System Pharmacy, 2000, 57, 1315-1322.	0.5	19
273	Genetics and the Multidisciplinary Breast Center. Surgical Oncology Clinics of North America, 2000, 9, 367-396.	0.6	1
274	The Breast Health Center at Women & Infants Hospital. Surgical Oncology Clinics of North America, 2000, 9, 199-216.	0.6	0
275	Reducing the Risk of Breast Cancer. New England Journal of Medicine, 2000, 343, 191-198.	13.9	61
276	Collective Fear, Individualized Risk: the social and cultural context of genetic testing forbreast cancer. Nursing Ethics, 2000, 7, 237-249.	1.8	46

#	Article	IF	Citations
277	Pricing Term Insurance in the Presence of a Family History of Breast or Ovarian Cancer. North American Actuarial Journal, 2000, 4, 75-87.	0.8	24
278	Re: Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost. Journal of the National Cancer Institute, 2000, 92, 657a-657.	3.0	7
279	Randomized Trial of a Specialist Genetic Assessment Service for Familial Breast Cancer. Journal of the National Cancer Institute, 2000, 92, 1345-1351.	3.0	89
280	Individual Risk Prediction and Population-wide Disease Prevention. Epidemiologic Reviews, 2000, 22, 176-180.	1.3	59
281	Genetic Susceptibility and Survival: Application to Breast Cancer. Journal of the American Statistical Association, 2000, 95, 28-42.	1.8	17
282	Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model. Journal of the National Cancer Institute, 2000, 92, 1217-1227.	3.0	263
283	Predicting the Cumulative Risk of False-Positive Mammograms. Journal of the National Cancer Institute, 2000, 92, 1657-1666.	3.0	165
284	The Effectiveness of One-to-one Risk-communication Interventions in Health Care. Medical Decision Making, 2000, 20, 290-297.	1.2	150
285	Predicting Breast Cancer: the Search for a Model. Journal of the National Cancer Institute, 2000, 92, 1196-1197.	3.0	6
286	A Cross-Cultural Consumer-Based Decision Aid for Screening Mammography. Preventive Medicine, 2000, 30, 200-208.	1.6	30
287	Breast cancer chemoprevention. American Journal of Surgery, 2000, 180, 249-251.	0.9	23
288	Gail model and breast cancer. Lancet, The, 2000, 355, 1017.	6.3	29
289	Life expectancy benefits of cancer screening in the end-stage renal disease population. American Journal of Kidney Diseases, 2000, 35, 237-243.	2.1	51
290	Hereditary cancer – the evidence for current recommended management. Lancet Oncology, The, 2000, 1, 9-16.	5.1	18
291	Tamoxifen for the prevention of breast cancer. European Journal of Cancer, 2000, 36, 142-145.	1.3	50
292	Current controversies in cancer tamoxifen for breast cancer prevention. European Journal of Cancer, 2000, 36, 146-147.	1.3	1
293	Progress in the prevention of breast cancer: concept to reality. Journal of Steroid Biochemistry and Molecular Biology, 2000, 74, 269-277.	1.2	29
294	Measuring the Projected Public Health Impact of Lung Cancer Through Lifetime and Age-Conditional Risk Estimates. Annals of Epidemiology, 2000, 10, 88-96.	0.9	7

#	ARTICLE	IF	CITATIONS
295	Inherited coagulopathies in OB/GYN. Primary Care Update for Ob/Gyns, 2000, 7, 70-73.	0.1	0
296	Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. European Journal of Cancer, 2000, 36, 694-709.	1.3	53
297	Use of risk determinants for different breast cancer prevention strategies. European Journal of Cancer, 2000, 36, 1283-1287.	1.3	3
298	Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial. European Journal of Cancer, 2000, 36, 1209-1214.	1.3	5
299	Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). European Journal of Cancer, 2000, 36, 49-50.	1.3	92
300	Breast cancer prevention. European Journal of Cancer, 2000, 36, 53-54.	1.3	6
301	Adoption of a health education intervention for family members of breast cancer patients. American Journal of Preventive Medicine, 2000, 18, 189-198.	1.6	12
302	Breast imaging technology Application of magnetic resonance imaging to early detection of breast cancer. Breast Cancer Research, 2000, 3, 17-21.	2.2	36
303	Assessing the Risk of Breast Cancer. New England Journal of Medicine, 2000, 342, 564-571.	13.9	263
304	Risk models in genetic epidemiology. Statistical Methods in Medical Research, 2000, 9, 589-601.	0.7	11
305	BREAST CANCER CHEMOPREVENTION. Hematology/Oncology Clinics of North America, 2000, 14, 727-738.	0.9	1
306	BREAST CANCER GENETICS. Hematology/Oncology Clinics of North America, 2000, 14, 705-725.	0.9	7
307	GENETIC TESTING. Hematology/Oncology Clinics of North America, 2000, 14, 939-952.	0.9	11
308	Breast cancer prevention: present and future. Cancer Treatment Reviews, 2001, 27, 261-273.	3.4	32
309	Results and Implications of the Royal Marsden and Other Tamoxifen Chemoprevention Trials. Clinical Breast Cancer, 2001, 2, 33-36.	1.1	7
310	Design considerations for efficient prostate cancer chemoprevention trials. Urology, 2001, 57, 205-212.	0.5	19
311	The risk of developing breast cancer within the next 5, 10, or 20 years of a woman's life. American Journal of Preventive Medicine, 2001, 20, 214-218.	1.6	8
312	Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncology, The, 2001, 2, 371-379.	5.1	103

#	ARTICLE	IF	CITATIONS
313	Predicting stages of adoption of mammography screening in a general population. European Journal of Cancer, 2001, 37, 1869-1877.	1.3	34
314	Variation in Mammographic Breast Density by Race. Annals of Epidemiology, 2001, 11, 257-263.	0.9	99
315	Measuring the Public Health Burden of Cancer in the United States Through Lifetime and Age-Conditional Risk Estimates. Annals of Epidemiology, 2001, 11, 547-553.	0.9	36
316	Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstetrics and Gynecology, 2001, 98, 996-1003.	1.2	27
317	ROC optimization may improve risk stratification of prostate cancer patients. Urology, 2001, 57, 286-290.	0.5	18
319	Health beliefs and endoscopic screening for colorectal cancer: Potential for cancer prevention. Preventive Medicine, 2001, 33, 128-136.	1.6	86
320	Tamoxifen and risk of endometrial cancer. Lancet, The, 2001, 357, 65.	6.3	17
321	Common hereditary cancers and implications for primary care. Lancet, The, 2001, 358, 56-63.	6.3	66
322	Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for Chemoprevention. Journal of the National Cancer Institute, 2001, 93, 358-366.	3.0	537
323	Chemoprevention of Breast Cancer. Southern Medical Journal, 2001, 94, 7-15.	0.3	3
324	Women's Interest in Chemoprevention for Breast Cancer. Archives of Internal Medicine, 2001, 161, 1639.	4.3	45
325	The Surgeon's Role in Breast Cancer Chemoprevention. Breast Disease, 2001, 12, 103-112.	0.4	1
326	Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 1095-1102.	3.0	306
327	Elaboration and Formalization of Current Scientific Knowledge of Risks and Preventive Measures Illustrated by Colorectal Cancer. Methods of Information in Medicine, 2001, 40, 323-330.	0.7	1
328	Too Early to Say That Pregnancy Has an Antitumor Effect on Breast Cancer. Journal of Clinical Oncology, 2001, 19, 3707-3708.	0.8	3
329	Breast cancer chemoprevention â€" Quo vadis?. Breast, 2001, 10, 58-61.	0.9	1
330	Breast Cancer Prevention. Clinical Obstetrics and Gynecology, 2001, 44, 478-484.	0.6	3
331	Expanding Role of Breast Cytopathology as a Risk Predictor. Advances in Anatomic Pathology, 2001, 8, 255-263.	2.4	5

#	ARTICLE	IF	CITATIONS
332	Cost-Effectiveness of Raloxifene and Hormone Replacement Therapy in Postmenopausal Women. Obstetrics and Gynecology, 2001, 98, 996-1003.	1.2	12
333	BREAST CANCER: Risk, Prevention, & Tamoxifen. American Journal of Nursing, 2001, 101, 26-35.	0.2	5
334	The privatization of risk. American Journal of Public Health, 2001, 91, 365-368.	1.5	81
335	Understanding risk and lessons for clinical risk communication about treatment preferences. Quality and Safety in Health Care, 2001, 10, i9-i13.	2.5	107
336	Cancer genetics in oncology practice. Annals of Oncology, 2001, 12, 895-908.	0.6	28
338	Educational Review: Role of the Surgeon in Hereditary Breast Cancer. Annals of Surgical Oncology, 2001, 8, 368-378.	0.7	5
339	The short-term impact of tailored mammography decision-making interventions. Patient Education and Counseling, 2001, 43, 271-287.	1.0	80
340	The Effectiveness of the Gail Model in Estimating Risk for Development of Breast Cancer in Women Under 40 Years of Age. Breast Journal, 2001, 7, 34-39.	0.4	35
341	From Adjuvant Therapy to Breast Cancer Prevention: BCPT and STAR. Breast Journal, 2001, 7, 144-157.	0.4	53
342	Biomarker Assays in Nipple Aspirate Fluid. Breast Journal, 2001, 7, 378-387.	0.4	38
343	Understanding Mathematical Models for Breast Cancer Risk Assessment and Counseling. Breast Journal, 2001, 7, 224-232.	0.4	104
344	Chemoprevention for High-Risk Women: Tamoxifen and Beyond. Breast Journal, 2001, 7, 311-320.	0.4	27
345	Hereditary breast/ovarian cancer - pitfalls in genetic counseling. Clinical Genetics, 2001, 60, 310-313.	1.0	5
346	A continuing medical education lecture and workshop, physician behavior, and barriers to change. Journal of Continuing Education in the Health Professions, 2001, 21, 110-116.	0.4	22
347	Frequency ofBRCA1 andBRCA2 mutations in a clinic-based series of breast and ovarian cancer families. Human Mutation, 2001, 17, 74-74.	1.1	6
348	Breast Cancer Risk Assessment in Indigent Women at a Public Hospital. Gynecologic Oncology, 2001, 81, 287-290.	0.6	29
349	Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Familial Cancer, 2001, 1, 197-206.	0.9	35
350	Participation in Breast Cancer Genetic Counseling: The Influence of Educational Level, Ethnic Background, and Risk Perception. Journal of Genetic Counseling, 2001, 10, 215-231.	0.9	42

#	ARTICLE	IF	CITATIONS
351	Adherence to recommendations for clinical follow-up after benign breast biopsy. Breast Cancer Research and Treatment, 2001, 69, 165-178.	1.1	29
352	Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes and Control, 2001, 12, 895-902.	0.8	38
353	Macronutrient Intake and Estrogen Metabolism in Healthy Postmenopausal Women. Breast Cancer Research and Treatment, 2001, 65, 1-10.	1.1	17
354	Beyond Tamoxifen. Annals of the New York Academy of Sciences, 2001, 952, 44-59.	1.8	27
355	Breast cancer chemoprevention: Current status and future directions. Seminars in Oncology, 2001, 28, 253-259.	0.8	14
356	Genetic susceptibility for breast cancer?Risk assessment and counseling. Seminars in Oncology, 2001, 28, 419-433.	0.8	25
357	Hereditary breast cancer. Current Problems in Surgery, 2001, 38, 387-480.	0.6	124
358	Screening for the major malignancies affecting women: Current guidelines. American Journal of Obstetrics and Gynecology, 2001, 184, 1021-1030.	0.7	38
359	Results of a Community Pharmacy-Based Breast Cancer Risk-Assessment and Education Program. Pharmacotherapy, 2001, 21, 243-253.	1.2	48
360	Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 334-335.	3.0	107
361	Risk-Reduction Mastectomy: Clinical Issues and Research Needs. Journal of the National Cancer Institute, 2001, 93, 1297-1297.	3.0	56
362	Does Timely Assessment Affect the Anxiety Associated with an Abnormal Mammogram Result?. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 599-605.	1.7	20
363	Ethnic differences in mammographic densities. International Journal of Epidemiology, 2001, 30, 959-965.	0.9	130
364	Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease. Journal of the National Cancer Institute, 2001, 93, 1449-1457.	3.0	157
365	Familiar drugs may prevent cancer. Postgraduate Medical Journal, 2001, 77, 492-497.	0.9	4
366	Women's Views on Breast Cancer Risk and Screening Mammography. Medical Decision Making, 2001, 21, 231-240.	1.2	86
367	Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 1624-1632.	3.0	262
368	Breast Cancer Risk Prediction: Should Nipple Aspiration Fluid Cytology Be Incorporated Into Clinical Practice?. Journal of the National Cancer Institute, 2001, 93, 1762-1763.	3.0	15

#	ARTICLE	IF	CITATIONS
369	Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2. JAMA - Journal of the American Medical Association, 2001, 286, 2251.	3.8	673
370	Frequency or Probability? A Qualitative Study of Risk Communication Formats Used in Health Care. Medical Decision Making, 2001, 21, 459-467.	1.2	226
371	MR Imaging of the Breast for the Detection, Diagnosis, and Staging of Breast Cancer. Radiology, 2001, 220, 13-30.	3.6	688
372	Cardiovascular Effects of Tamoxifen in Women With and Without Heart Disease: Breast Cancer Prevention Trial. Journal of the National Cancer Institute, 2001, 93, 16-21.	3.0	139
373	Informing Women About Their Breast Cancer Risks: Truth and Consequences. Health Communication, 2001, 13, 205-226.	1.8	72
374	Risk perceptions and knowledge of breast cancer genetics in women at increased risk of developing hereditary breast cancer. Psychology and Health, 2001, 16, 297-311.	1.2	37
375	Medical Management of Breast Cancer: Today and Tomorrow. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 137-149.	0.7	10
376	Motivations and Concerns of Women Considering Genetic Testing for Breast Cancer: A Comparison Between Affected and At-Risk Probands. Genetic Testing and Molecular Biomarkers, 2002, 6, 203-205.	1.7	25
377	American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. Journal of Clinical Oncology, 2002, 20, 3328-3343.	0.8	187
378	Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2002, 20, 9-16.	0.8	38
379	Loss of Heterozygosity in Benign Breast Epithelium in Relation to Breast Cancer Risk. Journal of the National Cancer Institute, 2002, 94, 858-860.	3.0	40
380	Concerns of women presenting to a comprehensive cancer centre for genetic cancer risk assessment. Journal of Medical Genetics, 2002, 39, 526-530.	1.5	22
381	Breast Cancer Prevention. Oncologist, 2002, 7, 60-64.	1.9	30
382	Population-based screening for hereditary breast cancer in a region of North-Central Italy. International Journal of Molecular Medicine, 2002, 10, 299.	1.8	1
383	Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene. JAMA - Journal of the American Medical Association, 2002, 287, 216.	3.8	190
384	Breast Cancer Risk in Ashkenazi BRCA1/2 Mutation Carriers: Effects of Reproductive History. Epidemiology, 2002, 13, 255-261.	1.2	35
385	Explaining risks: turning numerical data into meaningful pictures. BMJ: British Medical Journal, 2002, 324, 827-830.	2.4	536
386	The view of The International Menopause Society on the Women's Health Initiative. Climacteric, 2002, 5, 211-216.	1.1	30

#	ARTICLE	IF	CITATIONS
387	Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy. Journal of the National Cancer Institute, 2002, 94, 1564-1569.	3.0	73
388	Risk assessment and management of high risk familial breast cancer. Journal of Medical Genetics, 2002, 39, 865-871.	1.5	53
389	Breast Cancer in the Very Young Patient: A Multidisciplinary Case Presentation. Oncologist, 2002, 7, 547-554.	1.9	34
390	Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 2002, 94, 1504-1504.	3.0	51
391	Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. Medical Decision Making, 2002, 22, 386-393.	1.2	8
392	The credibility of the breast cancer risk assessment (BCRA) tool for Asians. Journal of Medical Engineering and Technology, 2002, 26, 185-192.	0.8	2
393	Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2002, 288, 321-333.	3.8	14,536
394	On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance. Journal of the National Cancer Institute, 2002, 94, 1221-1226.	3.0	182
395	Progress in breast cancer chemoprevention.. Endocrine-Related Cancer, 2002, 9, 15-32.	1.6	16
396	Can family history be used as a tool for public health and preventive medicine?. Genetics in Medicine, 2002, 4, 304-310.	1.1	314
397	Implementation of a Comprehensive Cancer Control Program at the Worksite: Year One Summary Report. Journal of Occupational and Environmental Medicine, 2002, 44, 398-406.	0.9	12
398	Psychological impact of benign breast biopsy: A longitudinal, comparative study.. Health Psychology, 2002, 21, 485-494.	1.3	70
399	Genetic testing: Psychological aspects and implications.. Journal of Consulting and Clinical Psychology, 2002, 70, 784-797.	1.6	280
400	Making Good Decisions about Breast Cancer Chemoprevention. Annals of Internal Medicine, 2002, 137, 52.	2.0	13
401	Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137, 59.	2.0	94
402	Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137, 347.	2.0	957
403	Who's liable for breast cancer prevention?. Postgraduate Medicine, 2002, 111, 83-92.	0.9	4
404	Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. Genetics in Medicine, 2002, 4, 359-365.	1.1	36

#	Article	IF	Citations
405	Breast Cancer Prevention and Surveillance. Clinical Obstetrics and Gynecology, 2002, 45, 778-783.	0.6	3
406	Depressive Realism and Health Risk Accuracy: The Negative Consequences of Positive Mood. Journal of Consumer Research, 2002, 29, 57-69.	3.5	71
407	The prognostic significance of Gail model risk factors for women with breast cancer. American Journal of Surgery, 2002, 184, 11-15.	0.9	18
408	The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. Fertility and Sterility, 2002, 78, 951-956.	0.5	36
409	Selective Estrogen Receptor Modulators as a New Therapeutic Drug Group: Concept to Reality in a Decade. Clinical Breast Cancer, 2002, 2, 272-281.	1.1	31
410	A Rationale for the Reinitiation of Adjuvant Tamoxifen Therapy in Women Receiving Fewer than 5 Years of Therapy. Clinical Breast Cancer, 2002, 2, 282-286.	1.1	19
411	Breast Cancer Chemoprevention: Current Challenges and a Look Toward the Future. Clinical Breast Cancer, 2002, 3, 113-124.	1.1	20
412	The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial. Clinical Breast Cancer, 2002, 3, 153-159.	1.1	75
413	Ductal Lavage and Ductoscopy: The Opportunities and the Limitations. Clinical Breast Cancer, 2002, 3, 185-191.	1.1	44
414	The utility of ductal lavage in breast cancer detection and risk assessment. Breast Cancer Research, 2002, 4, 51-3.	2.2	9
415	Breast Cancer Prevention. American Journal of Cancer, 2002, 1, 173-178.	0.4	0
416	Chemoprevention of Breast Cancer. Drugs and Aging, 2002, 19, 43-78.	1.3	6
417	Mammographic Tissue, Breast Cancer Risk, Serial Image Analysis, and Digital Mammography. Academic Radiology, 2002, 9, 298-316.	1.3	79
418	BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes. Journal of Clinical Oncology, 2002, 20, 2701-2712.	0.8	477
419	Breast Cancer Risk Reduction: Strategies for Women at Increased Risk. Annual Review of Medicine, 2002, 53, 519-540.	5.0	31
420	Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. Journal of Clinical Epidemiology, 2002, 55, 665-675.	2.4	24
421	Effects of a mammography decision-making intervention at 12 and 24 months. American Journal of Preventive Medicine, 2002, 22, 247-257.	1.6	132
422	Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncology, The, 2002, 3, 611-619.	5.1	36

#	ARTICLE	IF	CITATIONS
423	Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends in Molecular Medicine, 2002, 8, 82-88.	3.5	114
426	Decision-making in early breast cancer. European Journal of Cancer, 2002, 38, 745-749.	1.3	27
427	Tamoxifen ('Nolvadex'): a review. Cancer Treatment Reviews, 2002, 28, 165-180.	3.4	205
428	A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy. JAMA - Journal of the American Medical Association, 2002, 287, 2130.	3.8	35
429	Prevention in the year 2002: some news, some issues. Primary Care - Clinics in Office Practice, 2002, 29, 727-749.	0.7	5
430	Quimioprevención del cáncer de mama. Semergen, 2002, 28, 80-83.	0.2	0
431	Screening mammography: proven benefit, continued controversy. Radiologic Clinics of North America, 2002, 40, 395-407.	0.9	79
432	Counseling the at risk patient in the BRCA1 and BRCA2 Era. Obstetrics and Gynecology Clinics of North America, 2002, 29, 341-366.	0.7	8
433	Risk factors for breast cancer. Obstetrics and Gynecology Clinics of North America, 2002, 29, 159-172.	0.7	17
434	Mammographic Density. Academic Radiology, 2002, 9, 253-255.	1.3	10
435	Identifying and Counseling Women at Increased Risk for Breast Cancer. Mayo Clinic Proceedings, 2002, 77, 355-361.	1.4	14
436	A Tailored Intervention to Aid Decisionmaking About Hormone Replacement Therapy. American Journal of Public Health, 2002, 92, 1112-1114.	1.5	40
437	Overview of the clinical genetics of ovarian cancer. , 2002, , 43-72.		3
438	Risk estimation for familial breast and ovarian cancer. , 2002, , 125-140.		0
439	Management of <i>BRCA1/2</i> mutation carriers. , 2002, , 237-274.		1
440	Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2002, 20, 9-16.	0.8	55
441	Ductal Lavage for Breast Cancer Risk Assessment. Cancer Control, 2002, 9, 473-479.	0.7	5
443	Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. American Journal of Cardiology, 2002, 90, 1204-1210.	0.7	75

#	Article	IF	Citations
444	Evaluation and management of the woman with an abnormal ductal lavage. Journal of the American College of Surgeons, 2002, 194, 648-656.	0.2	34
445	Mammography screening and breast cancer biology in African American women—a review. Cancer Detection and Prevention, 2002, 26, 180-191.	2.1	10
446	Risk estimation for breast cancer development; a clinical perspective. Surgical Oncology, 2002, 10, 183-192.	0.8	46
447	Ductal lavage and the clinical management of women at high risk for breast carcinoma. Cancer, 2002, 94, 292-298.	2.0	51
448	Evaluating a risk-based model for mammographic screening of women in their forties. Cancer, 2002, 94, 2830-2835.	2.0	1
449	Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. Environmental and Molecular Mutagenesis, 2002, 39, 264-270.	0.9	11
450	Lavage and nipple aspiration of breast ductal fluids: A source of biomarkers for environmental mutagenesis. Environmental and Molecular Mutagenesis, 2002, 39, 127-133.	0.9	21
451	Limitations of the Gail Model in the Specialized Breast Cancer Risk Assessment Clinic. Breast Journal, 2002, 8, 23-27.	0.4	64
452	Breast cancer risk assessment in patients seen in a gynecologic oncology clinic. International Journal of Gynecological Cancer, 2002, 12, 389-393.	1.2	5
453	Evaluating participants' use of a hormone replacement therapy decision-making intervention. Patient Education and Counseling, 2002, 48, 283-291.	1.0	38
454	Anti-oestrogenic prevention of breast cancer — the make or break point. Nature Reviews Cancer, 2002, 2, 787-794.	12.8	50
455	Cancer Genetics and Women's Health. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2002, 31, 208-216.	0.2	1
456	Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy. Journal of Genetic Counseling, 2002, 11, 81-96.	0.9	24
457	High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes and Control, 2002, 13, 625-635.	0.8	206
458	Chemoprevention of breast cancer: current and future prospects. Cancer and Metastasis Reviews, 2002, 21, 311-321.	2.7	18
459	COMMENTARY: Apportioning causes, targeting populations and predicting risks: Population attributable fractions. European Journal of Epidemiology, 2002, 18, 933-935.	2.5	2
460	Health economics and genetic service development: a familial cancer genetic example. Familial Cancer, 2002, 3, 61-67.	0.9	10
462	Prevention of breast cancer using SERMs and aromatase inhibitors. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 5-18.	1.0	11

#	Article	IF	Citations
463	The Unmet Information and Support Needs of Women with a Family History of Breast Cancer: A Descriptive Survey. Journal of Genetic Counseling, 2003, 12, 61-76.	0.9	19
464	Leading Voices and the Power of One: 2002 Presidential Address to the National Society of Genetic Counselors. Journal of Genetic Counseling, 2003, 12, 97-107.	0.9	2
465	Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer, 2003, 10, 54-62.	1.3	19
466	The role of aromatase inhibitors in early breast cancer. Current Treatment Options in Oncology, 2003, 4, 133-140.	1.3	16
468	Epidemiology of breast cancer â€" selected highlights. Breast, 2003, 12, 405-411.	0.9	34
469	A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials. Seminars in Oncology, 2003, 30, 4-13.	0.8	15
470	Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case-fatality, and mortality?. Social Science and Medicine, 2003, 57, 2265-2279.	1.8	54
471	Secular stability and reliability of measurements of the percentage of dense tissue on mammograms. Cancer Detection and Prevention, 2003, 27, 266-274.	2.1	20
472	Decision analysis of hormone replacement therapy after the Women's Health Initiative. American Journal of Obstetrics and Gynecology, 2003, 189, 1228-1233.	0.7	16
473	Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients. Ca-A Cancer Journal for Clinicians, 2003, 53, 82-101.	157.7	37
474	American Cancer Society Guidelines for Breast Cancer Screening: Update 2003. Ca-A Cancer Journal for Clinicians, 2003, 53, 141-169.	157.7	636
475	A computer decision aid for medical prevention: a pilot qualitative study of the Personalized Estimate of Risks (EsPeR) system. BMC Medical Informatics and Decision Making, 2003, 3, 13.	1.5	20
476	Available models for breast cancer risk assessment: how accurate are they?. Journal of the American College of Surgeons, 2003, 197, 1029-1035.	0.2	4
477	Breast cancer risk assessment models. Cancer, 2003, 97, 230-235.	2.0	57
478	Mammography screening in African American women. Cancer, 2003, 97, 258-272.	2.0	54
479	Increasing the pool of academically oriented African-American medical and surgical oncologists. Cancer, 2003, 97, 329-334.	2.0	33
481	A multigene test for the risk of sporadic breast carcinoma. Cancer, 2003, 97, 2160-2170.	2.0	39
482	Adjustment for competing risk in kin-cohort estimation. Genetic Epidemiology, 2003, 25, 303-313.	0.6	13

#	ARTICLE	IF	CITATIONS
483	Cancer incidence among laboratory workers in biomedical research and routine laboratories in Israel: Part II-nested case-control study. American Journal of Industrial Medicine, 2003, 44, 611-626.	1.0	14
484	The prevention of breast cancer. British Journal of Surgery, 2003, 90, 772-783.	0.1	12
485	Breast Cancer in Reduction Mammaplasty Specimens: Case Reports and Guidelines. Breast Journal, 2003, 9, 120-125.	0.4	33
486	A randomized trial of three videos that differ in the framing of information about mammography in women 40 to 49 years old. Journal of General Internal Medicine, 2003, 18, 875-883.	1.3	27
487	Genetic predisposition to breast cancer. British Journal of Surgery, 2003, 85, 147-148.	0.1	2
488	Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2003, 2, 205-213.	21.5	676
489	Inference in Splineâ€Based Models for Multiple Timeâ€toâ€Event Data, with Applications to a Breast Cancer Prevention Trial. Biometrics, 2003, 59, 859-868.	0.8	14
490	Estimating Predictors for Longâ€or Shortâ€Term Survivors. Biometrics, 2003, 59, 1008-1015.	0.8	1
491	Molecular Epidemiology of Breast Cancer: A Review. African Journal of Reproductive Health, 2003, 7, 17.	1.1	10
492	Breast MR imaging. Radiologic Clinics of North America, 2003, 41, 43-50.	0.9	37
493	Advances in breast cancer detection and management. Medical Clinics of North America, 2003, 87, 997-1028.	1.1	22
494	Management of the high-risk patient. Surgical Clinics of North America, 2003, 83, 733-751.	0.5	13
496	Ovarian cancer screening. Hematology/Oncology Clinics of North America, 2003, 17, 989-1005.	0.9	68
497	Ductal lavage: clinical utility and future promise. Surgical Clinics of North America, 2003, 83, 753-769.	0.5	7
498	Hormonal and genetic risk factors for breast cancer. Journal of the Royal College of Surgeons of Edinburgh, 2003, 1, 23-31.	0.8	11
499	Oestrogens, Oestrogen Receptors and Breast Cancer. European Journal of Cancer, Supplement, 2003, 1, 1-12.	2.2	7
500	The curability of breast cancer. European Journal of Cancer, Supplement, 2003, 1, 24-34.	2.2	13
501	Gene screening and prevention of hereditary breast cancer. European Journal of Cancer, Supplement, 2003, 1, 13-23.	2.2	3

#	ARTICLE	IF	CITATIONS
502	The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies. Cancer Treatment Reviews, 2003, 29, 79-89.	3.4	17
503	Improving the Prediction of Complex Diseases by Testing for Multiple Disease-Susceptibility Genes. American Journal of Human Genetics, 2003, 72, 636-649.	2.6	141
504	Anti-oestrogenic chemoprevention of breast cancerâ€"the need to progress. European Journal of Cancer, 2003, 39, 572-579.	1.3	21
505	Validation of family history data in cancer family registries. American Journal of Preventive Medicine, 2003, 24, 190-198.	1.6	220
506	Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. Journal of Clinical Epidemiology, 2003, 56, 856-861.	2.4	75
507	Cancer prevention and delay are as important as cure. Lancet Oncology, The, 2003, 4, 72-73.	5.1	6
508	Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2mutation status. Breast Cancer Research, 2003, 5, R175-86.	2.2	37
509	Oestrogen exposure and breast cancer risk. Breast Cancer Research, 2003, 5, 239-47.	2.2	253
510	The Meaning of Risk to First Degree Relatives of Women with Breast Cancer. Women and Health, 2003, 37, 97-117.	0.4	18
511	Evidence-based management options for women at increased breast/ovarian cancer risk. Annals of Oncology, 2003, 14, 9-19.	0.6	43
512	The Impact of a Family History of Breast Cancer on Screening Practices and Attitudes in Low-Income, Rural, African American Women. Journal of Women's Health, 2003, 12, 779-787.	1.5	24
513	Early Experience with a Web-based Intervention to Inform Risk of Breast Cancer. Journal of Health Psychology, 2003, 8, 175-186.	1.3	10
514	Variations in Lung Cancer Risk Among Smokers. Journal of the National Cancer Institute, 2003, 95, 470-478.	3.0	547
515	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814.	1.5	261
516	Commentary: Case-control-family designs: a paradigm for future epidemiology research?. International Journal of Epidemiology, 2003, 32, 48-50.	0.9	15
517	Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention. Journal of the National Cancer Institute, 2003, 95, 526-532.	3.0	243
518	Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control-family study for assessing main effects and possible geneâ€"environment interaction. International Journal of Epidemiology, 2003, 32, 38-48.	0.9	37
519	Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. Journal of Medical Genetics, 2003, 40, 814-814.	1.5	2

#	ARTICLE	IF	CITATIONS
520	Tamoxifen for Prevention of Breast Cancer. Annals of Pharmacotherapy, 2003, 37, 268-273.	0.9	4
521	Predicting Breast Cancer Screening Intentions and Behavior with Emotion and Cognition. Journal of Social and Clinical Psychology, 2003, 22, 213-232.	0.2	64
522	Apoptotic Action of 17Â-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo. Journal of the National Cancer Institute, 2003, 95, 1586-1597.	3.0	140
523	Chemoprevention of Cancer - Focusing on Clinical Trials. Japanese Journal of Clinical Oncology, 2003, 33, 421-442.	0.6	60
524	Affect, Framing, and Persuasion. Journal of Marketing Research, 2003, 40, 54-64.	3.0	131
525	Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ: British Medical Journal, 2003, 327, 703-709.	2.4	105
526	Prophylactic mastectomy: why and when?. The Journal of the British Menopause Society, 2003, 9, 151-155.	1.3	1
527	Translations of risk: Decision making in a cancer genetics service. Health, Risk and Society, 2003, 5, 185-198.	0.9	31
528	Application of Breast Cancer Risk Prediction Models in Clinical Practice. Journal of Clinical Oncology, 2003, 21, 593-601.	0.8	174
529	Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.. Endocrine-Related Cancer, 2003, 10, 347-357.	1.6	21
530	A Training Course for Oncology Nurses in Familial Cancer Risk Assessment: Evaluation of Knowledge and Practice. Journal of Cancer Education, 2003, 18, 20-25.	0.6	10
531	Ductal Lavage for Breast Cancer Risk Assessment. , 2003, 8, 233-239.		1
532	Update on clinical role of tamoxifen. Current Opinion in Obstetrics and Gynecology, 2003, 15, 13-23.	0.9	17
533	HOME CARE AIDES. American Journal of Nursing, 2003, 103, 15.	0.2	0
534	Title is missing!. Annals of Surgery, 2003, 237, 474-482.	2.1	17
535	BREAST CANCER RATES IN BLACK WOMEN. American Journal of Nursing, 2003, 103, 15.	0.2	0
536	HOME CARE AIDES. American Journal of Nursing, 2003, 103, 15.	0.2	0
537	Ductal Lavage for Breast Cancer Risk Assessment. , 2003, 8, 233-239.		0

#	Article	IF	Citations
538	Ductal Lavage in Women at High Risk for Breast Cancer: Advantages and Limitations. Laboratory Medicine, 2003, 34, 842-846.	0.8	0
539	Preventing Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 91-93.	3.0	13
540	HOME CARE AIDES. American Journal of Nursing, 2003, 103, 15.	0.2	0
541	FOREIGN-GRADUATE NURSES. American Journal of Nursing, 2003, 103, 16.	0.2	0
542	STD Transmission Dynamics: Some Current Complexities. Sexually Transmitted Diseases, 2003, 30, 478-482.	0.8	6
543	HOME CARE AIDES. American Journal of Nursing, 2003, 103, 15-16.	0.2	0
544	FOREIGN-GRADUATE NURSES. American Journal of Nursing, 2003, 103, 16.	0.2	0
545	HOSPICE BENEFITS. American Journal of Nursing, 2003, 103, 16.	0.2	1
546	Rating the Risk Factors for Breast Cancer. Annals of Surgery, 2003, 237, 474-482.	2.1	222
547	Personalised risk communication for informed decision making about entering screening programs. , 2003, , CD001865.		44
548	Breast Cancer Risk Assessment: A Guide for Clinicians Using the NCCN Breast Cancer Risk Reduction Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 297-301.	2.3	3
549	Tamoxifen for Prevention of Breast Cancer. Annals of Pharmacotherapy, 2003, 37, 268-273.	0.9	76
550	The Advanced Practice Nursing Role in a High-Risk Breast Cancer Clinic. Oncology Nursing Forum, 2003, 30, 115-122.	0.5	24
551	Reliability and validity of Women's Health Initiative Insomnia Rating Scale.. Psychological Assessment, 2003, 15, 137-148.	1.2	230
553	Cancer Genetics in Primary Care. Journal of Nutrition, 2003, 133, 3767S-3772S.	1.3	8
554	Comprehensive breast cancer screening. Postgraduate Medicine, 2003, 113, 34-46.	0.9	4
555	Women's Perceptions of Breast Cancer Risk: Are They Accurate?. Canadian Journal of Public Health, 2003, 94, 422-426.	1.1	38
556	Chemoprevention of breast cancer. , 2003, , 37-60.		0

#	ARTICLE	IF	CITATIONS
558	The Use of Genetically Altered Mice for Breast Cancer Prevention Studies. Journal of Nutrition, 2003, 133, 2404S-2409S.	1.3	23
560	Progress in Lung Cancer Chemoprevention. Cancer Control, 2003, 10, 315-324.	0.7	17
561	Development of the Breast Cancer Education and Risk Assessment Program. Oncology Nursing Forum, 2003, 30, 803-808.	0.5	14
562	Environmental pollutants and breast cancer.. Environmental Health Perspectives, 2003, 111, 1007-1019.	2.8	235
563	Breast Cancer Risk in Primary Care. Archives of Internal Medicine, 2004, 164, 1897.	4.3	20
565	Raloxifene and its role in breast cancer prevention. Expert Review of Anticancer Therapy, 2004, 4, 523-532.	1.1	11
566	Breast Cancer Genetics. , 2004, , 91-133.		2
567	Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: Effect of ROI size and location. Medical Physics, 2004, 31, 549-555.	1.6	96
568	Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer. Molecular and Cellular Proteomics, 2004, 3, 302-310.	2.5	3
569	An overview of the status of imaging screening technology for breast cancer. Annals of Oncology, 2004, 15, i18-i26.	0.6	58
570	Ductal Lavage and Risk Assessment of Breast Cancer. Oncologist, 2004, 9, 599-605.	1.9	5
571	Risk Factors for Breast Cancer According to Estrogen and Progesterone Receptor Status. Journal of the National Cancer Institute, 2004, 96, 218-228.	3.0	442
572	Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. Journal of Medical Genetics, 2004, 41, 801-807.	1.5	45
573	Risk Estimation for Healthy Women from Breast Cancer Families: New Insights and New Strategies. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 87-93.	1.1	41
574	Constructing â€œHigh-Risk Womenâ€: The Development and Standardization of a Breast Cancer Risk Assessment Tool. Science Technology and Human Values, 2004, 29, 291-313.	1.7	61
575	Unraveling women's perceptions of risk for breast cancer. Health Education Research, 2004, 19, 469-475.	1.0	8
576	The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials. Oncologist, 2004, 9, 116-125.	1.9	36
577	Environmental Pollutants and Breast Cancer. Cancer Investigation, 2004, 22, 474-476.	0.6	0

#	Article	IF	Citations
578	A Single Mathematical Model Predicts Physicians' Recommendations and Postmenopausal Women's Decisions to Participate in a Clinical Trial to Prevent Breast Cancer or Coronary Heart Disease. Medical Decision Making, 2004, 24, 330-350.	1.2	7
579	Psychological Impact of Genetic Counseling for Familial Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2004, 96, 122-133.	3.0	168
580	Model building and quantitative analysis of a tandem immuno-capturing assay as a screening tool for breast cancer. International Journal of Oncology, 2004, 25, 1365-74.	1.4	0
581	Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors. Journal of Clinical Oncology, 2004, 22, 4951-4957.	0.8	134
582	Stroke Risk and Tamoxifen Therapy for Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 1528-1536.	3.0	51
583	Stepped-Care, Community Clinic Interventions to Promote Mammography Use among Low-Income Rural African American Women. Health Education and Behavior, 2004, 31, 29S-44S.	1.3	36
584	Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. British Journal of Rheumatology, 2004, 43, 1178-1181.	2.5	25
585	Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. Journal of Medical Genetics, 2004, 41, 81-91.	1.5	148
586	Recognition and Management of Hereditary Breast Cancer Syndromes. Oncologist, 2004, 9, 13-24.	1.9	96
587	Chemoprevention of Breast Cancer. Clinical Journal of Oncology Nursing, 2004, 8, 421-423.	0.3	1
588	Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results. Annals of Oncology, 2004, 15, 350-353.	0.6	23
589	Social and Dietary Changes Associated with Obesity and Breast Cancer Risk. Journal of Health Management, 2004, 6, 103-114.	0.4	4
590	A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity. Clinical Cancer Research, 2004, 10, 8332-8340.	3.2	10
591	Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Annals of Oncology, 2004, 15, i27-i34.	0.6	16
592	Development and validation study of the breast cancer risk appraisal for Korean women. Australian Journal of Cancer Nursing, 2004, 6, 201-207.	0.8	9
593	Case for blending pedigrees, genograms and ecomaps: Nursing's contribution to the 'big picture'. Australian Journal of Cancer Nursing, 2004, 6, 295-308.	0.8	16
594	Predictors of pessimistic breast cancer risk perceptions in a primary care population. Journal of General Internal Medicine, 2004, 19, 310-315.	1.3	83
595	Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk?. Journal of General Internal Medicine, 2004, 19, 302-309.	1.3	25

#	ARTICLE	IF	CITATIONS
596	The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 2004, 91, 1580-1590.	2.9	411
597	Feasibility of breast duct lavage performed by a physician extender. Surgery, 2004, 136, 1077-1082.	1.0	2
598	Genetic testing for breast and ovarian cancer susceptibility: a family experience. Journal of Midwifery and Women's Health, 2004, 49, 210-219.	0.7	17
599	The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a "free lunch"?. BMC Medical Research Methodology, 2004, 4, 24.	1.4	5
600	Chemoprevention of Cancer. Ca-A Cancer Journal for Clinicians, 2004, 54, 150-180.	157.7	275
601	Identifying and Testing for Hereditary Susceptibility to Common Cancers. Ca-A Cancer Journal for Clinicians, 2004, 54, 309-326.	157.7	39
602	Associations between perceived cancer risk and established risk factors in a national community sample. Cancer Detection and Prevention, 2004, 28, 1-7.	2.1	58
603	Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detection and Prevention, 2004, 28, 357-360.	2.1	35
604	Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy. American Journal of Obstetrics and Gynecology, 2004, 191, 1113-1123.	0.7	55
605	Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer. Breast Cancer Research and Treatment, 2004, 85, 81-88.	1.1	17
606	Failure of High Risk Women to Produce Nipple Aspirate Fluid Does Not Exclude Detection of Cytologic Atypia in Random Periareolar Fine Needle Aspiration Specimens. Breast Cancer Research and Treatment, 2004, 87, 59-64.	1.1	24
607	Risk perceptions and their relation to risk behavior. Annals of Behavioral Medicine, 2004, 27, 125-130.	1.7	621
608	Gail Model Risk Assessment and Risk Perceptions. Journal of Behavioral Medicine, 2004, 27, 205-214.	1.1	25
609	Genetic Cancer Risk Assessment and Counseling: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2004, 13, 83-114.	0.9	227
610	The Decision to Test in Women Receiving Genetic Counseling for BRCA1 and BRCA2 Mutations. Journal of Genetic Counseling, 2004, 13, 237-257.	0.9	24
612	Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Research and Treatment, 2004, 88, 63-73.	1.1	25
613	Radial bone density and breast cancer risk in white and African-American women. Osteoporosis International, 2004, 15, 535-40.	1.3	11
614	Breast cancer risk counseling improves women's functioning. Patient Education and Counseling, 2004, 53, 79-86.	1.0	60

#	ARTICLE	IF	CITATIONS
615	A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 2004, 23, 1111-1130.	0.8	1,052
616	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer, 2004, 100, 479-489.	2.0	77
617	Can the Gail model be useful in American Indian and Alaska Native populations?. Cancer, 2004, 100, 906-912.	2.0	13
618	Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer, 2004, 100, 1800-1806.	2.0	84
619	Breast carcinoma screening and risk perception among women at increased risk for breast carcinoma. Cancer, 2004, 100, 2338-2346.	2.0	24
620	Adequacy evaluation of fine-needle aspiration biopsy in the breast health clinic setting. Cancer, 2004, 102, 295-301.	2.0	17
621	Contralateral prophylactic mastectomy. Cancer, 2004, 101, 1977-1986.	2.0	102
622	Ductal lavage and its histopathologic basis: A cautionary tale. Diagnostic Cytopathology, 2004, 30, 166-171.	0.5	13
623	Cytology of ductal lavage fluid of the breast. Diagnostic Cytopathology, 2004, 30, 143-150.	0.5	29
624	Atypia in the assessment of breast cancer risk: Implications for management. Diagnostic Cytopathology, 2004, 30, 151-157.	0.5	22
625	Genetic epidemiology of cancer: From families to heritable genes. International Journal of Cancer, 2004, 111, 944-950.	2.3	49
626	Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker. American Journal of Epidemiology, 2004, 159, 882-890.	1.6	1,034
627	Prophylactic Bilateral Mastectomy for Breast Cancer Prevention. Journal of Women's Health, 2004, 13, 822-829.	1.5	16
628	Optimism, Perceived Risk of Breast Cancer, and Cancer Worry Among a Community-Based Sample of Women.. Health Psychology, 2004, 23, 339-344.	1.3	48
629	Supplemental screening sonography in dense breasts. Radiologic Clinics of North America, 2004, 42, 845-851.	0.9	132
630	Terapia hormonal sustitutiva. Estado actual de la cuestiÃ³n. Semergen, 2004, 30, 557-563.	0.2	0
631	Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs). Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 97-111.	2.2	6
632	Aromatase inhibitors for chemoprevention. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 113-130.	2.2	41

#	Article	IF	Citations
635	Should Tamoxifen Be Used in Breast Cancer Prevention?. Drug Safety, 2004, 27, 979-989.	1.4	11
636	Strategies for Managing Breast Cancer Risk After the Menopause. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 289-307.	1.8	3
637	Recent translational research: computational studies of breast cancer. Breast Cancer Research, 2004, 7, 37-40.	2.2	5
638	Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Research, 2004, 6, 213-8.	2.2	216
639	Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Research, 2004, 6, 75-81.	2.2	30
640	Cancer genetics in primary care. Primary Care - Clinics in Office Practice, 2004, 31, 649-683.	0.7	8
641	Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Letters, 2004, 210, 197-203.	3.2	55
642	Guidelines for the management of women at increased familial risk of breast cancer. European Journal of Cancer, 2004, 40, 653-665.	1.3	34
643	Comparing breast cancer risk between lesbians and their heterosexual sisters. Women's Health Issues, 2004, 14, 60-68.	0.9	105
644	Prevalence and correlates of repeat mammography among women aged 55â€"79 in the Year 2000 National Health Interview Survey. Preventive Medicine, 2004, 39, 1-10.	1.6	79
645	Impact of benign breast biopsy upon breast self-examination. Preventive Medicine, 2004, 38, 723-731.	1.6	13
646	Increasing the accuracy of perceived breast cancer risk: results from a randomized trial with Cancer Information Service callers. Preventive Medicine, 2004, 39, 64-73.	1.6	21
647	Incorporating predictions of individual patient risk in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 348-352.	0.8	19
648	Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk. Journal of Clinical Epidemiology, 2004, 57, 332-340.	2.4	62
649	Hereditary breast and ovarian cancer syndrome: should we test adolescents?. Journal of Pediatric and Adolescent Gynecology, 2004, 17, 161-167.	0.3	15
650	Cancer Risk Assessment. American Journal of Preventive Medicine, 2004, 27, 239-245.	1.6	67
651	Current comprehensive assessment and management of women at increased risk for breast cancer. American Journal of Surgery, 2004, 187, 349-362.	0.9	44
652	Patient and duct selection for nipple duct lavage. American Journal of Surgery, 2004, 188, 390-394.	0.9	20

#	ARTICLE	IF	CITATIONS
654	Intended Message Versus Message Received in Hypothetical Physician Risk Communications: Exploring the Gap. Risk Analysis, 2004, 24, 1337-1347.	1.5	75
655	Common hereditary cancer syndromes. Seminars in Oncology Nursing, 2004, 20, 164-177.	0.7	7
656	Role of raloxifene in breast cancer prevention in postmenopausal women: Clinical evidence and potential mechanisms of action. Clinical Therapeutics, 2004, 26, 830-840.	1.1	45
657	Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. European Journal of Cancer Prevention, 2004, 13, 183-191.	0.6	38
658	Tamoxifen for Breast Cancer Prevention: A Framework for Clinical Decisions. Obstetrics and Gynecology, 2004, 104, 433-442.	1.2	30
659	Chemoprevention of lung cancer. Current Opinion in Pulmonary Medicine, 2004, 10, 279-283.	1.2	27
660	Determining the Main Risk Factors and High-risk Groups of Breast Cancer Using a Predictive Model for Breast Cancer Risk Assessment in South Korea. Cancer Nursing, 2004, 27, 400???406.	0.7	31
661	Cancer Risk AssessmentQuality and Impact of the Family History Interview. American Journal of Preventive Medicine, 2004, 27, 239-245.	1.6	78
662	Beyond Medical Risk: Investigating the Psychological Factors Underlying Women's Perceptions of Susceptibility to Breast Cancer, Heart Disease, and Osteoporosis.. Health Psychology, 2004, 23, 247-258.	1.3	99
663	Short-term Menopausal Hormone Therapy for Symptom Relief. Archives of Internal Medicine, 2004, 164, 1634.	4.3	31
664	Assessing breast cancer risk. Postgraduate Medicine, 2004, 116, 6-34.	0.9	14
665	Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Annals of Internal Medicine, 2004, 141, 590.	2.0	225
666	The Swedish Family-Cancer Database: Update, Application to Colorectal Cancer and Clinical Relevance. Hereditary Cancer in Clinical Practice, 2005, 3, 7.	0.6	23
667	Patient Perspective on the Value of Genetic Counselling for Familial Pancreas Cancer. Hereditary Cancer in Clinical Practice, 2005, 3, 115-22.	0.6	24
668	Differences in Screening Mammography Outcomes Among White, Chinese, and Filipino Women. Archives of Internal Medicine, 2005, 165, 1862.	4.3	19
670	Prophylactic Mastectomy: Indications, Options, and Reconstructive Alternatives. Plastic and Reconstructive Surgery, 2005, 115, 891-909.	0.7	79
672	Patientsâ€™ interest in discussing cancer risk and risk management with primary care physicians. Patient Education and Counseling, 2005, 57, 77-87.	1.0	20
673	Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Education and Counseling, 2005, 56, 182-191.	1.0	69

#	Article	IF	Citations
674	Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Critical Reviews in Oncology/Hematology, 2005, 53, 225-239.	2.0	25
675	Coping with appraised breast cancer risk among women with family histories of breast cancer. Research in Nursing and Health, 2005, 28, 144-158.	0.8	7
676	Risk Comprehension and Judgments of Statistical Evidentiary Appeals.. Human Communication Research, 2005, 31, 423-452.	1.9	31
677	Race and family history assessment for breast cancer. Journal of General Internal Medicine, 2005, 20, 75-80.	1.3	33
678	Myocardial infarction risk and tamoxifen therapy for breast cancer. British Journal of Cancer, 2005, 92, 1614-1620.	2.9	25
679	Standard Errors for Attributable Risk for Simple and Complex Sample Designs. Biometrics, 2005, 61, 847-855.	0.8	56
680	Screening Mammography. Imaging Decisions (Berlin, Germany), 2005, 9, 23-34.	0.2	1
681	Breast Cancer Risk Communication: Modalities and Effectiveness. Breast Journal, 2005, 11, 527-528.	0.4	2
682	Risk Assessment: Controversies and Management of Moderate- to High-Risk Individuals. Breast Journal, 2005, 11, S11-S19.	0.4	13
683	Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer. Ca-A Cancer Journal for Clinicians, 2005, 55, 145-163.	157.7	36
684	Aromatase Inhibitors for the Treatment and Prevention of Breast Cancer. Clinical Breast Cancer, 2005, 6, 27-37.	1.1	10
685	Evaluation of Hereditary Risk in a Mammography Population. Clinical Breast Cancer, 2005, 6, 38-44.	1.1	23
686	Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer, 2005, 103, 1898-1905.	2.0	355
687	Barriers to minority participation in breast carcinoma prevention trials. Cancer, 2005, 104, 374-379.	2.0	45
688	A Predictive Model for the Development of Hormone-Responsive Breast Cancer. Annals of Surgical Oncology, 2005, 12, 48-56.	0.7	1
689	Expression of steroid receptors in intact rat uterus, mammary gland, and liver treated with selective estrogen receptor modulators and conjugated equine estrogens. Advances in Therapy, 2005, 22, 587-594.	1.3	2
691	Validation of a decision model for preventive pharmacological strategies in postmenopausal women. European Journal of Epidemiology, 2005, 20, 89-101.	2.5	8
692	Breast cancer screening barriers and mammography completion in older minority women. Breast Cancer Research and Treatment, 2005, 89, 111-118.	1.1	47

#	ARTICLE	IF	CITATIONS
693	Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population. Breast Cancer Research and Treatment, 2005, 94, 115-122.	1.1	219
694	How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide. Breast Cancer Research and Treatment, 2005, 94, 153-159.	1.1	16
695	Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer. Breast Cancer Research and Treatment, 2005, 94, 145-152.	1.1	57
696	Identifying target populations for screening or not screening using logic regression. Statistics in Medicine, 2005, 24, 1321-1338.	0.8	19
697	Combining Information From Multiple Data Sources to Create Multivariable Risk Models: Illustration and Preliminary Assessment of a New Method. Journal of Biomedicine and Biotechnology, 2005, 2005, 113-123.	3.0	17
704	Breast Cancer Prevention. , 2005, , 255-276.		5
705	Information and Involvement Preferences of Women in Their 40s Before Their First Screening Mammogram. Archives of Internal Medicine, 2005, 165, 1370.	4.3	21
706	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 2005, 97, 755-765.	3.0	391
707	Facilitating Informed Decision Making about Breast Cancer Risk and Genetic Counseling Among Women Calling the NCI's Cancer Information Service. Journal of Health Communication, 2005, 10, 119-136.	1.2	60
708	Outpatient Genetic Risk Assessment in Women With Breast Cancer: One Center's Experiencetions. Clinical Journal of Oncology Nursing, 2005, 9, 49-53.	0.3	8
709	Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump. Annals of Family Medicine, 2005, 3, 242-247.	0.9	68
710	Breast Cancer Chemoprevention: A Review of Selective Estrogen Receptor Modulators. Clinical Journal of Oncology Nursing, 2005, 9, 317-320.	0.3	5
711	A Population-Based Study of Bilateral Prophylactic Mastectomy Efficacy in Women at Elevated Risk for Breast Cancer in Community Practices. Archives of Internal Medicine, 2005, 165, 516.	4.3	50
712	Breast-tissue sampling for risk assessment and prevention. Endocrine-Related Cancer, 2005, 12, 185-213.	1.6	95
713	Breast Cancer in African–American Women. Oncologist, 2005, 10, 1-14.	1.9	140
714	A Risk Prediction Tool for Melanoma?. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 761-763.	1.1	34
716	Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-term Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1047-1051.	1.1	64
717	Comparing the Standard Rating Scale and the Magnifier Scale for Assessing Risk Perceptions. Medical Decision Making, 2005, 25, 560-570.	1.2	22

#	Article	IF	Citations
718	On criteria for evaluating models of absolute risk. Biostatistics, 2005, 6, 227-239.	0.9	195
719	A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1953-1960.	1.1	139
720	Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 324-328.	1.1	58
721	Excess Deaths Associated With Underweight, Overweight, and Obesity. JAMA - Journal of the American Medical Association, 2005, 293, 1861.	3.8	2,283
722	Endocrine Biomarkers in Ductal Lavage Samples from Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2620-2627.	1.1	22
723	Risk Factors and Individual Probabilities of Melanoma for Whites. Journal of Clinical Oncology, 2005, 23, 2669-2675.	0.8	174
724	Describing Elderly Women in Assisted Living's Risk for Breast Cancer and Participation in Screening Behaviors. Journal of Diagnostic Medical Sonography, 2005, 21, 320-328.	0.1	1
725	Patients' Resistance to Risk Information in Genetic Counseling for BRCA1/2. Archives of Internal Medicine, 2005, 165, 523.	4.3	75
726	Mathematical Models of Ovarian Cancer Incidence. Epidemiology, 2005, 16, 508-515.	1.2	40
727	Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application. Journal of the National Cancer Institute, 2005, 97, 715-723.	3.0	228
728	Multistage Carcinogenesis and Lung Cancer Mortality in Three Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1171-1181.	1.1	100
729	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 439-448.	3.0	539
730	Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut, 2005, 54, 759-763.	6.1	101
731	Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 786-789.	1.1	32
732	Breast Carcinogenesis—Can the Examination of Ductal Fluid Enhance Our Understanding?. Oncology Nursing Forum, 2005, 32, 33-39.	0.5	3
733	Strengths and Limitations of Breast Cancer Risk Assessment. Oncology Nursing Forum, 2005, 32, 605-616.	0.5	7
734	Assessing the Benefit of Radiation Therapy After Breast-Conserving Surgery for Ductal Carcinoma-In-Situ. Journal of Clinical Oncology, 2005, 23, 5171-5177.	0.8	24
735	Prevention of Hormone-Related Cancers: Breast Cancer. Journal of Clinical Oncology, 2005, 23, 357-367.	0.8	64

#	ARTICLE	IF	CITATIONS
736	Do Women in the Community Recognize Hereditary and Sporadic Breast Cancer Risk Factors?. Oncology Nursing Forum, 2005, 32, 617-623.	0.5	20
738	NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 2005, 173, 1518-1525.	0.2	155
739	Computerized Texture Analysis of Mammographic Parenchymal Patterns of Digitized Mammograms1. Academic Radiology, 2005, 12, 863-873.	1.3	103
740	Benign Breast Disease and the Risk of Breast Cancer. New England Journal of Medicine, 2005, 353, 229-237.	13.9	785
741	Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening. New England Journal of Medicine, 2005, 353, 1773-1783.	13.9	1,787
742	Benign Breast Disorders. New England Journal of Medicine, 2005, 353, 275-285.	13.9	268
743	Breast cancer risk perceptions and breast cancer worry: what predicts what?. Journal of Risk Research, 2005, 8, 439-452.	1.4	80
744	Identification of risk factors for prevention and early diagnosis of a-symptomatic post-menopausal women. Maturitas, 2005, 52, 7-22.	1.0	15
745	Karyometry in the early detection and chemoprevention of intraepithelial lesions. European Journal of Cancer, 2005, 41, 1875-1888.	1.3	16
746	Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups. Preventive Medicine, 2005, 41, 720-727.	1.6	17
747	Epidemiology of Breast Cancer. , 2005, , 3-14.		1
748	Prevention of Breast Cancer. , 2005, , 58-73.		0
749	Clinical Assessment of Breast Cancer and Benign Breast Disease. , 2005, , 181-210.		1
750	Genetic Counseling for Patients with Breast Cancer and Their Families. , 2005, , 319-330.		0
751	The Gail model predicts breast cancer in women with suspicious radiographic lesions. American Journal of Surgery, 2005, 190, 526-529.	0.9	8
752	Cohort study of women at risk for breast cancer and gross cystic disease. American Journal of Surgery, 2005, 190, 583-587.	0.9	6
753	The Problems with Risk Selection; Scientific and Psychosocial Aspects. , 2005, 166, 125-144.		4
754	Perceived Risk of Breast Cancer among Women at Average and Increased Risk. Journal of Women's Health, 2005, 14, 845-851.	1.5	73

#	ARTICLE	IF	CITATIONS
755	Ductal lavage for breast cancer risk assessment. Surgical Oncology Clinics of North America, 2005, 14, 45-68.	0.6	3
756	Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. Journal of the National Cancer Institute, 2005, 97, 1428-1437.	3.0	381
757	Prospective health care: the second transformation of medicine. Genome Biology, 2006, 7, 104.	13.9	48
758	Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). Breast Cancer Research, 2006, 8, 111.	2.2	1
759	Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3′-Diindolylmethane. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2477-2481.	1.1	138
761	Prophylactic mastectomy and the clinical management of high-risk breast cancer patients. Community Oncology, 2006, 3, 379-382.	0.2	1
762	Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-Term Prospective Study. Journal of Urology, 2006, 175, 250-251.	0.2	1
764	The Influence of Graphic Format on Breast Cancer Risk Communication. Journal of Health Communication, 2006, 11, 569-582.	1.2	90
765	Effects of Breast Cancer Risk Counseling for Sexual Minority Women. Health Care for Women International, 2006, 27, 59-74.	0.6	30
766	Paternal Relatives and Family History of Breast Cancer. American Journal of Preventive Medicine, 2006, 31, 265-268.	1.6	28
767	Predictors of breast cancer development in a high-risk population. American Journal of Surgery, 2006, 192, 474-477.	0.9	13
768	Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Letters, 2006, 233, 98-107.	3.2	55
769	Optimising endocrine approaches for the chemoprevention of breast cancer. European Journal of Cancer, 2006, 42, 2909-2913.	1.3	40
770	The basal and TRH stimulated levels of prolactin in low risk climacteric patients with increased breast density: A matched pair case control trial. Maturitas, 2006, 54, 103-109.	1.0	1
771	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas, 2006, 55, 103-115.	1.0	214
772	Effects of a telephone counseling intervention on sisters of young women with breast cancer. Preventive Medicine, 2006, 43, 379-384.	1.6	29
774	Chemoprevention of Breast Cancer in Postmenopausal Women. Breast Disease, 2006, 24, 79-92.	0.4	11
775	Prophylaxis and Screening Options: Recommendations for Young Women with BRCA Mutations. Breast Disease, 2006, 23, 31-35.	0.4	15

#	Article	IF	Citations
776	Prescription of Tamoxifen for Breast Cancer Prevention by Primary Care Physicians. Archives of Internal Medicine, 2006, 166, 2260.	4.3	65
778	A path analysis of factors associated with distress among first-degree female relatives of women with breast cancer diagnosis.. Health Psychology, 2006, 25, 413-424.	1.3	9
779	Effects of counseling Ashkenazi Jewish women about breast cancer risk.. Cultural Diversity and Ethnic Minority Psychology, 2006, 12, 45-56.	1.3	18
780	Digital Dermal Patterns in Carcinoma of Breast. Anthropologist, 2006, 8, 251-254.	0.1	3
781	Cancer Risk Assessment: Examining the Family Physician's Role. Journal of the American Board of Family Medicine, 2006, 19, 468-477.	0.8	59
782	Perception of Risk and Surveillance Practices of Women With a Family History of Breast Cancer. Cancer Nursing, 2006, 29, 227-235.	0.7	18
783	Breast Cancer Risk Assessment and Risk Perception on Nurses and Midwives in Bornova Health District in Turkey. Cancer Nursing, 2006, 29, 244-249.	0.7	31
784	Prediction of Pelvic Inflammatory Disease Among Young, Single, Sexually Active Women. Sexually Transmitted Diseases, 2006, 33, 137-142.	0.8	51
785	Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women. BMC Women's Health, 2006, 6, 10.	0.8	9
786	Breast Cancer Risk Assessment and Prevention: A Framework for Shared Decision-Making Consultations. Breast Journal, 2006, 12, 103-113.	0.4	79
787	Follow-Up Recommendations for Benign Breast Biopsies. Breast Journal, 2006, 12, 413-417.	0.4	29
788	Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clinical Genetics, 2006, 69, 171-178.	1.0	26
789	In search of a familial cancer risk assessment tool. Clinical Genetics, 2006, 71, 76-83.	1.0	18
790	The Role of Tamoxifen in Breast Cancer Prevention. Annals of the New York Academy of Sciences, 2001, 949, 99-108.	1.8	36
791	The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits of Selective Estrogen Receptor Modulators for Preventing Breast Cancer. Annals of the New York Academy of Sciences, 2001, 949, 286-291.	1.8	19
792	The Relation Between Projected Breast Cancer Risk, Perceived Cancer Risk, and Mammography Use. Results from the National Health Interview Survey. Journal of General Internal Medicine, 2006, 21, 158-164.	1.3	20
793	Breat cancer risk and provider recommendation for mammography among recently unscreened women in the United States. Journal of General Internal Medicine, 2006, 21, 285-291.	1.3	17
794	Breast cancer screening is risky business. Journal of General Internal Medicine, 2006, 21, 393-394.	1.3	2

#	Article	IF	Citations
795	Can differences in breast cancer utilities explain disparities in breast cancer care?. Journal of General Internal Medicine, 2006, 21, 1253-1260.	1.3	46
796	Selecting targets for cancer prevention: where do we go from here?. Nature Reviews Cancer, 2006, 6, 867-874.	12.8	34
797	Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Modern Pathology, 2006, 19, 622-629.	2.9	25
798	The Royal Marsden Hospital (RMH) Trial. Annals of the New York Academy of Sciences, 2001, 949, 109-112.	1.8	11
799	Preventing and Treating Osteoporosis. Annals of the New York Academy of Sciences, 2001, 949, 188-197.	1.8	21
800	Defining Benefits and Risks for SERMs in Clinical Trials and Clinical Practice. Annals of the New York Academy of Sciences, 2001, 949, 304-314.	1.8	3
801	BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Critical Reviews in Oncology/Hematology, 2006, 57, 1-23.	2.0	54
802	Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Education and Counseling, 2006, 64, 96-103.	1.0	65
803	Recent Results from Clinical Trials Using SERMs to Reduce the Risk of Breast Cancer. Annals of the New York Academy of Sciences, 2006, 1089, 127-142.	1.8	12
804	Decision making in cancer primary prevention and chemoprevention. Annals of Behavioral Medicine, 2006, 32, 179-187.	1.7	19
805	Predicting perceived vulnerability for breast cancer among women with an average breast cancer risk. British Journal of Health Psychology, 2006, 11, 607-621.	1.9	3
806	Psychological Impact of Genetic Counseling for Familial Cancer: A Systematic Review and Meta-Analysis. Familial Cancer, 2006, 5, 61-75.	0.9	91
807	Breast Cancer-Specific Intrusions are Associated with Increased Cortisol Responses to Daily Life Stressors in Healthy Women Without Personal or Family Histories of Breast Cancer. Journal of Behavioral Medicine, 2006, 29, 477-485.	1.1	10
808	Breast cancer risk assessment in the Czech female population – an adjustment of the original Gail model. Breast Cancer Research and Treatment, 2006, 95, 29-35.	1.1	34
809	Breast cancer risk factors and mammographic breast density in women over age 70. Breast Cancer Research and Treatment, 2006, 97, 157-166.	1.1	34
810	Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer. Breast Cancer Research and Treatment, 2006, 97, 191-197.	1.1	25
811	Estrogen Receptor Expression in Benign Breast Ductal Cells Obtained from Random Periareolar Fine Needle Aspiration Correlates with Menopausal Status and Cytomorphology Index Score. Breast Cancer Research and Treatment, 2006, 100, 71-76.	1.1	11
812	Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine, 2006, 84, 16-28.	1.7	149

#	Article	IF	Citations
813	"Hippocrates-mst" a prototype for computer-aided microcalcification analysis and risk assessment for breast cancer. Medical and Biological Engineering and Computing, 2006, 44, 1007-1015.	1.6	9
814	The relation between projected breast cancer risk, perceived cancer risk, and mammography use. Journal of General Internal Medicine, 2006, 21, 158-164.	1.3	34
815	Breast biopsy and race/ethnicity among women without breast cancer. Cancer Detection and Prevention, 2006, 30, 129-133.	2.1	13
816	Best surgical prophylaxis - risk-reducing mastectomy for women at high personal risk of breast cancer. Breast, 2006, 15, S21-S25.	0.9	3
817	Chemoprevention of Breast Cancer for Women at High Risk. Seminars in Oncology, 2006, 33, 642-646.	0.8	23
818	Formative research on adolescent and adult perceptions of risk factors for breast cancer. Social Science and Medicine, 2006, 63, 3124-3136.	1.8	34
819	Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers. Cancer, 2006, 106, 670-682.	2.0	16
820	Latin American Cancer Research Coalition. Cancer, 2006, 107, 2015-2022.	2.0	16
821	Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer, 2006, 107, 1769-1776.	2.0	80
822	Circulating MMP2 and MMP9 in breast cancer-Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. International Journal of Cancer, 2006, 119, 1403-1411.	2.3	127
823	Synchronous, bilateral mastectomy. Journal of Surgical Oncology, 1995, 59, 75-79.	0.8	9
824	Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3941-3946.	1.8	32
825	Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. JAMA - Journal of the American Medical Association, 2006, 295, 2742.	3.8	211
826	Resisting Good News: Reactions to Breast Cancer Risk Communication. Health Communication, 2006, 19, 115-123.	1.8	42
827	Personalised risk communication for informed decision making about taking screening tests. , 2006, , CD001865.		82
828	Retention in a Breast Cancer Risk Information Trial: Motivations of a Population-Based Sample of Women. Health Education and Behavior, 2006, 33, 591-603.	1.3	5
830	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward. Clinical Cancer Research, 2006, 12, 3661-3697.	3.2	263
831	Prospective Breast Cancer Risk Prediction Model for Women Undergoing Screening Mammography. Journal of the National Cancer Institute, 2006, 98, 1204-1214.	3.0	399

#	ARTICLE	IF	CITATIONS
832	Raloxifene and the prevention of breast cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 2301-2307.	0.9	17
833	Breast Cancer Risk Estimates for Relatives of White and African American Women With Breast Cancer in the Women's Contraceptive and Reproductive Experiences Study. Journal of Clinical Oncology, 2006, 24, 2498-2504.	0.8	19
834	Mammographic Density Correlation with Gail Model Breast Cancer Risk Estimates and Component Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1324-1330.	1.1	36
835	Value for the Future and Breast Cancer-Preventive Health Behavior. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 955-960.	1.1	23
836	Breast Cancer Risk Reduction Options: Awareness, Discussion, and Use among Women from Four Ethnic Groups. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 162-166.	1.1	70
837	Gail Model for Prediction of Absolute Risk of Invasive Breast Cancer: Independent Evaluation in the Florenceâ€"European Prospective Investigation Into Cancer and Nutrition Cohort. Journal of the National Cancer Institute, 2006, 98, 1686-1693.	3.0	92
838	Familial Relative Risk Estimates for Use in Epidemiologic Analyses. American Journal of Epidemiology, 2006, 164, 697-705.	1.6	19
839	Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer: Does the Association Vary by a Woman's Predicted Breast Cancer Risk?. Journal of Clinical Oncology, 2006, 24, 1823-1830.	0.8	77
840	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	3.8	1,499
841	Dietary Modification and Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 691.	3.8	7
842	Research translation: a new frontier for clinical laboratories. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1303-12.	1.4	38
843	Breast Cancer Risk and Immune Responses in Healthy Women. Oncology Nursing Forum, 2006, 33, 1151-1159.	0.5	12
844	Cancer Screening and Risk-Reducing Behaviors of Women Seeking Genetic Cancer Risk Assessment for Breast and Ovarian Cancers. Oncology Nursing Forum, 2006, 33, E27-E35.	0.5	14
845	Identifying Individuals at High Risk of Melanoma: A Practical Predictor of Absolute Risk. Journal of Clinical Oncology, 2006, 24, 3590-3596.	0.8	114
846	Measuring Perceptions of Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1893-1898.	1.1	66
847	Atypia and Ki-67 Expression from Ductal Lavage in Women at Different Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1311-1315.	1.1	11
848	Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. Clinical Cancer Research, 2006, 12, 6663-6676.	3.2	219
849	Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk. Clinical Cancer Research, 2006, 12, 5242-5247.	3.2	59

#	ARTICLE	IF	CITATIONS
850	The Risk of Cancer Risk Prediction: â€œWhat Is My Risk of Getting Breast Cancer?â€• Journal of the National Cancer Institute, 2006, 98, 1673-1675.	3.0	37
851	Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000. Journal of the National Cancer Institute Monographs, 2006, 2006, 86-95.	0.9	45
852	Variations in subjective breast cancer risk estimations when using different measurements for assessing breast cancer risk perception. Health, Risk and Society, 2006, 8, 197-210.	0.9	9
853	Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. Journal of Endocrinology, 2006, 191, 599-604.	1.2	6
854	Validation of a Self-Administered, Computerized Tool for Collecting and Displaying the Family History of Cancer. Journal of Clinical Oncology, 2006, 24, 5395-5402.	0.8	57
855	The Epidemiology of Second Primary Cancers. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2020-2026.	1.1	239
856	Risk prediction models for familial breast cancer. Future Oncology, 2006, 2, 257-274.	1.1	78
858	Healthy Women with a Family History of Breast Cancer: Impact of a Tailored Genetic Counseling Intervention on Risk Perception, Knowledge, and Menopausal Therapy Decision Making. Journal of Women's Health, 2006, 15, 843-856.	1.5	47
859	Projecting Absolute Invasive Breast Cancer Risk in White Women With a Model That Includes Mammographic Density. Journal of the National Cancer Institute, 2006, 98, 1215-1226.	3.0	317
860	Assessing Breast Cancer Risk: Evolution of the Gail Model. Journal of the National Cancer Institute, 2006, 98, 1172-1173.	3.0	33
861	Predicting Risk for the Appearance of Melanoma. Journal of Clinical Oncology, 2006, 24, 3522-3523.	0.8	8
862	Atypia and DNA Methylation in Nipple Duct Lavage in Relation to Predicted Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1812-1821.	1.1	31
863	SERMs: Meeting the Promise of Multifunctional Medicines. Journal of the National Cancer Institute, 2007, 99, 350-356.	3.0	104
864	Informed Choice in Mammography Screening. Archives of Internal Medicine, 2007, 167, 2039.	4.3	133
865	Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. Journal of the National Cancer Institute, 2007, 99, 727-737.	3.0	218
866	Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status. Journal of the National Cancer Institute, 2007, 99, 1695-1705.	3.0	117
867	Aromatase Inhibitors for Treatment of Breast Cancer. Current Cancer Therapy Reviews, 2007, 3, 67-79.	0.2	12
868	Evaluation of the Risk of Therapy-Associated Complications in Survivors of Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2007, 2007, 192-196.	0.9	7

#	ARTICLE	IF	CITATIONS
869	Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 45-60.	0.3	38
870	Colonoscopy Screening for Detection of Advanced Neoplasia. New England Journal of Medicine, 2007, 356, 632-634.	13.9	4
871	Breast Cancer and the Risk of Osteoporotic Fracture: A Paradox. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 42-43.	1.8	7
872	Raloxifene: A Selective Estrogen Receptor Modulator for Reducing the Risk of Invasive Breast Cancer in Postmenopausal Women. Women's Health, 2007, 3, 139-153.	0.7	16
873	Preventive Oncology in the Postmenopausal Woman. Women's Health, 2007, 3, 689-697.	0.7	0
874	Cancer genetic risk assessment for individuals at risk of familial breast cancer. , 2007, , CD003721.		24
875	Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2007, 99, 1782-1792.	3.0	284
876	Role of Physical Activity in Modulating Breast Cancer Risk as Defined by APC and RASSF1A Promoter Hypermethylation in Nonmalignant Breast Tissue. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 192-196.	1.1	49
877	Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study. Journal of Clinical Oncology, 2007, 25, 2671-2677.	0.8	226
878	Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax, 2007, 62, 335-340.	2.7	60
879	C-reactive Protein in Nipple Aspirate Fluid Associated With Gail Model Factors. Biological Research for Nursing, 2007, 9, 108-116.	1.0	14
880	Heightened Risk of Breast Cancer Following Pregnancy: Could Lasting Systemic Immune Alterations Contribute?: Figure 1.. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1082-1086.	1.1	25
881	Primary Prevention of Breast Cancer by Hormone-Induced Differentiation. , 2007, 174, 111-130.		39
883	Projecting Individualized Probabilities of Developing Bladder Cancer in White Individuals. Journal of Clinical Oncology, 2007, 25, 4974-4981.	0.8	67
884	PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 1417-1422.	0.8	183
885	Prospective Study of Hyperglycemia and Cancer Risk. Diabetes Care, 2007, 30, 561-567.	4.3	325
886	Analysis of percent density estimates from digital breast tomosynthesis projection images. , 2007, , .		2
887	Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians. Annals of Internal Medicine, 2007, 146, 516.	2.0	187

#	ARTICLE	IF	CITATIONS
888	Assessing Breast Cancer Risk and BRCA1/2 Carrier Probability. Breast Disease, 2007, 27, 5-20.	0.4	20
889	The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 817-822.	2.3	17
890	Screening and Follow-up of the Patient at High Risk for Breast Cancer. Obstetrics and Gynecology, 2007, 110, 1404-1416.	1.2	21
891	Models of Smoking and Lung Cancer Risk. Epidemiology, 2007, 18, 649-651.	1.2	11
892	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. European Journal of Cancer Prevention, 2007, 16, 216-224.	0.6	27
893	Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. European Journal of Cancer Prevention, 2007, 16, 232-242.	0.6	19
894	Menopausal Hormone Therapy. Obstetrics and Gynecology, 2007, 109, 578-580.	1.2	2
895	Analysis of parenchymal texture properties in breast tomosynthesis images. , 2007, , .		7
896	Screening in women 40 to 49 years old. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 16-17.	0.1	0
897	How accurately could we screen for individual risk? Using summary data to examine discriminatory accuracy of a risk marker. Preventive Medicine, 2007, 45, 342-347.	1.6	3
898	Cancer Genetics. Seminars in Oncology Nursing, 2007, 23, 2-9.	0.7	5
899	Population attributable fraction: Its implications for genetic epidemiology and illness prevention. American Heart Journal, 2007, 154, 607-609.	1.2	3
900	eHealth Research from the User's Perspective. American Journal of Preventive Medicine, 2007, 32, S97-S103.	1.6	121
901	Development of a Risk Score for Colorectal Cancer in Men. American Journal of Medicine, 2007, 120, 257-263.	0.6	121
902	The use of ductal lavage as a screening tool in women at high risk for developing breast carcinoma. American Journal of Surgery, 2007, 194, 463-466.	0.9	10
903	Biostatistics and epidemiology: measuring the risk attributable to an environmental or genetic factor. Comptes Rendus - Biologies, 2007, 330, 281-298.	0.1	37
904	BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Letters, 2007, 247, 259-265.	3.2	13
905	BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Letters, 2007, 248, 308-320.	3.2	17

#	Article	IF	Citations
906	Use of biomarkers for breast cancer risk assessment and prevention. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 31-39.	1.2	18
908	Risk and risk assessment for breast cancer: Molecular and clinical aspects. Maturitas, 2007, 57, 56-60.	1.0	18
909	Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Medical Hypotheses, 2007, 68, 756-766.	0.8	52
910	Age-Related Structural and Functional Changes in the Breast: Multimodality Correlation With Digital Mammography, Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography. Seminars in Nuclear Medicine, 2007, 37, 146-153.	2.5	17
911	Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer, 2007, 7, 46-53.	12.8	198
912	1–6 Breast Cancer Risk Estimates for Relatives of White and African American Women With Breast Cancer in the Women's Contraceptive and Reproductive Experiences Study. Breast Diseases, 2007, 18, 32.	0.0	0
913	Evaluation of Mammography Performance in the United States: The Breast Cancer Surveillance Consortium. Seminars in Breast Disease, 2007, 10, 89-101.	0.0	1
914	Mammographic density, breast cancer risk and risk prediction. Breast Cancer Research, 2007, 9, 217.	2.2	270
915	Breast cancer risk-assessment models. Breast Cancer Research, 2007, 9, 213.	2.2	142
916	Fractal Analysis of Mammographic Parenchymal Patterns in Breast Cancer Risk Assessment. Academic Radiology, 2007, 14, 513-521.	1.3	86
917	Estrogen Receptor Modulators and Down Regulators. Drugs, 2007, 67, 2335-2353.	4.9	45
918	A Risk Model for Prediction of Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 715-726.	3.0	362
919	Beyond Standard Mammographic Screening: Mammography at Age Extremes, Ultrasound, and MR Imaging. Radiologic Clinics of North America, 2007, 45, 895-906.	0.9	29
920	Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nature Clinical Practice Oncology, 2007, 4, 415-423.	4.3	76
921	Possible Linkage between the Ability to Change the Period (Ï„) of the Prolactin and Cortisol Rhythms in Women and Breast Cancer Risk. Chronobiology International, 2007, 24, 365-381.	0.9	9
923	Breast Cancer Risk and Screening: A Comparison of Lesbian and Heterosexual Women. Women and Health, 2007, 45, 109-130.	0.4	46
924	Breast Cancer Risk Assessment and Risk Reduction. Surgical Clinics of North America, 2007, 87, 307-316.	0.5	7
925	1–7 Validation of a Tool for Identifying Women at High Risk for Hereditary Breast Cancer in Population-Based Screening. Breast Diseases, 2007, 18, 33.	0.0	0

#	Article	IF	Citations
926	Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine, 2007, 357, 154-162.	13.9	222
927	A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 999-1012.	1.4	39
928	A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Review of Molecular Diagnostics, 2007, 7, 533-544.	1.5	16
930	Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 800-808.	2.3	3
932	Lung cancer risk prediction: A tool for early detection. International Journal of Cancer, 2007, 120, 1-6.	2.3	95
933	The molecular etiology of breast cancer: Evidence from biomarkers of risk. International Journal of Cancer, 2008, 122, 1949-1957.	2.3	113
934	Patient variables that predict atypical cytology by nipple duct lavage. Cancer, 2007, 109, 1247-1254.	2.0	8
935	Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer, 2007, 109, 1940-1948.	2.0	45
936	Disparities in Breast Cancer. Current Problems in Cancer, 2007, 31, 134-156.	1.0	38
937	Decision-making at menopause: A randomized controlled trial of a computer-based hormone therapy decision-aid. Patient Education and Counseling, 2007, 67, 100-107.	1.0	21
938	Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Women's Health, 2007, 7, 6.	0.8	25
939	Estimation of attributable number of deaths and standard errors from simple and complex sampled cohorts. Statistics in Medicine, 2007, 26, 2639-2649.	0.8	24
940	Stress, Breast Cancer Risk, and Breast Self‑Examination: Chronic Effects of Risk and Worry1. Journal of Applied Biobehavioral Research, 2004, 9, 91-105.	2.0	6
941	Diagnostic Accuracy of the Gail Model in the Black Women?s Health Study. Breast Journal, 2007, 13, 329-331.	0.4	1
942	Diagnostic Accuracy of the Gail Model in the Black Women?s Health Study. Breast Journal, 2007, 13, 332-336.	0.4	35
943	American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. Ca-A Cancer Journal for Clinicians, 2007, 57, 75-89.	157.7	2,234
944	Breast Cancer Risk Management. Clinical Breast Cancer, 2007, 7, 833-840.	1.1	15
945	Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast, 2007, 16, 105-113.	0.9	20

#	Article	IF	Citations
946	Breast cancer risk assessment and management in primary care: Provider attitudes, practices, and barriers. Cancer Detection and Prevention, 2007, 31, 375-383.	2.1	92
947	Practical Aspects of Delivering Hereditary Cancer Risk Counseling. Seminars in Oncology, 2007, 34, 369-378.	0.8	26
948	The Prevention of Hereditary Breast Cancer. Seminars in Oncology, 2007, 34, 401-405.	0.8	13
949	Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?. European Radiology, 2007, 17, 873-887.	2.3	112
950	Risk assessment to guide the prevention of cervical cancer. American Journal of Obstetrics and Gynecology, 2007, 197, 356.e1-356.e6.	0.7	140
951	Results of MRI Screening for Breast Cancer in High-Risk Patients with LCIS and Atypical Hyperplasia. Annals of Surgical Oncology, 2007, 14, 1051-1057.	0.7	111
952	Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporosis International, 2007, 18, 629-639.	1.3	78
953	SERMs for the treatment and prevention of breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 229-239.	2.6	72
954	Genetic susceptibility to breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 255-267.	2.6	78
955	Clinical Characterization and Risk Profile of Individuals Seeking Genetic Counseling for Hereditary Breast Cancer in Brazil. Journal of Genetic Counseling, 2007, 16, 363-371.	0.9	22
956	Cancer Family History Reporting: Impact of Method and Psychosocial Factors. Journal of Genetic Counseling, 2007, 16, 373-382.	0.9	21
957	Recommendation Recall and Satisfaction After Attending Breast/Ovarian Cancer Risk Counseling. Journal of Genetic Counseling, 2007, 16, 755-762.	0.9	27
958	The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Research and Treatment, 2007, 101, 95-104.	1.1	18
959	Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Research and Treatment, 2007, 102, 181-188.	1.1	25
960	Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Research and Treatment, 2007, 106, 75-84.	1.1	53
961	Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes and Control, 2007, 18, 439-447.	0.8	48
962	Chemoprevention Strategies 2006. Current Treatment Options in Oncology, 2007, 8, 74-88.	1.3	17
963	Risk assessment models to estimate cancer probabilities. Current Oncology Reports, 2007, 9, 503-508.	1.8	2

#	Article	IF	Citations
964	Missed Opportunities: Family History and Behavioral Risk Factors in Breast Cancer Risk Assessment Among a Multiethnic Group of Women. Journal of General Internal Medicine, 2007, 22, 308-314.	1.3	17
965	Interest in breast cancer chemoprevention among older women. Breast Cancer Research and Treatment, 2008, 108, 435-453.	1.1	16
966	Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Research and Treatment, 2008, 111, 157-163.	1.1	108
967	Reproducibility of ductal lavage cytology and cellularity over a six month interval in high risk women. Breast Cancer Research and Treatment, 2008, 112, 327-333.	1.1	19
968	Physical activity as a negative modulator of estrogen-induced breast cancer. Cancer Causes and Control, 2008, 19, 1021-1029.	0.8	33
969	The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women. Cell and Tissue Banking, 2008, 9, 109-120.	0.5	7
970	Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. Lifetime Data Analysis, 2008, 14, 18-36.	0.4	11
971	Subcutaneous mastectomy and immediate reconstruction for prevention of breast cancer for high-risk patients. Breast Cancer, 2008, 15, 185-191.	1.3	47
972	Making Sense of Cancer Risk Calculators on the Web. Journal of General Internal Medicine, 2008, 23, 229-235.	1.3	25
973	The Trajectory of Psychological Impact in BRCA1/2 Genetic Testing: Does Time Heal?. Annals of Behavioral Medicine, 2008, 36, 107-116.	1.7	76
975	Power Spectral Analysis of Mammographic Parenchymal Patterns for Breast Cancer Risk Assessment. Journal of Digital Imaging, 2008, 21, 145-152.	1.6	51
976	Frequency format diagram and probability chart for breast cancer risk communication: a prospective, randomized trial. BMC Women's Health, 2008, 8, 18.	0.8	23
977	Nonparametric inference on the E/O ratio in model validation. Statistics in Medicine, 2008, 27, 3340-3349.	0.8	2
978	Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psycho-Oncology, 2008, 17, 767-773.	1.0	71
979	Hip bone density predicts breast cancer risk independently of Gail score. Cancer, 2008, 113, 907-915.	2.0	74
980	The power of prediction. Cancer, 2008, 113, 890-892.	2.0	23
981	Communicating side effect risks in a tamoxifen prophylaxis decision aid: The debiasing influence of pictographs. Patient Education and Counseling, 2008, 73, 209-214.	1.0	150
982	DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1051-1059.	1.1	76

#	Article	IF	Citations
984	MRI Screening in a Clinic Population with a Family History of Breast Cancer. Annals of Surgical Oncology, 2008, 15, 452-461.	0.7	28
985	Staging mammography nonadherent women: A qualitative study. Journal of Cancer Education, 2008, 23, 114-21.	0.6	10
986	The LLP risk model: an individual risk prediction model for lung cancer. British Journal of Cancer, 2008, 98, 270-276.	2.9	406
987	Gail Model Risk Factors: Impact of Adding an Extended Family History for Breast Cancer. Breast Journal, 2008, 14, 221-227.	0.4	11
988	Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction. Ca-A Cancer Journal for Clinicians, 2008, 58, 347-371.	157.7	74
989	Perceptions and Management Approaches of Physicians Who Care for Women with Ductal Carcinoma In Situ. Clinical Breast Cancer, 2008, 8, 275-280.	1.1	35
990	Understanding genetic analysis for breast cancer and its implications for plastic surgery. Aesthetic Surgery Journal, 2008, 28, 85-91.	0.9	7
991	Breast Cancer Risk Assessment and Risk Reduction. Apollo Medicine, 2008, 5, 143-149.	0.0	0
992	Assessment of Risk for Breast Cancer Utilizing History & Quantitative Models in Primary Care. Journal for Nurse Practitioners, 2008, 4, 361-369.	0.4	3
993	Current indications and future perspective of fluorescence bronchoscopy: A review study. Photodiagnosis and Photodynamic Therapy, 2008, 5, 238-246.	1.3	31
994	Raloxifene. Drugs, 2008, 68, 2059-2083.	4.9	43
995	The Future of Molecular-Targeted Cancer Chemoprevention. Gastroenterology, 2008, 135, 1834-1841.	0.6	9
996	Methods of Cancer Diagnosis, Therapy and Prognosis. , 2008, , .		23
997	Natural products as inhibitors of carcinogenesis. Expert Opinion on Investigational Drugs, 2008, 17, 1341-1352.	1.9	52
999	Assessing risk for breast cancer. Breast Cancer Research, 2008, 10, S13.	2.2	12
1003	Predicting the Use of Individualized Risk Assessment for Breast Cancer. Women's Health Issues, 2008, 18, 100-109.	0.9	5
1004	Issues in Bilateral Prophylacticâ€ƒMastectomy. Cancer Practice, 2001, 9, 6-10.	0.8	0
1005	Converting evidence to practice: A guide for the clinical application of MRI for the screening and management of breast cancer. European Journal of Cancer, 2008, 44, 2742-2752.	1.3	20

#	Article	IF	Citations
1006	A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer. European Journal of Surgical Oncology, 2008, 34, 149-153.	0.5	14
1008	Effect of oncologist-based counseling on patient-perceived breast cancer risk and psychological distress. Community Oncology, 2008, 5, 108-114.	0.2	1
1009	Second Primary Cancers: An Overview. Hematology/Oncology Clinics of North America, 2008, 22, 271-289.	0.9	60
1010	Breast Disease: Benign and Malignant. Medical Clinics of North America, 2008, 92, 1115-1141.	1.1	21
1011	Age-Related Lobular Involution and Risk of Breast Cancer. Breast Diseases, 2008, 19, 50-51.	0.0	0
1012	Raloxifene: an agent for breast cancer prevention. Expert Review of Obstetrics and Gynecology, 2008, 3, 277-285.	0.4	0
1013	*BRCA1/2* in High-Risk African American Women with Breast Cancer: Providing Genetic Testing through Various Recruitment Strategies. Genetic Testing and Molecular Biomarkers, 2008, 12, 401-407.	1.7	18
1014	Breast Health Behavior Among Lesbians: The Role of Health Beliefs, Heterosexism, and Homophobia. Women and Health, 2008, 48, 409-427.	0.4	34
1015	Chemoprevention of breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 443-452.	1.1	28
1016	Decision Models. Lecture Notes in Computer Science, 2008, , 153-168.	1.0	9
1017	Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes. Journal of Molecular Diagnostics, 2008, 10, 383-395.	1.2	26
1019	Familial Risks for Cancer as the Basis for Evidence-Based Clinical Referral and Counseling. Oncologist, 2008, 13, 239-247.	1.9	40
1020	Theoretical Framework to Study Exercise Motivation for Breast Cancer Risk Reduction. Oncology Nursing Forum, 2008, 35, 89-95.	0.5	22
1021	Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2008, 26, 5374-5379.	0.8	94
1022	Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2008, 15, 485-497.	1.6	228
1023	Breast Cancer Relative Hazard Estimates From Case–Control and Cohort Designs With Missing Data on Mammographic Density. Journal of the American Statistical Association, 2008, 103, 976-988.	1.8	6
1024	Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk. Journal of the National Cancer Institute, 2008, 100, 1037-1041.	3.0	208
1025	Chemoprevention of breast and prostate cancers: where do we stand?. Annals of Oncology, 2008, 19, vii234-vii237.	0.6	8

#	Article	IF	Citations
1026	Chemoprevention of breast cancer. American Journal of Health-System Pharmacy, 2008, 65, 2221-2228.	0.5	31
1027	Lung Cancer Risk Models Come of Age: Fig. 1. Cancer Prevention Research, 2008, 1, 226-228.	0.7	18
1028	Estimating the capacity for improvement in risk prediction with a marker. Biostatistics, 2008, 10, 172-186.	0.9	45
1030	Interviews with primary care physicians regarding taking and interpreting the cancer family history. Family Practice, 2008, 25, 334-340.	0.8	70
1031	Criteria for the Evaluation of Large Cohort Studies: An Application to the Nurses' Health Study. Journal of the National Cancer Institute, 2008, 100, 918-925.	3.0	15
1032	Duration of an Intervention's Impact on Perceived Breast Cancer Risk. Health Education and Behavior, 2008, 35, 855-865.	1.3	6
1034	Validation of Biomarker-Based Risk Prediction Models. Clinical Cancer Research, 2008, 14, 5977-5983.	3.2	163
1035	Localizing the Global. Science Technology and Human Values, 2008, 33, 299-325.	1.7	29
1036	Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1034-1042.	1.1	83
1037	Breast-specific Gamma Imaging as an Adjunct Imaging Modality for the Diagnosis of Breast Cancer. Radiology, 2008, 247, 651-657.	3.6	167
1038	Cellular and hormonal content of breast nipple aspirate fluid in relation to the risk of breast cancer. Biomarkers in Medicine, 2008, 2, 479-493.	0.6	5
1039	Primer: first do no harm—when is it appropriate to plan a cancer prevention clinical trial?. Nature Clinical Practice Oncology, 2008, 5, 348-356.	4.3	5
1040	A Theory of Medical Decision Making and Health: Fuzzy Trace Theory. Medical Decision Making, 2008, 28, 850-865.	1.2	554
1041	Accuracy of Personal Breast Cancer Risk Estimation in Cancer-Free Women During Primary Care Visits. Women and Health, 2008, 47, 113-130.	0.4	5
1042	Encyclopaedia of tumour-associated familial disorders. Part I: from AIMAH to CHIME syndrome. Hereditary Cancer in Clinical Practice, 2008, 6, 22.	0.6	3
1043	Predictors of perceived susceptibility of breast cancer and changes over time: A mixed modeling approach.. Health Psychology, 2008, 27, 68-77.	1.3	33
1044	Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model. Annals of Internal Medicine, 2008, 148, 337.	2.0	450
1045	A Risk Model for Prediction of Lung Cancer. Yearbook of Pulmonary Disease, 2008, 2008, 105-107.	0.4	0

#	Article	IF	Citations
1046	Implications of Systematic Review for Breast Cancer Prediction. Cancer Nursing, 2008, 31, E40-E46.	0.7	5
1047	Percutaneous tissue acquisition: a treatment for breast cancer? Vacuum-assisted biopsy devices are not indicated for extended tissue removal. European Journal of Cancer Prevention, 2008, 17, 323-330.	0.6	9
1048	Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause, 2008, 15, 782-789.	0.8	49
1049	Chemoprevention in postmenopausal women. Menopause, 2008, 15, 810-815.	0.8	8
1050	Risk Assessment to Guide the Prevention of Cervical Cancer. Journal of Lower Genital Tract Disease, 2008, 12, 1-7.	0.9	59
1051	Prophylactic Mastectomy and Reconstruction: Clinical Outcomes and Patient Satisfaction. Plastic and Reconstructive Surgery, 2008, 122, 1-9.	0.7	157
1052	The Role of Magnetic Resonance Imaging in Screening Women at High Risk of Breast Cancer. Topics in Magnetic Resonance Imaging, 2008, 19, 163-169.	0.7	31
1053	Cancer Stem Cells and New Therapeutic Approaches. , 0, , 217-232.		0
1056	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clinical Interventions in Aging, 2008, Volume 3, 601-609.	1.3	4
1057	ESTUDIO POR IMÃGENES EN PACIENTES CON ALTO RIESGO DE CÃNCER MAMARIO. Revista Chilena De Radiologia, 2008, 14, .	0.2	0
1058	CÃNCER HEREDITARIO DE MAMA. Revista Chilena De Radiologia, 2008, 14, .	0.2	0
1059	Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil. Genetics and Molecular Biology, 2009, 32, 447-455.	0.6	17
1060	Urine Biomarkers of Risk in the Molecular Etiology of Breast Cancer. Breast Cancer: Basic and Clinical Research, 2009, 3, BCBCR.S2112.	0.6	51
1063	Perceived Breast Cancer Risk, Social Support, and Distress Among a Community-Based Sample of Women. Journal of Psychosocial Oncology, 2009, 27, 230-247.	0.6	12
1064	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology, 2009, 27, 3235-3258.	0.8	254
1065	Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. New England Journal of Medicine, 2009, 360, 573-587.	13.9	412
1066	Ductal Lavage in Women from *BRCA1/2* Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1243-1251.	1.1	25
1067	Physical Activity, Weight Control, and Breast Cancer Risk and Survival: Clinical Trial Rationale and Design Considerations. Journal of the National Cancer Institute, 2009, 101, 630-643.	3.0	110

#	Article	IF	Citations
1068	Colorectal Cancer Risk Prediction Tool for White Men and Women Without Known Susceptibility. Journal of Clinical Oncology, 2009, 27, 686-693.	0.8	209
1069	Laypersons' Responses to the Communication of Uncertainty Regarding Cancer Risk Estimates. Medical Decision Making, 2009, 29, 391-403.	1.2	69
1070	Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Women's Health Initiative Randomized Trial. Journal of Clinical Oncology, 2009, 27, 6135-6143.	0.8	58
1071	Mammographic Screening and Risk Factors for Breast Cancer. American Journal of Epidemiology, 2009, 170, 1422-1432.	1.6	50
1072	Ductal Lavage Is an Inefficient Method of Biomarker Measurement in High-Risk Women. Cancer Prevention Research, 2009, 2, 265-273.	0.7	14
1073	Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene. Journal of Clinical Oncology, 2009, 27, 5144-5152.	0.8	43
1074	Novel Breast Tissue Feature Strongly Associated With Risk of Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5893-5898.	0.8	44
1075	A Logistic Regression Model Based on the National Mammography Database Format to Aid Breast Cancer Diagnosis. American Journal of Roentgenology, 2009, 192, 1117-1127.	1.0	74
1076	Hormone Replacement Therapy, Family History, and Breast Cancer Risk Among Postmenopausal Women. Epidemiology, 2009, 20, 752-756.	1.2	18
1077	Visual Analytic Methods for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2009, , .		1
1078	Predicting dementia: role of dementia risk indices. Future Neurology, 2009, 4, 555-560.	0.9	24
1080	Breast cancer risk communication: Assessment of primary care physicians by standardized patients. Genetics in Medicine, 2009, 11, 735-741.	1.1	26
1081	Breast Percent Density: Estimation on Digital Mammograms and Central Tomosynthesis Projections. Radiology, 2009, 252, 40-49.	3.6	58
1082	Tailored Supplemental Screening for Breast Cancer: What Now and What Next?. American Journal of Roentgenology, 2009, 192, 390-399.	1.0	158
1083	Reproductive Health as a Sentinel of Chronic Disease in Women. Women's Health, 2009, 5, 101-105.	0.7	32
1084	The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Review of Anticancer Therapy, 2009, 9, 51-60.	1.1	103
1085	Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2009, 27, 1526-1526.	0.8	4
1086	Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts. PLoS Medicine, 2009, 6, e1000201.	3.9	202

#	Article	IF	Citations
1087	American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment. Journal of Clinical Oncology, 2009, 27, 986-993.	0.8	55
1088	Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes: Need for Prospective and Comprehensive Data. Journal of Clinical Oncology, 2009, 27, 1524-1526.	0.8	4
1089	Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. Journal of the National Cancer Institute, 2009, 101, 384-398.	3.0	226
1090	Landmarks in the History of Cancer Epidemiology. Cancer Research, 2009, 69, 2151-2162.	0.4	28
1092	Predicting risk of dementia in older adults. Neurology, 2009, 73, 173-179.	1.5	194
1093	Prevalence of Breast Cancer and Atypia in Patients With High Bone Mineral Density. , 2009, 19, 260-262.		0
1095	Quality of Care Review: Some Progress, and Toward What Goal?. Journal of Clinical Oncology, 2009, 27, 1524-1524.	0.8	5
1096	Diffusion of Breast Cancer Risk Assessment in Primary Care. Journal of the American Board of Family Medicine, 2009, 22, 272-279.	0.8	41
1097	Anchoring-and-Adjustment Bias in Communication of Disease Risk. Medical Decision Making, 2009, 29, 193-201.	1.2	56
1098	Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care. BMC Cancer, 2009, 9, 283.	1.1	61
1099	Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer, 2009, 9, 84.	1.1	111
1100	Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Services Research, 2009, 9, 9.	0.9	81
1101	Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2009, 59, 27-41.	157.7	363
1102	Genetic assessment of breast cancer risk in primary care practice. American Journal of Medical Genetics, Part A, 2009, 149A, 349-356.	0.7	60
1103	Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health Across the Nation. International Journal of Cancer, 2009, 124, 1169-1177.	2.3	44
1104	Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer, 2009, 115, 962-971.	2.0	56
1105	Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. Breast Cancer Research and Treatment, 2009, 115, 381-390.	1.1	88
1106	Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months. Breast Cancer Research and Treatment, 2009, 115, 661-668.	1.1	7

#	Article	IF	Citations
1107	The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Research and Treatment, 2009, 116, 521-527.	1.1	12
1108	Vascular endothelial growth factor and breast cancer risk. Cancer Causes and Control, 2009, 20, 375-386.	0.8	11
1109	Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia. Cancer Causes and Control, 2009, 20, 559-566.	0.8	12
1110	Consistency of self-reported first-degree family history of cancer in a population-based study. Familial Cancer, 2009, 8, 195-202.	0.9	19
1111	Cancer Genetics Service Interest in Women with a Limited Family History of Breast Cancer. Journal of Genetic Counseling, 2009, 18, 339-349.	0.9	11
1112	Breast cancer risk assessment for possible tailored screening for Japanese women. Breast Cancer, 2009, 16, 243-247.	1.3	5
1113	Medical Product Development, Innovation, andÂLife-Cycle Regulation: The Challenges forÂBiostatistics. Statistics in Biosciences, 2009, 1, 1-9.	0.6	1
1114	Refining risk assessment in women with atypical hyperplasia. Current Breast Cancer Reports, 2009, 1, 167-174.	0.5	1
1115	Mammographic density as a marker of breast cancer risk?. Current Breast Cancer Reports, 2009, 1, 175-180.	0.5	0
1116	How to evaluate the calibration of a disease risk prediction tool. Statistics in Medicine, 2009, 28, 901-916.	0.8	44
1117	Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Women's Health, 2009, 9, 20.	0.8	12
1118	Differences in reproductive risk factors for breast cancer in middle-aged women in Marin County, California and a sociodemographically similar area of Northern California. BMC Women's Health, 2009, 9, 6.	0.8	11
1119	Molecular targets for cancer chemoprevention. Nature Reviews Drug Discovery, 2009, 8, 213-225.	21.5	126
1120	Breast cancer risk elements and nurse practitionersâ€™ knowledge, use, and perceived comfort level of breast cancer risk assessment. Journal of the American Academy of Nurse Practitioners, 2009, 21, 270-277.	1.4	25
1121	Estrogen Metabolism and Breast Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 68-75.	1.8	62
1122	Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention. Annals of the New York Academy of Sciences, 2009, 1155, 141-161.	1.8	19
1123	Assessing Breast Cancer Risk and Providing Treatment Recommendations: Immediate Impact of an Educational Session. Breast Journal, 2009, 15, S39-S45.	0.4	5
1124	Breast Cancer Risk Assessments Comparing Gail and CARE Models in African-American Women. Breast Journal, 2009, 15, S72-S75.	0.4	25

#	ARTICLE	IF	CITATIONS
1125	Big gap between risk perception for breast cancer and risk factors: Nationwide survey in Korea. Patient Education and Counseling, 2009, 76, 113-119.	1.0	14
1126	Assessing risk communication in breast cancer: Are continuous measures of patient knowledge better than categorical?. Patient Education and Counseling, 2009, 76, 106-112.	1.0	6
1127	Breast Cancer Risk Factors in Younger and Older Women. Annals of Surgical Oncology, 2009, 16, 96-99.	0.7	15
1128	High Risk Indicators: Microscopic Lesions, Personal and Family History, Assessment, and Management. , 2009, , 1495-1508.		0
1129	Using Lifetime Risk Estimates in Personal Genomic Profiles: Estimation of Uncertainty. American Journal of Human Genetics, 2009, 85, 786-800.	2.6	30
1130	Genetic Issues in Patients with Breast Cancer. Surgical Oncology Clinics of North America, 2009, 18, 53-71.	0.6	5
1131	Projecting the probability of survival free from cancer and cardiovascular incidence through lifestyle modification in Japan. Preventive Medicine, 2009, 48, 128-133.	1.6	8
1132	Perceived risk prior to mammography as an independent predictor of breast cancer. Journal of Psychosomatic Research, 2009, 66, 245-247.	1.2	3
1133	Familial Risk for Common Diseases in Primary Care. American Journal of Preventive Medicine, 2009, 36, 506-514.	1.6	104
1134	Overview of Risk Prediction Models in Cardiovascular Disease Research. Annals of Epidemiology, 2009, 19, 711-717.	0.9	39
1135	Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving Surgery. New England Journal of Medicine, 2009, 360, 63-70.	13.9	113
1136	Can we Do Better? Optimization Models for Breast Cancer Screening. Springer Optimization and Its Applications, 2009, , 1-28.	0.6	4
1137	Beyond Standard Mammographic Screening: Mammography at Age Extremes, Ultrasound, and MR Imaging. Ultrasound Clinics, 2009, 4, 135-147.	0.2	1
1138	Cancer Registry Databases: An Overview of Techniques of Statistical Analysis and Impact on Cancer Epidemiology. Methods in Molecular Biology, 2009, 471, 31-49.	0.4	17
1139	Mammographic density. Breast Cancer Research, 2009, 11, S4.	2.2	38
1140	Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know. Journal of the American Board of Family Medicine, 2009, 22, 43-50.	0.8	23
1141	A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgraduate Medical Journal, 2009, 85, 515-524.	0.9	54
1142	Mammography Screening after Risk-Tailored Messages: The Women Improving Screening through Education and Risk Assessment (WISER) Randomized, Controlled Trial. Journal of Women's Health, 2009, 18, 41-47.	1.5	18

#	ARTICLE	IF	CITATIONS
1143	Approaches to applying breast cancer risk prediction models in clinical practice. Community Oncology, 2009, 6, 373-382.	0.2	6
1144	Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study. Health Expectations, 2009, 12, 4-17.	1.1	48
1145	Estimating the Absolute Risk of Disease Associated with Identified Mutations. , 2009, , 289-305.		0
1146	Gail Model Risk Factors: Impact of Adding an Extended Family History for Breast Cancer. Breast Diseases, 2009, 19, 321-322.	0.0	0
1147	Cancer Risk Assessment for the Primary Care Physician. Primary Care - Clinics in Office Practice, 2009, 36, 471-488.	0.7	6
1148	Phyllodes Tumor of the Breast. Breast Diseases, 2009, 19, 322-323.	0.0	0
1149	Parenchymal Texture Analysis in Digital Breast Tomosynthesis for Breast Cancer Risk Estimation. Academic Radiology, 2009, 16, 283-298.	1.3	71
1150	Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia. Breast Diseases, 2009, 20, 143-144.	0.0	0
1151	Screening and Prevention of Breast Cancer in Primary Care. Primary Care - Clinics in Office Practice, 2009, 36, 533-558.	0.7	24
1152	Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Breast Diseases, 2009, 20, 368-369.	0.0	0
1153	Raloxifene use in clinical practice. Menopause, 2009, 16, 413-421.	0.8	36
1154	Risk Factors and Complications in Reduction Mammaplasty: Novel Associations and Preoperative Assessment. Plastic and Reconstructive Surgery, 2009, 124, 1040-1046.	0.7	55
1155	Breast Cancer Screening and Diagnosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 1060-1096.	2.3	317
1156	Prediction of HIV Acquisition Among Men Who Have Sex With Men. Sexually Transmitted Diseases, 2009, 36, 547-555.	0.8	148
1157	Influence of stressors on breast cancer incidence in the Women's Health Initiative.. Health Psychology, 2009, 28, 137-146.	1.3	79
1158	Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer. Annals of Internal Medicine, 2009, 151, 703.	2.0	80
1159	Estrogen Exposure, Metabolism, and Enzyme Variants in a Model for Breast Cancer Risk Prediction. Cancer Informatics, 2009, 7, CIN.S2262.	0.9	19
1160	Underestimation of Breast Cancer Risk: Influence on Screening Behavior. Oncology Nursing Forum, 2009, 36, 306-314.	0.5	65

#	ARTICLE	IF	CITATIONS
1161	Breast Cancer Chemoprevention: Current Perspectives. Current Enzyme Inhibition, 2009, 5, 198-208.	0.3	2
1162	Breast Cancer in the Personal Genomics Era. Current Genomics, 2010, 11, 146-161.	0.7	70
1163	Objective and Subjective Breast Cancer Risk. Cancer Nursing, 2010, 33, 411-420.	0.7	4
1164	Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. Menopause, 2010, 17, 908-916.	0.8	45
1165	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
1166	Clinical Assessment of Breast Cancer Risk Based on Family History. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1148-1155.	2.3	12
1167	The Background Review for the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 537.	2.0	5
1168	The Background Review for the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 537.	2.0	4
1169	The Background Review for the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 538.	2.0	3
1170	The Background Review for the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 538.	2.0	2
1171	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 540.	2.0	5
1172	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 541.	2.0	4
1173	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 541.	2.0	3
1174	Editors' Note on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 544.	2.0	0
1175	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 539.	2.0	2
1176	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 539.	2.0	2
1177	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 542.	2.0	2
1178	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 543.	2.0	1

#	ARTICLE	IF	CITATIONS
1179	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 540.	2.0	4
1180	Comments and Response on the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 542.	2.0	2
1181	Perceived susceptibility measures are not interchangeable: Absolute, direct comparative, and indirect comparative risk.. Health Psychology, 2010, 29, 20-28.	1.3	40
1182	Breast Cancer Risk Reduction. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1112-1146.	2.3	34
1183	Validation of the Pedigree Assessment Tool (PAT) in Families with BRCA1 and BRCA2 Mutations. Annals of Surgical Oncology, 2010, 17, 240-246.	0.7	19
1184	Use of Breast MRI Surveillance in Women at High Risk for Breast Cancer: A Single-Institutional Experience. Annals of Surgical Oncology, 2010, 17, 263-267.	0.7	115
1185	Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. European Radiology, 2010, 20, 734-742.	2.3	407
1186	Outcomes of Multimodality Breast Screening for Women at Increased Risk of Familial Breast Cancer. World Journal of Surgery, 2010, 34, 979-986.	0.8	11
1187	Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Research and Treatment, 2010, 119, 511-527.	1.1	3
1188	Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?. Breast Cancer Research and Treatment, 2010, 121, 133-141.	1.1	16
1189	Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. Breast Cancer Research and Treatment, 2010, 120, 419-424.	1.1	25
1190	Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. Breast Cancer Research and Treatment, 2010, 120, 425-426.	1.1	2
1191	Womenâ€™s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Research and Treatment, 2010, 119, 613-620.	1.1	83
1192	Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Research and Treatment, 2010, 123, 245-255.	1.1	33
1193	Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Research and Treatment, 2010, 121, 101-110.	1.1	26
1194	Breast Cancer Prevention Trials: Large and Small Trials. Seminars in Oncology, 2010, 37, 367-383.	0.8	18
1195	Cancer Prevention I: Introduction. Seminars in Oncology, 2010, 37, 190-201.	0.8	3
1196	Phase II Cancer Prevention Clinical Trials. Seminars in Oncology, 2010, 37, 359-366.	0.8	3

#	ARTICLE	IF	CITATIONS
1197	Cancer Prevention II: Introduction. Seminars in Oncology, 2010, 37, 321-326.	0.8	1
1198	Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare. Journal for Nurse Practitioners, 2010, 6, 585-594.	0.4	5
1200	Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening. Ca-A Cancer Journal for Clinicians, 2010, 60, 99-119.	157.7	405
1201	Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecologic Oncology, 2010, 118, 202-207.	0.6	39
1202	Breast cancer risk estimation with artificial neural networks revisited. Cancer, 2010, 116, 3310-3321.	2.0	103
1203	Comparative analysis of breast cancer risk factors among hispanic and non‐hispanic white women. Cancer, 2010, 116, 3215-3223.	2.0	41
1204	Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Cancer, 2010, 116, 4944-4953.	2.0	39
1205	Risk prediction using genome‐wide association studies. Genetic Epidemiology, 2010, 34, 643-652.	0.6	116
1206	A nomogram to predict for malignant diagnosis of BI‐RADS category 4 breast lesions. Journal of Surgical Oncology, 2010, 102, 220-224.	0.8	8
1207	Testing whether decision aids introduce cognitive biases: Results of a randomized trial. Patient Education and Counseling, 2010, 80, 158-163.	1.0	47
1208	Prevalence and correlates of recent and repeat mammography among California women ages 55–79. Cancer Epidemiology, 2010, 34, 168-177.	0.8	12
1209	Unwanted effects of risk notification for breast cancer regarding intention toward mammography utilization. Psycho-Oncology, 2010, 19, 823-829.	1.0	2
1210	Assessing risk prediction models in case–control studies using semiparametric and nonparametric methods. Statistics in Medicine, 2010, 29, 1391-1410.	0.8	39
1211	Evaluating health risk models. Statistics in Medicine, 2010, 29, 2438-2452.	0.8	28
1212	Breast Cancer Prevention: Patient Decision Making and Risk Communication in the High Risk Setting. Breast Journal, 2010, 16, 38-47.	0.4	26
1213	Pre‐and posttest evaluation of a breast cancer risk assessment program for nurse practitioners. Journal of the American Academy of Nurse Practitioners, 2010, 22, 376-381.	1.4	6
1214	Optimal two‐stage breast cancer screening for countries with intermediate or low incidence of breast cancer. Journal of Evaluation in Clinical Practice, 2010, 16, 1345-1352.	0.9	1
1215	Age of onset in familial breast cancer as background data for medical surveillance. British Journal of Cancer, 2010, 102, 42-47.	2.9	26

#	Article	IF	Citations
1216	Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. British Journal of Cancer, 2010, 102, 1284-1293.	2.9	82
1217	Comparison of discriminatory power and accuracy of three lung cancer risk models. British Journal of Cancer, 2010, 103, 423-429.	2.9	62
1218	Clinical validity assessment of a breast cancer risk model combining genetic and clinical information. Nature Precedings, 2010, , .	0.1	1
1220	Role of Imaging in Breast Cancer Detection. AAOHN Journal, 2010, 58, 131-134.	0.5	0
1221	Tipping the Balance for the Primary Prevention of Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 1683-1685.	3.0	14
1222	Breast Tissue Composition and Susceptibility to Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 1224-1237.	3.0	378
1223	Effect of Baseline Breast Density on Breast Cancer Incidence, Stage, Mortality, and Screening Parameters: 25-Year Follow-up of a Swedish Mammographic Screening. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1219-1228.	1.1	155
1224	Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. Journal of Clinical Oncology, 2010, 28, 3582-3590.	0.8	182
1225	External Validity of Risk Models: Use of Benchmark Values to Disentangle a Case-Mix Effect From Incorrect Coefficients. American Journal of Epidemiology, 2010, 172, 971-980.	1.6	191
1226	AHRQ White Paper: Use of Clinical Decision Rules for Point-of-Care Decision Support. Medical Decision Making, 2010, 30, 712-721.	1.2	38
1227	Family History, Mammographic Density, and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 456-463.	1.1	88
1228	Five-Year and Lifetime Risk of Breast Cancer among U.S. Subpopulations: Implications for Magnetic Resonance Imaging Screening. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2430-2436.	1.1	29
1229	Reduction in Ki-67 in Benign Breast Tissue of High-Risk Women with the Lignan Secoisolariciresinol Diglycoside. Cancer Prevention Research, 2010, 3, 1342-1350.	0.7	41
1230	Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2010, 28, 3591-3596.	0.8	103
1231	Adherence to a Breast Cancer Screening Program and Its Predictors in Underserved Women in Southern Brazil. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2673-2679.	1.1	24
1232	Effect of Changing Breast Cancer Incidence Rates on the Calibration of the Gail Model. Journal of Clinical Oncology, 2010, 28, 2411-2417.	0.8	34
1233	Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. Journal of the National Cancer Institute, 2010, 102, 680-691.	3.0	413
1234	Genetic and Clinical Predictors for Breast Cancer Risk Assessment and Stratification Among Chinese Women. Journal of the National Cancer Institute, 2010, 102, 972-981.	3.0	90

#	Article	IF	Citations
1235	Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Human Reproduction Update, 2010, 16, 745-760.	5.2	94
1236	Treatment of postmenopausal osteoporosis in a patient with celiac disease. Nature Reviews Endocrinology, 2010, 6, 167-171.	4.3	6
1237	Individualised risk estimation and the nature of prevention. Health, Risk and Society, 2010, 12, 441-452.	0.9	23
1238	Prevención en cáncer. Revista Médica Clínica Las Condes, 2010, 21, 771-778.	0.2	1
1239	Application of Screening Principles to the Reconstructed Breast. Journal of Clinical Oncology, 2010, 28, 173-180.	0.8	55
1240	Effects of a Mail and Telephone Intervention on Breast Health Behaviors. Health Education and Behavior, 2010, 37, 479-489.	1.3	22
1241	Clinical application of breast cancer risk assessment models. Future Oncology, 2010, 6, 355-365.	1.1	11
1242	Ï‰-3 Fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. American Journal of Clinical Nutrition, 2010, 91, 1185-1194.	2.2	81
1243	Independent Association of Lobular Involution and Mammographic Breast Density With Breast Cancer Risk. Journal of the National Cancer Institute, 2010, 102, 1716-1723.	3.0	66
1244	The evolving discipline of molecular epidemiology of cancer. Carcinogenesis, 2010, 31, 127-134.	1.3	42
1245	Delivering on the promise of personalized healthcare. Personalized Medicine, 2010, 7, 327-337.	0.8	12
1246	Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. Journal of the National Cancer Institute, 2010, 102, 26-38.	3.0	182
1247	Carcinoma In Situ Outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Journal of the National Cancer Institute Monographs, 2010, 2010, 181-186.	0.9	15
1248	Effect Size Measures in Genetic Association Studies and Age-Conditional Risk Prediction. Human Heredity, 2010, 70, 205-218.	0.4	10
1249	The Lack, Need, and Opportunities for Decision-Making and Informational Tools to Educate Primary-Care Physicians and Women about Breast Cancer Chemoprevention. Cancer Prevention Research, 2010, 3, 686-688.	0.7	49
1250	Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurology, 2010, 5, 501-517.	0.9	23
1251	Mammographic density as a predictor of breast cancer outcome. Future Oncology, 2010, 6, 351-354.	1.1	10
1252	Effects of Personal Characteristics on African-American Women's Beliefs About Breast Cancer. American Journal of Health Promotion, 2010, 24, 371-377.	0.9	21

#	Article	IF	Citations
1253	Automated estimation of breast density on mammogram using combined information of histogram statistics and boundary gradients. , 2010, , .		4
1254	The special case of complicated grief in women at high risk for breast cancer. Palliative and Supportive Care, 2010, 8, 7-15.	0.6	5
1255	Reasons Women at Elevated Risk of Breast Cancer Refuse Breast MR Imaging Screening: ACRIN 6666. Radiology, 2010, 254, 79-87.	3.6	163
1256	Evaluation of Quantitative IFN-Î³ Response for Risk Stratification of Active Tuberculosis Suspects. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 87-93.	2.5	32
1257	Screening Criteria for Breast Cancer. Advances in Surgery, 2010, 44, 87-100.	0.6	26
1258	Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer. Journal of the American College of Radiology, 2010, 7, 18-27.	0.9	667
1259	The Use of Breast Imaging to Screen Women at High Risk for Cancer. Radiologic Clinics of North America, 2010, 48, 859-878.	0.9	80
1260	Relative Effects of Tamoxifen, Raloxifene, and Conjugated Equine Estrogens on Cognition. Journal of Women's Health, 2010, 19, 371-379.	1.5	26
1261	Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clinic Proceedings, 2010, 85, 1111-1120.	1.4	137
1262	Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities. Recent Results in Cancer Research, 2010, 188, 21-47.	1.8	21
1263	Recent developments in the ability to predict and modify breast cancer risk. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 1581-1587.	0.5	9
1264	Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study. Breast Cancer Research, 2010, 12, R82.	2.2	17
1265	Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information. Journal of the National Cancer Institute, 2010, 102, 1618-1627.	3.0	151
1266	The Timing of Puberty: Is It Changing? Does It Matter?. Journal of Adolescent Health, 2010, 47, 433-439.	1.2	230
1267	Cognitive changes associated with endocrine therapy for breast cancer. Maturitas, 2010, 67, 209-214.	1.0	41
1268	La prÃ©vention des cancers du sein. Medecine Nucleaire, 2010, 34, 3-13.	0.2	4
1270	Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone, 2010, 47, 966-974.	1.4	23
1271	Familial risks of breast and prostate cancers: Does the definition of the at risk period matter?. European Journal of Cancer, 2010, 46, 752-757.	1.3	12

#	ARTICLE	IF	CITATIONS
1272	Living in the Context of Poverty and Trajectories of Breast Cancer Worry, Knowledge, and Perceived Risk after a Breast Cancer Risk Education Session. Women's Health Issues, 2010, 20, 406-413.	0.9	6
1273	Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Dementia risk indices: A framework for identifying individuals with a high dementia risk. Alzheimer's and Dementia, 2010, 6, 138-141.	0.4	37
1275	Handbook on Analyzing Human Genetic Data. , 2010, , .		7
1276	Performance of Common Genetic Variants in Breast-Cancer Risk Models. New England Journal of Medicine, 2010, 362, 986-993.	13.9	376
1277	The Role of Genomics in Enabling Prospective Health Care. , 2010, , 201-208.		1
1278	Update on Screening Breast MRI in High-Risk Women. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 241-247.	0.6	4
1279	Risk factors for breast cancer in postmenopausal Caucasian and Chinese-Canadian women. Breast Cancer Research, 2010, 12, R2.	2.2	12
1280	Statistical methods for assessment of added usefulness of new biomarkers. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1703-1711.	1.4	287
1281	Using ontologies and probabilistic networks to develop a preventive stroke diagnosis system (PSDS). , 2010, , .		3
1282	Translating biomarkers to clinical practice. Molecular Psychiatry, 2011, 16, 1076-1087.	4.1	107
1283	Nonparametric Evaluation of Biomarker Accuracy Under Nested Case-Control Studies. Journal of the American Statistical Association, 2011, 106, 569-580.	1.8	17
1284	Risk Factors for Breast Cancer, Including Occupational Exposures. Safety and Health at Work, 2011, 2, 1-8.	0.3	45
1285	Hormone replacement therapy dependent changes in breast cancer–related gene expression in breast tissue of healthy postmenopausal women. Molecular Oncology, 2011, 5, 504-516.	2.1	7
1286	Endocrine Therapy of Breast Cancer. Current Medicinal Chemistry, 2011, 18, 513-522.	1.2	140
1287	A Preview Study on UWB Imaging System to Detect Early Breast Tumor. Communications in Computer and Information Science, 2011, , 104-115.	0.4	2
1288	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	13.9	847
1290	Update on Screening Breast MRI in High-Risk Women. Obstetrics and Gynecology Clinics of North America, 2011, 38, 149-158.	0.7	10
1291	Chemoprevention – History and general principles. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 445-459.	1.0	44

#	ARTICLE	IF	CITATIONS
1292	A Perturbation Method for Inference on Regularized Regression Estimates. Journal of the American Statistical Association, 2011, 106, 1371-1382.	1.8	70
1293	Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. Journal of Steroid Biochemistry and Molecular Biology, 2011, 125, 169-180.	1.2	126
1294	Strategies for Risk Reduction. , 2011, , 89-103.		0
1295	Preventive therapy for breast cancer: a consensus statement. Lancet Oncology, The, 2011, 12, 496-503.	5.1	196
1296	Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncology, The, 2011, 12, 306-312.	5.1	153
1297	Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Research, 2011, 13, 223.	2.2	485
1298	Urinary rubidium in breast cancers. Clinica Chimica Acta, 2011, 412, 2305-2309.	0.5	25
1299	Magnetic Resonance Imaging and Breast Ultrasonography as an Adjunct to Mammographic Screening in High-Risk Patients. Seminars in Ultrasound, CT and MRI, 2011, 32, 266-272.	0.7	35
1300	Clinical utility of family history for cancer screening and referral in primary care: A report from the Family Healthware Impact Trial. Genetics in Medicine, 2011, 13, 956-965.	1.1	76
1301	Prevalence of the STK15 F31I polymorphism and its relationship with mammographic density. Brazilian Journal of Medical and Biological Research, 2011, 44, 291-296.	0.7	6
1302	The relationship of psychosocial factors to mammograms, physical activity, and fruit and vegetable consumption among sisters of breast cancer patients. International Journal of Women's Health, 2011, 3, 257.	1.1	6
1303	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer: Targets and Therapy, 2011, 3, 127.	1.0	5
1304	Endocrinology of breast cancer: results, tasks and hopes. Expert Review of Endocrinology and Metabolism, 2011, 6, 293-297.	1.2	1
1305	Urban-rural differences in a population-based breast cancer screening program in Croatia. Croatian Medical Journal, 2011, 52, 76-86.	0.2	23
1306	Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011, 13, 853-860.	1.1	19
1307	Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer. European Journal of Cancer Prevention, 2011, 20, 396-402.	0.6	15
1308	Breast cancer risk assessment. Menopause, 2011, 18, 621-624.	0.8	2
1309	Estimated risk of invasive breast cancer in postmenopausal women with and without family history of the disease. Menopause, 2011, 18, 515-520.	0.8	1

#	Article	IF	Citations
1310	Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials. Current Drug Targets, 2011, 12, 1983-1988.	1.0	5
1311	Relationship between breast sound speed and mammographic percent density. , 2011, , .		7
1312	Comparison of Breast Cancer Risk Estimations, Risk Perception, and Screening Behaviors in Obese Rural Korean Women. Oncology Nursing Forum, 2011, 38, E394-E401.	0.5	3
1313	Sonobreast: Predicting Individualized Probabilities of Malignancy in Solid Breast Masses with Echographic Expression. Breast Journal, 2011, 17, 152-159.	0.4	11
1314	Clustering of Strength, Physical Function, Muscle, and Adiposity Characteristics and Risk of Disability in Older Adults. Journal of the American Geriatrics Society, 2011, 59, 781-787.	1.3	66
1315	Increasing cancer mortality among opioid€dependent persons in Australia: a new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health, 2011, 35, 220-225.	0.8	51
1316	The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast, 2011, 20, S1-S11.	0.9	23
1317	Variants of Uncertain Significance in Breast Cancer€"Related Genes: Real-World Implications for a Clinical Conundrum. Part One: Clinical Genetics Recommendations. Seminars in Oncology, 2011, 38, 469-480.	0.8	14
1318	Cancer screening in the United States, 2011. Ca-A Cancer Journal for Clinicians, 2011, 61, 8-30.	157.7	291
1319	Prediction models in cancer care. Ca-A Cancer Journal for Clinicians, 2011, 61, 315-326.	157.7	75
1320	Genetics, genomics, and cancer risk assessment. Ca-A Cancer Journal for Clinicians, 2011, 61, 327-359.	157.7	172
1321	Correlation of Ductal Lavage Cytology with Ductoscopy-Directed Duct Excision Histology in Women at High Risk for Developing Breast Cancer: A Prospective, Single-Institution Trial. Annals of Surgical Oncology, 2011, 18, 3192-3197.	0.7	14
1322	Risk Prediction of Complex Diseases from Family History and Known Susceptibility Loci, with Applications for Cancer Screening. American Journal of Human Genetics, 2011, 88, 548-565.	2.6	80
1323	Correlates of unrealistic risk beliefs in a nationally representative sample. Journal of Behavioral Medicine, 2011, 34, 225-235.	1.1	59
1324	Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. Breast Cancer Research and Treatment, 2011, 127, 479-487.	1.1	15
1325	Women€™s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Research and Treatment, 2011, 127, 681-688.	1.1	69
1326	Breast cancer risk assessment in women aged 70 and older. Breast Cancer Research and Treatment, 2011, 130, 291-299.	1.1	21
1327	The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1053-1060.	1.2	44

#	ARTICLE	IF	CITATIONS
1329	The Distinct Role of Comparative Risk Perceptions in a Breast Cancer Prevention Program. Annals of Behavioral Medicine, 2011, 42, 262-268.	1.7	29
1330	Most Breast Cancer Screening Trials Have a Flawed Design. Indian Journal of Surgery, 2011, 73, 419-422.	0.2	1
1331	Update on Estrogen Receptor–Positive Breast Cancer Risk Reduction. Current Breast Cancer Reports, 2011, 3, 156-164.	0.5	0
1332	Effects of a Web-based intervention on women's breast health behaviors. Translational Behavioral Medicine, 2011, 1, 155-164.	1.2	18
1333	Genome Wide Association Study to predict severe asthma exacerbations in children using random forests classifiers. BMC Medical Genetics, 2011, 12, 90.	2.1	66
1334	Protocol for implementation of family health history collection and decision support into primary care using a computerized family health history system. BMC Health Services Research, 2011, 11, 264.	0.9	50
1335	Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in Medicine, 2011, 30, 11-21.	0.8	1,989
1336	Personalized estimates of breast cancer risk in clinical practice and public health. Statistics in Medicine, 2011, 30, 1090-1104.	0.8	65
1337	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. Statistics in Medicine, 2011, 30, 1410-1418.	0.8	29
1338	The prognostic significance of the insulin–like growth factor–1 ligand and receptor expression in breast cancer tissue. Journal of Surgical Oncology, 2011, 104, 228-235.	0.8	7
1339	Breast cancer prevention based on gene–environment interaction. Molecular Carcinogenesis, 2011, 50, 280-290.	1.3	42
1340	A review of body size and breast cancer risk in Hispanic and African American women. Cancer, 2011, 117, 5271-5281.	2.0	32
1341	Variance computations for functionals of absolute risk estimates. Statistics and Probability Letters, 2011, 81, 807-812.	0.4	4
1342	Risk modeling strategies for pharmacogenetic studies. Pharmacogenomics, 2011, 12, 397-410.	0.6	1
1343	Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention. Current Drug Targets, 2011, 12, 1874-1887.	1.0	18
1344	Estimating Individual Risk for Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 003-009.	0.8	21
1345	Components of family history associated with women's disease perceptions for cancer: A report from the Family Healthware™ Impact Trial. Genetics in Medicine, 2011, 13, 52-62.	1.1	19
1346	Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women. Journal of the National Cancer Institute, 2011, 103, 951-961.	3.0	148

#	ARTICLE	IF	CITATIONS
1347	Problems With Risk Reclassification Methods for Evaluating Prediction Models. American Journal of Epidemiology, 2011, 173, 1327-1335.	1.6	92
1348	Implementation in a Large Health System of a Program to Identify Women at High Risk for Breast Cancer. Journal of Oncology Practice, 2011, 7, 85-88.	2.5	35
1349	Emerging Technologies for Improved Stratification of Cancer Patients. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	6
1350	Lung Cancer Risk Prediction to Select Smokers for Screening CTâ€"a Model Based on the Italian COSMOS Trial. Cancer Prevention Research, 2011, 4, 1778-1789.	0.7	104
1351	Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research, 2011, 4, 311-323.	0.7	46
1352	Use of reclassification for assessment of improved prediction: an empirical evaluation. International Journal of Epidemiology, 2011, 40, 1094-1105.	0.9	57
1353	Tamoxifen, Mammographic Density, and Breast Cancer Prevention. Journal of the National Cancer Institute, 2011, 103, 704-705.	3.0	21
1354	Estrogen Metabolism and Exposure in a Genotypicâ€"Phenotypic Model for Breast Cancer Risk Prediction. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1502-1515.	1.1	26
1355	Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prevention Research, 2011, 4, 1393-1400.	0.7	57
1356	Risk Factor Modification and Projections of Absolute Breast Cancer Risk. Journal of the National Cancer Institute, 2011, 103, 1037-1048.	3.0	81
1357	Oxidative Stress in the Metabolism of Estrogens Leading to Cancer Initiation: Prevention by Specific Antioxidants. ACS Symposium Series, 2011, , 83-98.	0.5	0
1358	Localized Fibroglandular Tissue as a Predictor of Future Tumor Location within the Breast. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1718-1725.	1.1	38
1359	Helping Patients Decide: Ten Steps to Better Risk Communication. Journal of the National Cancer Institute, 2011, 103, 1436-1443.	3.0	460
1360	Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older. Journal of Clinical Oncology, 2011, 29, 2327-2333.	0.8	177
1361	Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers. Journal of the National Cancer Institute, 2011, 103, 562-570.	3.0	88
1362	Confirmation of Family Cancer History Reported in a Population-Based Survey. Journal of the National Cancer Institute, 2011, 103, 788-797.	3.0	91
1363	Reconsidering the Criteria for Evaluating Proposed Screening Programs: Reflections From 4 Current and Former Members of the U.S. Preventive Services Task Force. Epidemiologic Reviews, 2011, 33, 20-35.	1.3	94
1364	Breast Density Influences Tumor Subtypes and Tumor Aggressiveness. Journal of the National Cancer Institute, 2011, 103, 1143-1145.	3.0	15

#	Article	IF	Citations
1365	Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 2. The Women's Health Initiative: estrogen plus progestogen. Journal of Family Planning and Reproductive Health Care, 2011, 37, 165-172.	0.9	46
1366	Performing Breast Cancer Risk Assessments in a Community Setting. Clinical Journal of Oncology Nursing, 2011, 15, 361-364.	0.3	0
1367	Comparison of Family History and SNPs for Predicting Risk of Complex Disease. PLoS Genetics, 2012, 8, e1002973.	1.5	102
1368	Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prevention Research, 2012, 5, 1321-1329.	0.7	23
1369	How Should the Screening Programs be planned for the Early Diagnosis of Breast Cancer. TAF Preventive Medicine Bulletin, 2012, 11, 225.	0.1	1
1370	Detection and management of women at increased risk of breast cancer. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overl	0.1	0
1371	Application of the Rosner-Colditz Risk Prediction Model to Estimate Sexual Orientation Group Disparities in Breast Cancer Risk in a U.S. Cohort of Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2201-2208.	1.1	26
1372	Interpreting Incremental Value of Markers Added to Risk Prediction Models. American Journal of Epidemiology, 2012, 176, 473-481.	1.6	397
1373	Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project. Hypertension, 2012, 59, 802-810.	1.3	210
1374	Risk Prediction Measures for Case-Cohort and Nested Case-Control Designs: An Application to Cardiovascular Disease. American Journal of Epidemiology, 2012, 175, 715-724.	1.6	75
1375	Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. Journal of Medical Genetics, 2012, 49, 601-608.	1.5	58
1376	Perceived and Objective Breast Cancer Risk Assessment in Chilean Women Living in an Underserved Area. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1716-1721.	1.1	14
1377	Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. European Journal of Human Genetics, 2012, 20, 547-551.	1.4	37
1378	Clinical and epidemiological issues in mammographic density. Nature Reviews Clinical Oncology, 2012, 9, 33-40.	12.5	98
1379	Multidisciplinary Considerations in the Management of High-Risk Breast Lesions. American Journal of Roentgenology, 2012, 198, W132-W140.	1.0	77
1380	Increased Breast Cancer Prevalence Among Female Orthopedic Surgeons. Journal of Women's Health, 2012, 21, 683-689.	1.5	79
1381	Estimation of breast percent density in raw and processed full field digital mammography images via adaptive fuzzy câ€means clustering and support vector machine segmentation. Medical Physics, 2012, 39, 4903-4917.	1.6	149
1382	Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials. Cancer Prevention Research, 2012, 5, 583-592.	0.7	93

#	ARTICLE	IF	CITATIONS
1383	Risk Prediction Models: A Framework for Assessment. Public Health Genomics, 2012, 15, 98-105.	0.6	8
1384	Absolute Recidivism Rates Predicted By Static-99R and Static-2002R Sex Offender Risk Assessment Tools Vary Across Samples. Criminal Justice and Behavior, 2012, 39, 1148-1171.	1.1	170
1385	Assessing the Effects of Estrogen on the Dynamics of Breast Cancer. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-14.	0.7	41
1386	Breast Diseases. , 2012, , 369-403.e3.		2
1387	A Multistage Genetic Association Study Identifies Breast Cancer Risk Loci at 10q25 and 16q24. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1565-1573.	1.1	14
1388	Prevalence of Breast Cancer Risk Factors in Japan. Japanese Journal of Clinical Oncology, 2012, 42, 1008-1012.	0.6	15
1390	Communicating risk to patients and the public. British Journal of General Practice, 2012, 62, 213-216.	0.7	69
1391	A retrospective study predicting psychological vulnerability in adult daughters of breast cancer patients.. Families, Systems and Health, 2012, 30, 253-264.	0.4	13
1392	An overview of risk prediction models and the implications for nursing practice. British Journal of Cardiac Nursing, 2012, 7, 259-265.	0.0	1
1393	Risk Calculators. , 2012, , 529-554.		0
1394	Molecular Pathology of the Breast. Surgical Pathology Clinics, 2012, 5, 793-819.	0.7	0
1395	Genetic Determinants of Breast Cancer Risk: A Review of Current Literature and Issues Pertaining to Clinical Application. Breast Journal, 2012, 18, 436-442.	0.4	40
1396	Why are Tailored Messages More Effective? A Multiple Mediation Analysis of a Breast Cancer Screening Intervention. Journal of Communication, 2012, 62, 851-868.	2.1	114
1397	Prevention of breast cancer in the context of a national breast screening programme. Journal of Internal Medicine, 2012, 271, 321-330.	2.7	31
1398	Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Research, 2012, 14, R144.	2.2	95
1399	Computerized Analysis of Mammographic Parenchymal Patterns on a Large Clinical Dataset of Full-Field Digital Mammograms: Robustness Study with Two High-Risk Datasets. Journal of Digital Imaging, 2012, 25, 591-598.	1.6	41
1400	Lifetime risk for cancer death by sex and smoking status: the lifetime risk pooling project. Cancer Causes and Control, 2012, 23, 1729-1737.	0.8	10
1401	Vitamin D Receptor Polymorphisms and Breast Cancer Risk in a High-Incidence Population: A Pilot Study. Journal of the American College of Surgeons, 2012, 215, 652-657.	0.2	29

#	Article	IF	Citations
1402	Fuzzy-probabilistic multi agent system for breast cancer risk assessment and insurance premium assignment. Journal of Biomedical Informatics, 2012, 45, 1021-1034.	2.5	28
1403	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. Breast Diseases, 2012, 23, 226-227.	0.0	0
1404	Breast Cancer Risk Assessment in 64,659 Women at a Single High-Volume Mammography Clinic. Academic Radiology, 2012, 19, 95-99.	1.3	28
1405	Breast cancer screening in high risk populations. Radiologia, 2012, 54, 490-502.	0.3	4
1406	Challenges to building a platform for a breast cancer risk score. , 2012, , .		3
1407	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. Cancer Prevention Research, 2012, 5, 943-951.	0.7	104
1408	Aromatase inhibitors and breast cancer prevention. Expert Opinion on Pharmacotherapy, 2012, 13, 325-331.	0.9	26
1409	Chemoprevention of Breast Cancer. Women's Health, 2012, 8, 635-646.	0.7	6
1410	Familial breast cancer: less emotional distress in adult daughters if they provide emotional support to their affected mother. Familial Cancer, 2012, 11, 645-652.	0.9	10
1411	A Clinical Risk Prediction Model for Barrett Esophagus. Cancer Prevention Research, 2012, 5, 1115-1123.	0.7	67
1412	Genetics for the General Internist. American Journal of Medicine, 2012, 125, 7-13.	0.6	6
1413	Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 73-79.	1.2	41
1414	Probability of fractures predicted by FRAXÂ® and observed incidence in the Spanish ECOSAP Study cohort. Bone, 2012, 50, 373-377.	1.4	76
1415	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treatment Reviews, 2012, 38, 318-328.	3.4	77
1416	Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study. BMC Cancer, 2012, 12, 299.	1.1	9
1417	Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	18
1418	The changes in female physical and childbearing characteristics in china and potential association with risk of breast cancer. BMC Public Health, 2012, 12, 368.	1.2	29
1420	Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade. British Journal of Radiology, 2012, 85, e212-e216.	1.0	42

#	Article	IF	Citations
1421	Biomarkers in the diagnosis of primary and recurrent breast cancer. Biomarkers in Medicine, 2012, 6, 567-585.	0.6	25
1422	Cancer risk models and preselection for screening. Cancer Epidemiology, 2012, 36, 461-469.	0.8	8
1423	Selecting families eligible for pancreatic cancer screening: Another brick in the wall for the early detection of pancreatic ductal adenocarcinoma and its precursors. Digestive and Liver Disease, 2012, 44, 539-540.	0.4	1
1424	Unlocking the value of personalised healthcare in Europe—breast cancer stratification. Health Policy and Technology, 2012, 1, 63-68.	1.3	8
1426	Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). Oncology Reports, 2012, 28, 418-428.	1.2	36
1427	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine, 2012, 14, 633-642.	1.1	36
1428	Genetic Polymorphisms as Predictors of Breast Cancer Risk. Current Breast Cancer Reports, 2012, 4, 232-239.	0.5	1
1429	La prévention des cancers du sein. Imagerie De La Femme, 2012, 22, 18-29.	0.0	1
1431	Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European Spine Journal, 2012, 21, 2407-2417.	1.0	7
1432	Nutritional Epidemiology of Breast Cancer. , 2012, , .		4
1433	Cancer Epigenetics. Methods in Molecular Biology, 2012, , .	0.4	5
1434	The Changes They are A-Timed: Metabolism, Endogenous Clocks, and the Timing of Puberty. Frontiers in Endocrinology, 2012, 3, 45.	1.5	19
1435	Individual Breast Cancer Risk Assessment in Underserved Populations: Integrating Empirical Bioethics and Health Disparities Research. Journal of Health Care for the Poor and Underserved, 2012, 23, 34-46.	0.4	14
1436	Cancer du sein et tamoxifène: la gestion d'une incertitude thérapeutique. Sciences Sociales Et Sante, 2012, 30, 73-83.	0.0	0
1437	Understanding how decisions influence health. , 0, , 26-73.		0
1438	DNA Damage Response and Breast Cancer: An Overview. , 0, , .		0
1439	Prevalence of ERα-397 PvuII C/T, ERα-351 XbaI A/G and PGR PROGINS polymorphisms in Brazilian breast cancer-unaffected women. Brazilian Journal of Medical and Biological Research, 2012, 45, 891-897.	0.7	5
1440	Estimation of the Relative Risk for Breast Cancer in Korean Women Using Gail Model. The Journal of Korean Society of Menopause, 2012, 18, 180.	0.6	3

#	Article	IF	Citations
1441	GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening. Revista Brasileira De Epidemiologia, 2012, 15, 246-255.	0.3	20
1442	Enriched designs for assessing discriminatory performance â€" analysis of bias and variance. Statistics in Medicine, 2012, 31, 501-515.	0.8	7
1443	Using multiple risk models with preventive interventions. Statistics in Medicine, 2012, 31, 2687-2696.	0.8	4
1444	TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. Laryngoscope, 2012, 122, 1043-1050.	1.1	25
1445	Breast Cancer Chemoprevention: Current Approachesand Future Directions. Current Obstetrics and Gynecology Reports, 2012, 1, 33-41.	0.3	1
1446	Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Research and Treatment, 2012, 134, 299-306.	1.1	44
1447	Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study. Breast Cancer Research and Treatment, 2012, 134, 839-851.	1.1	7
1448	Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2012, 21, 151-161.	0.9	287
1449	The Effect of Imaging on the Clinical Management of Breast Pain. Journal of General Internal Medicine, 2012, 27, 817-824.	1.3	32
1450	Breast Cancer and Fertility. Current Treatment Options in Oncology, 2012, 13, 137-145.	1.3	24
1451	Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Medical Oncology, 2012, 29, 1308-1313.	1.2	17
1452	Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Research and Treatment, 2012, 133, 169-177.	1.1	64
1453	A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Research and Treatment, 2012, 132, 365-377.	1.1	146
1454	Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Research and Treatment, 2012, 133, 1-10.	1.1	106
1455	Inclusion of Gene-Gene and Gene-Environment Interactions Unlikely to Dramatically Improve Risk Prediction for Complex Diseases. American Journal of Human Genetics, 2012, 90, 962-972.	2.6	96
1456	Implementation and Outcomes of a Multidisciplinary High-Risk Breast Cancer Program: The William Beaumont Hospital Experience. Clinical Breast Cancer, 2012, 12, 215-218.	1.1	9
1457	Effect of Pregnancy and Obesity on Arch of Foot. Orthopaedic Surgery, 2012, 4, 101-104.	0.7	10
1458	Cancer screening in the United States, 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 129-142.	157.7	123

#	Article	IF	Citations
1459	Familial Breast Cancer. Clinical Genetics, 2012, 82, 105-114.	1.0	147
1460	Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate. BMC Medical Research Methodology, 2012, 12, 25.	1.4	10
1461	Expanding the perspective of translational medicine: the value of observational data. Journal of Translational Medicine, 2012, 10, 61.	1.8	11
1462	A breast cancer prediction model incorporating familial and personal risk factors. Hereditary Cancer in Clinical Practice, 2012, 10, .	0.6	3
1463	Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Research, 2012, 14, R19.	2.2	40
1464	Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Research, 2012, 14, R25.	2.2	108
1465	Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Research, 2012, 14, R32.	2.2	43
1466	Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers. Annals of Surgical Oncology, 2012, 19, 1732-1737.	0.7	96
1467	Genetic susceptibility to pancreatic cancer. Molecular Carcinogenesis, 2012, 51, 14-24.	1.3	192
1468	Updating risk prediction tools: A case study in prostate cancer. Biometrical Journal, 2012, 54, 127-142.	0.6	26
1469	Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Research and Treatment, 2012, 131, 267-275.	1.1	72
1470	Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Research and Treatment, 2012, 132, 347-353.	1.1	27
1471	Evaluating incremental values from new predictors with net reclassification improvement in survival analysis. Lifetime Data Analysis, 2013, 19, 350-370.	0.4	14
1472	Estimating improvement in prediction with matched case–control designs. Lifetime Data Analysis, 2013, 19, 170-201.	0.4	6
1474	Beyond Mammography: New Frontiers in Breast Cancer Screening. American Journal of Medicine, 2013, 126, 472-479.	0.6	167
1475	Statins and Breast Cancer: Future Directions in Chemoprevention. Current Breast Cancer Reports, 2013, 5, 161-169.	0.5	14
1476	Enabling the use of hereditary information from pedigree tools in medical knowledge-based systems. Journal of Biomedical Informatics, 2013, 46, 710-720.	2.5	3
1477	Mammographic Density: Potential as a Risk Factor and Surrogate Marker in the Clinical Setting. Current Breast Cancer Reports, 2013, 5, 183-193.	0.5	6

#	ARTICLE	IF	CITATIONS
1478	Risk-Reducing Mastectomy: Who Is a Candidate and What Are the Outcomes?. Current Breast Cancer Reports, 2013, 5, 73-85.	0.5	0
1479	State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports, 2013, 5, 125-133.	0.5	0
1480	Genetic Counseling and Clinical Risk Assessment. , 2013, , 1-40.		0
1481	Cancer of the Breast and Female Reproductive Tract. , 2013, , 1-31.		1
1482	Personalised risk communication for informed decision making about taking screening tests. The Cochrane Library, 2013, , CD001865.	1.5	180
1483	Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women's Health Initiative observational study. Breast Cancer Research and Treatment, 2013, 139, 821-831.	1.1	3
1484	Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. Breast Cancer Research and Treatment, 2013, 139, 887-896.	1.1	33
1485	Communicating Genetic Risk Information for Common Disorders in the Era of Genomic Medicine. Annual Review of Genomics and Human Genetics, 2013, 14, 491-513.	2.5	135
1486	Cancer Prevention for the Next Generation. Journal of Adolescent Health, 2013, 52, S1-S7.	1.2	41
1487	A Model to Determine Absolute Risk for Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, 138-144.e2.	2.4	68
1488	Breast Magnetic Resonance Imaging for Screening High-Risk Women. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 509-517.	0.6	21
1489	Breast Cancer Risk Assessment, Prevention, and the Future. Obstetrics and Gynecology Clinics of North America, 2013, 40, 525-549.	0.7	9
1490	Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Research and Treatment, 2013, 138, 611-619.	1.1	7
1491	Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 1043-1049.	3.0	99
1492	Risk Factors of Breast Cancer. Asia-Pacific Journal of Public Health, 2013, 25, 368-387.	0.4	135
1493	Family History and Health Risk Assessment. , 2013, , 306-323.		1
1494	DNA promoter hypermethylation profiles in breast duct fluid. Breast Cancer Research and Treatment, 2013, 139, 341-350.	1.1	15
1496	Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Research and Treatment, 2013, 138, 889-898.	1.1	9

#	ARTICLE	IF	CITATIONS
1497	Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case–control study in Japanese women. BMC Cancer, 2013, 13, 565.	1.1	37
1498	An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain. BMC Cancer, 2013, 13, 587.	1.1	8
1499	Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Research, 2013, 15, R74.	2.2	37
1500	Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Research and Treatment, 2013, 142, 187-202.	1.1	45
1501	A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder. Biological Psychiatry, 2013, 74, 7-14.	0.7	142
1502	Impact of correlation on predictive ability of biomarkers. Statistics in Medicine, 2013, 32, 4196-4210.	0.8	17
1503	Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. British Journal of Cancer, 2013, 109, 1296-1301.	2.9	44
1504	Breast cancer anxiety's associations with responses to a chemoprevention decision aid. Social Science and Medicine, 2013, 77, 13-19.	1.8	21
1505	Self-reported family history of leiomyoma: not a reliable marker of high risk. Annals of Epidemiology, 2013, 23, 286-290.	0.9	6
1506	Validation, calibration and refitting of a familial breast cancer model in sisterships: a case study in the Swedish sisters data. Statistics in Medicine, 2013, 32, 3486-3500.	0.8	1
1507	Structural equation modeling for implementation intentions, cancer worry, and stages of mammography adoption. Psycho-Oncology, 2013, 22, 2339-2346.	1.0	21
1508	Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Research, 2013, 15, 212.	2.2	52
1509	Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Aging, Neuropsychology, and Cognition, 2013, 20, 532-552.	0.7	30
1510	Carcinogenesis alters fatty acid profile in breast tissue. Molecular and Cellular Biochemistry, 2013, 374, 223-232.	1.4	42
1511	Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design. Journal of Statistical Planning and Inference, 2013, 143, 368-377.	0.4	0
1512	Identifying people at a high risk of developing pancreatic cancer. Nature Reviews Cancer, 2013, 13, 66-74.	12.8	127
1513	Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Research and Treatment, 2013, 137, 883-892.	1.1	151
1514	Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2013, 137, 915-925.	1.1	14

#	ARTICLE	IF	CITATIONS
1515	Reader Variability in Breast Density Estimation from Full-Field Digital Mammograms. Academic Radiology, 2013, 20, 560-568.	1.3	25
1517	Breast cancer detection risk in screening mammography after a false-positive result. Cancer Epidemiology, 2013, 37, 85-90.	0.8	24
1518	Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer Among Premenopausal Women. Breast Diseases, 2013, 24, 34-35.	0.0	0
1519	Hereditary Breast/Ovarian Cancer Syndrome. Obstetrics and Gynecology Clinics of North America, 2013, 40, 475-512.	0.7	11
1520	Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts. Clinical Imaging, 2013, 37, 480-486.	0.8	127
1521	Estimated risks and optimistic self-perception of breast cancer risk in Korean women. Applied Nursing Research, 2013, 26, 180-185.	1.0	11
1522	Classification System for Identifying Women at Risk for Altered Partial Breast Irradiation Recommendations After Breast Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2013, 87, 127-133.	0.4	4
1523	Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer. Journal of Clinical Oncology, 2013, 31, 119-127.	0.8	47
1524	Correlation of Age and HRT Use with Breast Density as Assessed by Quantra™. Breast Journal, 2013, 19, 79-86.	0.4	27
1525	Mammographic Density and Estimation of Breast Cancer Risk in Intermediate Risk Population. Breast Journal, 2013, 19, 71-78.	0.4	15
1526	Cancer screening in the United States, 2013. Ca-A Cancer Journal for Clinicians, 2013, 63, 87-105.	157.7	249
1527	Ductal Carcinoma in Situ. Surgical Clinics of North America, 2013, 93, 393-410.	0.5	17
1528	NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling, 2013, 22, 155-163.	0.9	124
1529	Assessing risk in chronic kidney disease: a methodological review. Nature Reviews Nephrology, 2013, 9, 18-25.	4.1	27
1530	Can we really predict risk of cancer?. Cancer Epidemiology, 2013, 37, 349-352.	0.8	21
1531	Breast Cancer Risk Prediction and Mammography Biopsy Decisions. American Journal of Preventive Medicine, 2013, 44, 15-22.	1.6	13
1532	Can the Gail model increase the predictive value of a positive mammogram in a European population screening setting? Results from a Spanish cohort. Breast, 2013, 22, 83-88.	0.9	7
1533	Hereditary cancer risk assessment: essential tools for a better approach. Hereditary Cancer in Clinical Practice, 2013, 11, 16.	0.6	8

#	Article	IF	Citations
1534	Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Research and Treatment, 2013, 138, 249-259.	1.1	23
1535	Ways of Regulating Drugs in the 19th and 20th Centuries. , 2013, , .		19
1536	Texture feature standardization in digital mammography for improving generalizability across devices. Proceedings of SPIE, 2013, , .	0.8	1
1537	Tailored Breast Cancer Screening Program with Microdose Mammography, US, and MR Imaging: Short-term Results of a Pilot Study in 40â€"49-Year-Old Women. Radiology, 2013, 268, 347-355.	3.6	26
1538	Breast density measurements with ultrasound tomography: A comparison with film and digital mammography. Medical Physics, 2013, 40, 013501.	1.6	54
1539	Optimal Policies for Reducing Unnecessary Follow-Up Mammography Exams in Breast Cancer Diagnosis. Decision Analysis, 2013, 10, 200-224.	1.2	32
1540	Multiple Bilateral Circumscribed Masses at Screening Breast US: Consider Annual Follow-up. Radiology, 2013, 268, 673-683.	3.6	56
1541	A focus group study on breast cancer risk presentation: one format does not fit all. European Journal of Human Genetics, 2013, 21, 719-724.	1.4	17
1542	Differences in breast density assessment using mammography, tomosynthesis and MRI and their implications for practice. British Journal of Radiology, 2013, 86, 20130528.	1.0	6
1543	FACTORS AFFECTING BREAST CANCER RISK PERCEPTION IN WOMEN AND COMPARISON OF RISK LEVELS TO THE GAIL MODEL. The Journal of Breast Health, 2013, 9, 156-162.	0.4	3
1544	Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies. PLoS Medicine, 2013, 10, e1001492.	3.9	142
1546	Taking Stock of Unrealistic Optimism. Perspectives on Psychological Science, 2013, 8, 395-411.	5.2	247
1547	Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease. Menopause, 2013, 20, 852-859.	0.8	5
1548	Potential breast cancer risk factors among Saudi women aged 19â€"50 years in Jeddah. Journal of the Egyptian Public Health Association, The, 2013, 88, 165-170.	1.0	3
1549	Assessment of Autoantibodies to Meningioma in a Population-based Study. American Journal of Epidemiology, 2013, 177, 75-83.	1.6	10
1550	Breast Cancer. JAMA Surgery, 2013, 148, 971.	2.2	138
1551	Making sense of personal health information: Challenges for information visualization. Health Informatics Journal, 2013, 19, 198-217.	1.1	55
1552	Liu et al. Respond to "Epstein-Barr Virus Screening for Nasopharyngeal Carcinoma". American Journal of Epidemiology, 2013, 177, 254-255.	1.6	0

#	ARTICLE	IF	CITATIONS
1553	Breast MRI Use Uncommon among U.S. Women. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 159-166.	1.1	14
1554	Cost-effectiveness of a Genetic Test for Breast Cancer Risk. Cancer Prevention Research, 2013, 6, 1328-1336.	0.7	9
1556	Risk Factors for Second Screen-Detected or Interval Breast Cancers in Women with a Personal History of Breast Cancer Participating in Mammography Screening. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 946-961.	1.1	49
1557	Inflammatory Cytokine Levels and Breast Cancer Risk Factors: Racial Differences of Healthy Caucasian and African American Women. Oncology Nursing Forum, 2013, 40, 490-500.	0.5	37
1558	National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities. Clinical Trials, 2013, 10, 280-291.	0.7	21
1559	Lipid Metabolism Genes in Contralateral Unaffected Breast and Estrogen Receptor Status of Breast Cancer. Cancer Prevention Research, 2013, 6, 321-330.	0.7	40
1560	Assessing the Breast Cancer Risk Distribution for Women Undergoing Screening in British Columbia. Cancer Prevention Research, 2013, 6, 1084-1092.	0.7	11
1561	Validation of a Breast Cancer Risk Prediction Model Developed for Black Women. Journal of the National Cancer Institute, 2013, 105, 361-367.	3.0	13
1562	Mortality Risk Score Prediction in an Elderly Population Using Machine Learning. American Journal of Epidemiology, 2013, 177, 443-452.	1.6	156
1563	Web‐based self‐monitoring for weight loss among overweight/obese women at increased risk for breast cancer: the HELP pilot study. Psycho-Oncology, 2013, 22, 1821-1828.	1.0	28
1564	The risk of developing invasive breast cancer in Hispanic women. Cancer, 2013, 119, 1373-1380.	2.0	18
1565	Variants of uncertain significance in <i><scp>BRCA</scp></i> testing: evaluation of surgical decisions, risk perception, and cancer distress. Clinical Genetics, 2013, 84, 464-472.	1.0	88
1566	Breast Cancer Screening Preferences Among Hospitalized Women. Journal of Women's Health, 2013, 22, 637-642.	1.5	17
1567	Testing for improvement in prediction model performance. Statistics in Medicine, 2013, 32, 1467-1482.	0.8	191
1568	Suitable trial designs and cohorts for preventive breast cancer agents. Nature Reviews Clinical Oncology, 2013, 10, 677-687.	12.5	5
1569	Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies. Journal of Family Planning and Reproductive Health Care, 2013, 39, 80-88.	0.9	25
1570	Breast Cancer Among Nurses: Is the Intensity of Night Work Related to Hormone Receptor Status?. American Journal of Epidemiology, 2013, 178, 110-117.	1.6	24
1571	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2013, 31, 2942-2962.	0.8	279

#	ARTICLE	IF	CITATIONS
1572	Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2013, 158, 604.	2.0	150
1574	ENDOCRINE PREVENTION OF BREAST CANCER. , 2013, , 361-390.		0
1575	Epidemiology and Long-term Clinical and Biologic Risk Factors for Pneumonia in Community-Dwelling Older Americans. Chest, 2013, 144, 1008-1017.	0.4	40
1576	Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. Genetical Research, 2013, 95, 174-177.	0.3	17
1577	Epidemiology of Lung Cancer. Chest, 2013, 143, e1S-e29S.	0.4	559
1578	Breast cancer risk scores in a standard screening population. Breast Cancer Management, 2013, 2, 463-479.	0.2	5
1579	The genomic medicine model: an integrated approach to implementation of family health history in primary care. Personalized Medicine, 2013, 10, 295-306.	0.8	22
1580	Cancer Genetic Counselor Information Needs for Risk Communication: A Qualitative Evaluation of Interview Transcripts. Journal of Personalized Medicine, 2013, 3, 238-250.	1.1	5
1581	Development and Validation of a Risk Score Predicting Substantial Weight Gain over 5 Years in Middle-Aged European Men and Women. PLoS ONE, 2013, 8, e67429.	1.1	17
1582	HORMONE REPLACEMENT THERAPY AND WOMEN'S HEALTH. , 2013, , 81-109.		0
1583	Pathogenesis, prevention, diagnosis and treatment of breast cancer. World Journal of Clinical Oncology, 2014, 5, 283.	0.9	184
1584	Boosting the Concordance Index for Survival Data â€" A Unified Framework To Derive and Evaluate Biomarker Combinations. PLoS ONE, 2014, 9, e84483.	1.1	84
1585	Impact of Risk Factors on Different Interval Cancer Subtypes in a Population-Based Breast Cancer Screening Programme. PLoS ONE, 2014, 9, e110207.	1.1	24
1587	Predicting Adverse Health Outcomes in Long-Term Survivors of a Childhood Cancer. Children, 2014, 1, 63-73.	0.6	3
1588	Development and Application of Chronic Disease Risk Prediction Models. Yonsei Medical Journal, 2014, 55, 853.	0.9	15
1589	Validation of Risk Assessment Models for Predicting the Incidence of Breast Cancer in Korean Women. Journal of Breast Cancer, 2014, 17, 226.	0.8	18
1590	A Pictorial Schema for a Comprehensive User-oriented Identification of Medical Apps. Methods of Information in Medicine, 2014, 53, 208-224.	0.7	15
1591	Current strategies for the prevention of breast cancer. Breast Cancer: Targets and Therapy, 2014, 6, 59.	1.0	30

#	ARTICLE	IF	CITATIONS
1592	The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects. Journal of Managed Care Pharmacy, 2014, 20, 555-563.	2.2	8
1597	Probability perceptions and preventive health care. Journal of Risk and Uncertainty, 2014, 49, 43-71.	0.8	43
1598	Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 823-832.	1.1	38
1599	Inclusion of Endogenous Hormone Levels in Risk Prediction Models of Postmenopausal Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3111-3117.	0.8	57
1600	Breast cancer risk perceptions of Turkish women attending primary care: a cross-sectional study. BMC Women's Health, 2014, 14, 152.	0.8	18
1601	Genome-wide association studies and the clinic: a focus on breast cancer. Biomarkers in Medicine, 2014, 8, 287-296.	0.6	13
1602	Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study. British Journal of Cancer, 2014, 110, 1898-1907.	2.9	28
1603	Tools of the Trade: Individualized Breast Cancer Risk Assessment. Journal of Women's Health, 2014, 23, 434-436.	1.5	2
1604	A Randomized, Controlled Trial to Increase Discussion of Breast Cancer in Primary Care. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1245-1253.	1.1	33
1605	A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. BBA Clinical, 2014, 2, 94-102.	4.1	4
1606	Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model. Neoplasia, 2014, 16, 950-960.	2.3	74
1607	Decision Making After <i>BRCA</i> Genetic Testing. Clinical Journal of Oncology Nursing, 2014, 18, E58-E63.	0.3	13
1608	Evaluation of Women over 20 Years Living in the Province of Samsun in Terms of Risk of Breast Cancer. The Journal of Breast Health, 2014, 10, 229-233.	0.4	1
1609	Clinical prediction rules in practice: review of clinical guidelines and survey of GPs. British Journal of General Practice, 2014, 64, e233-e242.	0.7	37
1610	Comparative analysis of image-based phenotypes of mammographic density and parenchymal patterns in distinguishing between<i>BRCA1/2</i>cases, unilateral cancer cases, and controls. Journal of Medical Imaging, 2014, 1, 031009.	0.8	31
1611	How does semi-automated computer-derived CT measure of breast density compare with subjective assessments to assess mean glandular breast density, in patients with breast cancer?. British Journal of Radiology, 2014, 87, 20140530.	1.0	2
1612	Additive Interactions Between Susceptibility Single-Nucleotide Polymorphisms Identified in Genome-Wide Association Studies and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology, 2014, 180, 1018-1027.	1.6	36
1613	An Alternative Approach to Selecting Patients for High-risk Screening with Breast MRI. Breast Journal, 2014, 20, 192-197.	0.4	16

#	ARTICLE	IF	CITATIONS
1614	Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. Cancer, 2014, 120, 214-221.	2.0	107
1615	Perceived Versus Objective Breast Cancer Risk in Diverse Women. Journal of Women's Health, 2014, 23, 420-427.	1.5	32
1616	Development and validation of risk models and molecular diagnostics to permit personalized management of cancer. Cancer, 2014, 120, 11-19.	2.0	11
1617	Identifying hereditary cancer: Genetic counseling and cancer risk assessment. Current Problems in Cancer, 2014, 38, 216-225.	1.0	8
1618	Benign Breast Diseases. , 2014, , .		5
1619	Breast density and parenchymal texture measures as potential risk factors for estrogen-receptor positive breast cancer. Proceedings of SPIE, 2014, 9035, 90351D.	0.8	12
1621	Relationships between computer-extracted mammographic texture pattern features and BRCA1/2mutation status: a cross-sectional study. Breast Cancer Research, 2014, 16, 424.	2.2	44
1622	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. Cancer Prevention Research, 2014, 7, 993-1001.	0.7	37
1623	Contralateral Prophylactic Mastectomy After Unilateral Breast Cancer. Annals of Surgery, 2014, 260, 1000-1010.	2.1	100
1624	Net Reclassification Indices for Evaluating Risk Prediction Instruments. Epidemiology, 2014, 25, 114-121.	1.2	304
1625	Germline DNA Variations in Breast Cancer Predisposition and Prognosis: A Systematic Review of the Literature. Cytogenetic and Genome Research, 2014, 144, 77-91.	0.6	32
1626	Using absolute risks to assess the risks and benefits of treatment. Thorax, 2014, 69, 604-605.	2.7	5
1627	Changes in Breast Cancer Risk Distribution Among Vermont Women Using Screening Mammography. Journal of the National Cancer Institute, 2014, 106, dju157-dju157.	3.0	3
1629	Omics Approaches in Breast Cancer. , 2014, , .		10
1630	Breast Cancer Genomics. , 2014, , 53-103.		0
1631	Screening Mammography in Older Women. JAMA - Journal of the American Medical Association, 2014, 311, 1336.	3.8	194
1632	A Systematic Assessment of Benefits and Risks to Guide Breast Cancer Screening Decisions. JAMA - Journal of the American Medical Association, 2014, 311, 1327.	3.8	374
1633	Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer. JAMA Internal Medicine, 2014, 174, 1550.	2.6	51

#	Article	IF	Citations
1634	Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population. Breast Cancer Research, 2014, 16, R64.	2.2	30
1635	A review of clinical aspects of breast cancer. International Review of Psychiatry, 2014, 26, 4-15.	1.4	129
1636	Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy. Surgical Oncology Clinics of North America, 2014, 23, 423-430.	0.6	10
1637	The molecular etiology and prevention of estrogen-initiated cancers. Molecular Aspects of Medicine, 2014, 36, 1-55.	2.7	82
1638	Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men. Molecular Biology Reports, 2014, 41, 2501-2508.	1.0	5
1639	Developing and validating risk prediction models in an individual participant data meta-analysis. BMC Medical Research Methodology, 2014, 14, 3.	1.4	75
1640	Guideline-Inconsistent Breast Cancer Screening for Women over 50: A Vignette-Based Survey. Journal of General Internal Medicine, 2014, 29, 82-89.	1.3	12
1641	Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Research and Treatment, 2014, 144, 185-192.	1.1	23
1642	Development of a personalized decision aid for breast cancer risk reduction and management. BMC Medical Informatics and Decision Making, 2014, 14, 4.	1.5	38
1643	Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2014, 64, 30-51.	157.7	167
1644	Reclassification of predictions for uncovering subgroup specific improvement. Statistics in Medicine, 2014, 33, 1914-1927.	0.8	4
1645	Assessing Breast Cancer Risk Models in Marin County, a Population With High Rates of Delayed Childbirth. Clinical Breast Cancer, 2014, 14, 212-220.e1.	1.1	25
1646	Risk Prediction Models for Incident Primary Cutaneous Melanoma. JAMA Dermatology, 2014, 150, 434.	2.0	74
1647	Mammographic Breast Density as a Risk Factor for Breast Cancer: Awareness in a Recently Screened Clinical Sample. Women's Health Issues, 2014, 24, e321-e326.	0.9	29
1648	Risk Assessment, Genetic Counseling, and Clinical Care for Hereditary Breast Cancer. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2014, 43, 361-373.	0.2	6
1649	Development and validation of a brief dementia screening indicator forÂprimary care. Alzheimer's and Dementia, 2014, 10, 656.	0.4	114
1651	Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios. Lung, 2014, 192, 55-63.	1.4	36
1653	Breast Papilloma without Atypia and Risk of Breast Carcinoma. Breast Journal, 2014, 20, 525-533.	0.4	14

#	Article	IF	Citations
1654	Reproductive and Hormonal Risk Profile According to Language Acculturation and Country of Residence in the <i>Ella</i> Binational Breast Cancer Study. Journal of Women's Health, 2014, 23, 532-540.	1.5	10
1655	Assessing the goodness of fit of personal risk models. Statistics in Medicine, 2014, 33, 3179-3190.	0.8	10
1656	Cross-sectional Study to Assess the Association of Population Density with Predicted Breast Cancer Risk. Breast Journal, 2014, 20, 615-621.	0.4	6
1657	Use of the Gail Model and Breast Cancer Preventive Therapy Among Three Primary Care Specialties. Journal of Women's Health, 2014, 23, 746-752.	1.5	45
1659	MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model. International Journal of Health Promotion and Education, 2014, 52, 144-152.	0.4	7
1660	Mathematical modeling for novel cancer drug discovery and development. Expert Opinion on Drug Discovery, 2014, 9, 1133-1150.	2.5	21
1661	Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women. Tumor Biology, 2014, 35, 10861-10869.	0.8	9
1662	The Cytokinesis-Blocked Micronucleus Assay as a Strong Predictor of Lung Cancer: Extension of a Lung Cancer Risk Prediction Model. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2462-2470.	1.1	35
1663	The Angelina effect: immediate reach, grasp, and impact of going public. Genetics in Medicine, 2014, 16, 516-521.	1.1	128
1664	Implementing family health history risk stratification in primary care: Impact of guideline criteria on populations and resource demand. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 24-33.	0.7	41
1665	An assessment of the relationship between clinical utility and predictive ability measures and the impact of mean risk in the population. BMC Medical Research Methodology, 2014, 14, 86.	1.4	7
1666	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nature Medicine, 2014, 20, 1193-1198.	15.2	510
1667	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	2.2	248
1668	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Research and Treatment, 2014, 144, 539-549.	1.1	65
1669	Application of the Rosner–Wei risk-prediction model to estimate sexual orientation patterns in colon cancer risk in a prospective cohort of US women. Cancer Causes and Control, 2014, 25, 999-1006.	0.8	4
1670	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Research, 2014, 16, R30.	2.2	22
1671	ALERT - Adverse Late Effects of Cancer Treatment. Medical Radiology, 2014, , .	0.0	2
1672	Estimating Risk With Time-to-Event Data: An Application to the Women's Health Initiative. Journal of the American Statistical Association, 2014, 109, 514-524.	1.8	15

#	Article	IF	Citations
1673	Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women with a Previous Breast Biopsy. Applied Health Economics and Health Policy, 2014, 12, 203-217.	1.0	10
1674	Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid. BMC Cancer, 2014, 14, 359.	1.1	11
1675	In utero and peripubertal exposure to phthalates and BPA in relation to female sexual maturation. Environmental Research, 2014, 134, 233-241.	3.7	90
1676	Estimation du risque individuelÂde cancer du seinÂ: intÃ©rÃªt et limites des modÃ¨les de calcul de risque. Imagerie De La Femme, 2014, 24, 97-104.	0.0	1
1677	Opportunities and challenges of next-generation DNA sequencing for breast units. British Journal of Surgery, 2014, 101, 889-898.	0.1	7
1678	Complementary Role of Semiquantitative Analysis of Breast-Specific Gamma Imaging in the Diagnosis of Breast Cancer. American Journal of Roentgenology, 2014, 202, 690-695.	1.0	13
1679	An Architecture for Integrating Genetic and Clinical Data. Procedia Computer Science, 2014, 29, 1959-1969.	1.2	1
1680	Breast Cancer Disparities. Surgical Oncology Clinics of North America, 2014, 23, 579-592.	0.6	50
1681	A Review of Cancer Risk Prediction Models with Genetic Variants. Cancer Informatics, 2014, 13s2, CIN.S13788.	0.9	15
1682	Risk Factors for Breast Cancer Among Chinese Women: A 10-Year Nationwide Multicenter Cross-Sectional Study. Journal of Epidemiology, 2014, 24, 67-76.	1.1	38
1683	Predicting melanoma risk: theory, practice and future challenges. Melanoma Management, 2014, 1, 105-114.	0.1	3
1684	International screening and early detection of breast cancer: resource-sensitive, age- and risk-specific guidelines. Breast Cancer Management, 2014, 3, 397-407.	0.2	3
1685	Patterns of Breast Magnetic Resonance Imaging Use in Community Practice. JAMA Internal Medicine, 2014, 174, 125.	2.6	126
1686	A novel caseâ€"control design to estimate the extent of over-diagnosis of breast cancer due to organised population-based mammography screening. Breast Diseases, 2015, 26, 211-214.	0.0	0
1687	Vision 20/20: Mammographic breast density and its clinical applications. Medical Physics, 2015, 42, 7059-7077.	1.6	38
1690	Risk Prediction Models: Applications in Cancer Prevention. Current Epidemiology Reports, 2015, 2, 245-250.	1.1	7
1691	Can the breast screening appointment be used to provide risk assessment and prevention advice?. Breast Cancer Research, 2015, 17, 84.	2.2	30
1692	Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Medical Genomics, 2015, 8, 72.	0.7	13

#	ARTICLE	IF	CITATIONS
1693	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research, 2015, 17, 147.	2.2	186
1694	Combined effect of donor and recipient risk on outcome after liver transplantation: Research of the Eurotransplant database. Liver Transplantation, 2015, 21, 1486-1493.	1.3	31
1695	Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast Journal, 2015, 21, 377-386.	0.4	34
1696	The impact of covariate measurement error on risk prediction. Statistics in Medicine, 2015, 34, 2353-2367.	0.8	18
1697	Breast Cancer Risk Reduction Therapy: The Low-Hanging Fruit. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 376-378.	2.3	3
1698	What do hospitalists think about inpatient mammography for hospitalized women who are overdue for their breast cancer screening?. Journal of Hospital Medicine, 2015, 10, 242-245.	0.7	4
1699	Mining the Human Proteome. Cancer Journal (Sudbury, Mass), 2015, 21, 327-336.	1.0	11
1700	Computational Discrimination of Breast Cancer for Korean Women Based on Epidemiologic Data Only. Journal of Korean Medical Science, 2015, 30, 1025.	1.1	9
1701	Evaluation of a Mammography Screening Decision Aid for Women Aged 75 and Older: Protocol for a Cluster-randomized Controlled Trial. Journal of Clinical Trials, 2015, 04, 191.	0.1	9
1702	Mammographic Breast Density and Common Genetic Variants in Breast Cancer Risk Prediction. PLoS ONE, 2015, 10, e0136650.	1.1	20
1703	Predictors of Non-Adherence to Breast Cancer Screening among Hospitalized Women. PLoS ONE, 2015, 10, e0145492.	1.1	15
1704	Development of a User-Friendly Graphic Tool to Estimate Individualized Survival Curves for Advanced Cancer Patients in Hospice Care. Journal of Palliative Care, 2015, 31, 29-35.	0.4	2
1705	A Review on Automatic Mammographic Density and Parenchymal Segmentation. International Journal of Breast Cancer, 2015, 2015, 1-31.	0.6	40
1706	Aromatase inhibitors for prevention of breast cancer in postmenopausal women. Menopause, 2015, 22, 342-350.	0.8	8
1707	Tests of calibration and goodnessâ€ofâ€fit in the survival setting. Statistics in Medicine, 2015, 34, 1659-1680.	0.8	216
1708	Breast Health and Reducing Breast Cancer Risk: A Functional Medicine Approach. Journal of Alternative and Complementary Medicine, 2015, 21, 321-326.	2.1	5
1709	Management of the High-Risk Breast Lesion. , 2015, , 93-112.		0
1710	Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports, 2015, 7, 98-104.	0.5	1

#	Article	IF	Citations
1711	Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Current Pharmacology Reports, 2015, 1, 312-323.	1.5	23
1712	Prospective Approach to Breast Cancer Risk Prediction in African American Women: The Black Women's Health Study Model. Journal of Clinical Oncology, 2015, 33, 1038-1044.	0.8	32
1713	Practical Problems With Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk. Journal of the National Cancer Institute, 2015, 107, djv124-djv124.	3.0	34
1714	Assessing absolute changes in breast cancer risk due to modifiable risk factors. Breast Cancer Research and Treatment, 2015, 152, 193-197.	1.1	9
1715	MRI screening for breast cancer in women at high risk; isÂthe Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?. Journal of Medical Radiation Sciences, 2015, 62, 212-225.	0.8	11
1716	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast, 2015, 24, S51-S55.	0.9	31
1717	Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study. Journal of Oncology Practice, 2015, 11, e460-e467.	2.5	18
1718	One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 889-897.	1.1	30
1719	Oxidative Metabolism of Estrogens in Cancer Initiation and Prevention. ACS Symposium Series, 2015, , 35-51.	0.5	0
1720	Current and future methods for measuring breast density: a brief comparative review. Breast Cancer Management, 2015, 4, 209-221.	0.2	24
1721	Cancer chemoprevention at the crossroads?. Breast Cancer Management, 2015, 4, 285-288.	0.2	0
1722	Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. , 2015, 56, 2192.		79
1723	Genetics of breast cancer: a topic in evolution. Annals of Oncology, 2015, 26, 1291-1299.	0.6	314
1724	A Model to Determine Colorectal Cancer Risk Using Common Genetic Susceptibility Loci. Gastroenterology, 2015, 148, 1330-1339.e14.	0.6	129
1725	Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast, 2015, 24, 51-56.	0.9	41
1726	Alternative Screening for Dense Breasts: MRI. American Journal of Roentgenology, 2015, 204, W141-W149.	1.0	18
1727	Current management of lesions associated with an increased risk of breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 227-238.	12.5	110
1728	Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy. Journal of Clinical Oncology, 2015, 33, 923-929.	0.8	51

#	Article	IF	Citations
1729	Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2015, 65, 30-54.	157.7	299
1730	The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. Breast Cancer, 2015, 22, 16-27.	1.3	10
1731	Women In Steady Exercise Research (WISER) Sister: Study design and methods. Contemporary Clinical Trials, 2015, 41, 17-30.	0.8	19
1732	Biomarkers for Assessing Risk of Cancer. , 2015, , 317-330.e3.		0
1733	Atypical Hyperplasia of the Breast â€" Risk Assessment and Management Options. New England Journal of Medicine, 2015, 372, 78-89.	13.9	281
1734	Twenty-five Years of Breast Cancer Risk Models and Their Applications. Journal of the National Cancer Institute, 2015, 107, djv042-djv042.	3.0	44
1735	Risk Factors for the Development of Uterine Cancer in Breast Cancer Survivors: An Army of Women Study. Annals of Surgical Oncology, 2015, 22, 1974-1979.	0.7	4
1736	Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology. Cancer Prevention Research, 2015, 8, 359-364.	0.7	20
1737	The Effect of an Evidence-Based Medicine Curriculum on Breast Cancer Knowledge and Satisfaction of Surgical Residents. Journal of Surgical Education, 2015, 72, 717-725.	1.2	3
1738	Is mammography screening history a predictor of future breast cancer risk?. European Journal of Epidemiology, 2015, 30, 143-149.	2.5	1
1739	JNCI and Cancer Prevention. Journal of the National Cancer Institute, 2015, 107, djv021-djv021.	3.0	3
1740	Does a High-Risk Recommendation in Mammography Reports Increase Attendance atÂaÂBreast Cancer Risk Assessment Clinic?. Journal of the American College of Radiology, 2015, 12, 923-929.	0.9	8
1741	Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. Journal of Biomedical Informatics, 2015, 56, 87-93.	2.5	34
1742	Breast Cancer Risk in Sexual Minority Women during Routine Screening at an Urban LGBT Health Center. Women's Health Issues, 2015, 25, 341-348.	0.9	17
1743	Initial Experience With the New York State Breast Density Inform Law at a Communityâ€Based Breast Center. Journal of Ultrasound in Medicine, 2015, 34, 993-1000.	0.8	11
1744	A new framework to enhance the interpretation of external validation studies of clinical prediction models. Journal of Clinical Epidemiology, 2015, 68, 279-289.	2.4	395
1745	Incidental Internal Mammary Lymph Nodes Visualized on Screening Breast MRI. American Journal of Roentgenology, 2015, 205, 209-214.	1.0	23
1746	A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. Breast Cancer Research and Treatment, 2015, 150, 415-426.	1.1	10

#	ARTICLE	IF	CITATIONS
1747	Reported breast symptoms in the National Breast and Cervical Cancer Early Detection Program. Cancer Causes and Control, 2015, 26, 733-740.	0.8	12
1748	Current Multidisciplinary Management of High-Risk Breast Lesions. Current Breast Cancer Reports, 2015, 7, 81-89.	0.5	0
1749	The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. Breast Cancer Research, 2015, 17, 1.	2.2	124
1750	Breast Cancer Risks and Risk Prediction Models. Breast Care, 2015, 10, 7-12.	0.8	47
1751	Breast Cancer Prevention Across the Cancer Care Continuum. Seminars in Oncology Nursing, 2015, 31, 89-99.	0.7	8
1752	Update on breast cancer risk prediction and prevention. Current Opinion in Obstetrics and Gynecology, 2015, 27, 92-97.	0.9	27
1753	Genetic risk assessment for breast and gynecological malignancies. Current Opinion in Obstetrics and Gynecology, 2015, 27, 1-5.	0.9	3
1754	â€œOmicsâ€•Translation. , 2015, , 15-24.		0
1755	Predicting reattendance at a high-risk breast cancer clinic. Palliative and Supportive Care, 2015, 13, 1441-1448.	0.6	5
1756	The effects of phthalate and nonylphenol exposure on body size and secondary sexual characteristics during puberty. International Journal of Hygiene and Environmental Health, 2015, 218, 603-615.	2.1	57
1757	Predictors of preoperative MRI for breast cancer: differences by data source. Journal of Comparative Effectiveness Research, 2015, 4, 215-226.	0.6	1
1758	Promoting the early detection of cancer: A systematic review of community pharmacy-based education and screening interventions. Cancer Epidemiology, 2015, 39, 673-681.	0.8	30
1759	Doseâ€"response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. Breast Cancer Research and Treatment, 2015, 154, 309-318.	1.1	34
1760	Reply to M.H. Gail et al. Journal of Clinical Oncology, 2015, 33, 2830-2831.	0.8	0
1761	FamiliÃ¤rer Brustkrebs â€“ empirische Erkrankungsrisiken und Risikoberechnungsmodelle. Medizinische Genetik, 2015, 27, 217-222.	0.1	4
1762	Personalized Assessment and Management of Women at Risk for Breast Cancer in North America. Women's Health, 2015, 11, 213-224.	0.7	5
1763	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Research and Treatment, 2015, 152, 627-636.	1.1	48
1764	Chemoprevention for Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3230-3235.	0.7	49

#	ARTICLE	IF	CITATIONS
1765	Independent Validation of Six Melanoma Risk Prediction Models. Journal of Investigative Dermatology, 2015, 135, 1377-1384.	0.3	33
1766	Predicting Cancer Risk: Practical Considerations in Developing and Validating a Cancer Risk Prediction Model. Current Epidemiology Reports, 2015, 2, 197-204.	1.1	5
1767	Incorporation of eicosapentaenioic and docosahexaenoic acids into breast adipose tissue of women at high risk of breast cancer: A randomized clinical trial of dietary fish and n−3 fatty acid capsules. Molecular Nutrition and Food Research, 2015, 59, 1780-1790.	1.5	23
1768	Cancer Risk Assessment Tools in Primary Care: A Systematic Review of Randomized Controlled Trials. Annals of Family Medicine, 2015, 13, 480-489.	0.9	36
1769	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 3137-3143.	0.8	170
1770	A comparison of digital mammography detectors and emerging technology. Radiography, 2015, 21, 315-323.	1.1	4
1771	Preliminary evaluation of the publicly available Laboratory for Breast Radiodensity Assessment (LIBRA) software tool: comparison of fully automated area and volumetric density measures in a case–control study with digital mammography. Breast Cancer Research, 2015, 17, 117.	2.2	68
1772	Certified Genetic Counselors. Surgical Oncology Clinics of North America, 2015, 24, 653-666.	0.6	6
1773	The Genetics of Breast Cancer. Surgical Oncology Clinics of North America, 2015, 24, 705-732.	0.6	5
1774	Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing?. American Journal of Roentgenology, 2015, 205, 1365-1371.	1.0	11
1775	Effects of personalized colorectal cancer risk information on laypersons' interest in colorectal cancer screening: The importance of individual differences. Patient Education and Counseling, 2015, 98, 1280-1286.	1.0	8
1776	The challenges for cancer chemoprevention. Chemical Society Reviews, 2015, 44, 8836-8847.	18.7	57
1777	Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. Breast, 2015, 24, 758-766.	0.9	25
1778	Ongoing Use of Data and Specimens From National Cancer Institute–Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Seminars in Oncology, 2015, 42, 748-763.	0.8	2
1779	Risk Classification With an Adaptive Naive Bayes Kernel Machine Model. Journal of the American Statistical Association, 2015, 110, 393-404.	1.8	20
1780	Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention. Journal of the National Cancer Institute, 2015, 107, 354.	3.0	40
1781	Breast Cancer Detection with Short-Interval Follow-up Compared with Return to Annual Screening in Patients with Benign Stereotactic or US-guided Breast Biopsy Results. Radiology, 2015, 275, 54-60.	3.6	16
1782	Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ. Journal of Surgical Research, 2015, 193, 519-522.	0.8	30

#	Article	IF	Citations
1783	Breast Cancer Screening and Diagnosis. , 2015, , .		8
1784	Real World Data Mining Applications. Annals of Information Systems, 2015, , .	0.5	4
1785	American BRCA Outcomes and Utilization of Testing (ABOUT) Study: A Pragmatic Research Model that Incorporates Personalized Medicine/Patientâ€Centered Outcomes in a Real World Setting. Journal of Genetic Counseling, 2015, 24, 18-28.	0.9	9
1786	Genetic Polymorphisms Associated With Breast Cancer in Malaysian Cohort. Indian Journal of Clinical Biochemistry, 2015, 30, 134-139.	0.9	16
1787	Evolution of Emotional Symptoms Over Time Among Daughters of Patients With Breast Cancer. Psychosomatics, 2015, 56, 504-512.	2.5	6
1788	Breast Cancer Screening in the Older Woman. , 2016, , 189-217.		0
1789	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56.	1.8	19
1790	Prevention of breast cancer. Medical Journal of Australia, 2016, 205, 475-479.	0.8	15
1791	Premenopausal Obesity and Breast Cancer Growth Rates in a Rodent Model. Nutrients, 2016, 8, 214.	1.7	4
1792	A model for predicting individualsâ€™ absolute risk of esophageal adenocarcinoma: Moving toward tailored screening and prevention. International Journal of Cancer, 2016, 138, 2813-2819.	2.3	31
1793	A Breast Cancer Risk Classification Model Based on the Features Selected by Novel F-Score Index for the Imbalanced Multi-Feature Dataset. , 2016, , .		4
1794	Heterodyne frequencyâ€domain multispectral diffuse optical tomography of breast cancer in the parallelâ€plane transmission geometry. Medical Physics, 2016, 43, 4383-4395.	1.6	21
1795	Clinico-epidemiological profile of breast cancer patients and the retrospective application of Gail model 2: An Indian perspective. Breast Disease, 2016, 36, 15-22.	0.4	9
1796	A framework to predict outcome for cancer patients using data from a nursing EHR. , 2016, , .		2
1797	Should We Offer Medication to Reduce Breast Cancer Risk?. Annals of Internal Medicine, 2016, 165, 194.	2.0	4
1798	Predicting risk of substantial weight gain in German adultsâ€"a multi-center cohort approach. European Journal of Public Health, 2017, 27, ckw216.	0.1	5
1799	Cancer Prevention: Lessons Learned and Future Directions. Trends in Cancer, 2016, 2, 713-722.	3.8	15
1800	Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice. Annals of Internal Medicine, 2016, 165, 457.	2.0	148

#	ARTICLE	IF	CITATIONS
1801	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. Breast Cancer Research, 2016, 18, 124.	2.2	52
1802	High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study. Breast Cancer Research and Treatment, 2016, 156, 527-538.	1.1	7
1803	Breast cancer risk feedback to women in the UK NHS breast screening population. British Journal of Cancer, 2016, 114, 1045-1052.	2.9	73
1804	Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity. Epidemiology, 2016, 27, 531-537.	1.2	26
1805	Population-based screening for cancer: hope and hype. Nature Reviews Clinical Oncology, 2016, 13, 550-565.	12.5	98
1806	The Dose–Response Effects of Aerobic Exercise on Body Composition and Breast Tissue among Women at High Risk for Breast Cancer: A Randomized Trial. Cancer Prevention Research, 2016, 9, 581-588.	0.7	24
1807	Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nature Reviews Genetics, 2016, 17, 392-406.	7.7	559
1808	Nurse practitioners & genetic counselors. Nurse Practitioner, 2016, 41, 43-49.	0.2	6
1809	Physician and Patient Barriers to Breast Cancer Preventive Therapy. Current Breast Cancer Reports, 2016, 8, 158-164.	0.5	25
1810	Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case–control study. Breast Cancer Research and Treatment, 2016, 159, 163-172.	1.1	48
1811	Technology- and Phone-Based Weight Loss Intervention. American Journal of Preventive Medicine, 2016, 51, 714-721.	1.6	87
1812	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2016, 66, 95-114.	157.7	198
1813	Augmented Case-Only Designs for Randomized Clinical Trials with Failure Time Endpoints. Biometrics, 2016, 72, 30-38.	0.8	9
1814	Dense Breasts: What Do Our Patients Need to Be Told and Why?. Annals of Surgical Oncology, 2016, 23, 3119-3127.	0.7	3
1815	Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Research and Treatment, 2016, 159, 513-525.	1.1	129
1816	Dietary Associations with a Breast Cancer Risk Biomarker Depend on Menopause Status. Nutrition and Cancer, 2016, 68, 1115-1122.	0.9	3
1817	Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Review of Clinical Pharmacology, 2016, 9, 1263-1272.	1.3	13
1818	In utero exposure to organochlorine pesticides and early menarche in the Avon Longitudinal Study of Parents and Children. Environment International, 2016, 94, 467-472.	4.8	19

#	ARTICLE	IF	CITATIONS
1819	Bayesian joint ordinal and survival modeling for breast cancer risk assessment. Statistics in Medicine, 2016, 35, 5267-5282.	0.8	20
1820	Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer. European Journal of Epidemiology, 2016, 31, 1091-1099.	2.5	6
1821	ConfidentCare: A Clinical Decision Support System for Personalized Breast Cancer Screening. IEEE Transactions on Multimedia, 2016, 18, 1942-1955.	5.2	34
1823	A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. Breast Cancer Research and Treatment, 2016, 158, 553-561.	1.1	11
1824	Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Annals of Internal Medicine, 2016, 165, 700.	2.0	90
1825	Affective forecasting and medication decision making in breast-cancer prevention.. Health Psychology, 2016, 35, 594-603.	1.3	31
1826	Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. Breast Cancer Research and Treatment, 2016, 160, 547-562.	1.1	8
1828	Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study. BMJ Open, 2016, 6, e012550.	0.8	10
1829	Using the weighted area under the net benefit curve for decision curve analysis. BMC Medical Informatics and Decision Making, 2016, 16, 94.	1.5	49
1830	Risk assessment model for invasive breast cancer in Hong Kong women. Medicine (United States), 2016, 95, e4515.	0.4	11
1831	Breast Cancer: Genetics and Risk Assessment. Clinical Obstetrics and Gynecology, 2016, 59, 673-687.	0.6	2
1832	The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology. American Journal of Surgical Pathology, 2016, 40, e94-e102.	2.1	307
1833	Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer, 2016, 122, 378-385.	2.0	31
1834	Development and External Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk Factors. JAMA Dermatology, 2016, 152, 889.	2.0	53
1835	An adaptive online learning framework for practical breast cancer diagnosis. , 2016, , .		1
1836	Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. Cancer Prevention Research, 2016, 9, 673-682.	0.7	9
1837	The use of machine learning for the identification of peripheral artery disease and future mortality risk. Journal of Vascular Surgery, 2016, 64, 1515-1522.e3.	0.6	95
1838	A Novel Breast Cancer Risk Assessment Scheme Design Using Dual View Mammograms. Lecture Notes in Computer Science, 2016, , 392-399.	1.0	1

#	ARTICLE	IF	CITATIONS
1839	A utility/cost analysis of breast cancer risk prediction algorithms. , 2016, 9787, .		1
1840	Cytologic atypia in the contralateral unaffected breast is related to parity and estrogen-related genes. Surgical Oncology, 2016, 25, 449-456.	0.8	1
1841	Risk Stratification and Shared Decision Making for Colorectal Cancer Screening. Medical Decision Making, 2016, 36, 526-535.	1.2	25
1842	Depurinating estrogen–DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clinical and Translational Medicine, 2016, 5, 12.	1.7	76
1843	Breast Imaging. Lecture Notes in Computer Science, 2016, , .	1.0	9
1844	Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 359-365.	1.1	96
1845	Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prevention Research, 2016, 9, 225-233.	0.7	8
1846	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. British Journal of Cancer, 2016, 114, 221-229.	2.9	18
1847	Defining Probability in Sex Offender Risk Assessment. International Journal of Offender Therapy and Comparative Criminology, 2016, 60, 1928-1941.	0.8	5
1848	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	1.4	20
1849	Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy. Academic Radiology, 2016, 23, 62-69.	1.3	11
1850	Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. Journal of the National Cancer Institute, 2016, 108, djv348.	3.0	16
1851	Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum. Advances in Experimental Medicine and Biology, 2016, 882, 33-68.	0.8	34
1852	Incorporating Biomarkers in Studies of Chemoprevention. Advances in Experimental Medicine and Biology, 2016, 882, 69-94.	0.8	6
1853	Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer, 2016, 122, 611-617.	2.0	55
1854	Randomized trial of a phone- and web-based weight loss program for women at elevated breast cancer risk: the HELP study. Journal of Behavioral Medicine, 2016, 39, 551-559.	1.1	16
1855	Unbiased Prediction and Feature Selection in High-Dimensional Survival Regression. Journal of Computational Biology, 2016, 23, 279-290.	0.8	21
1856	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. Digestive Diseases and Sciences, 2016, 61, 2076-2086.	1.1	11

#	Article	IF	Citations
1857	Multigene testing of moderate-risk genes: be mindful of the missense. Journal of Medical Genetics, 2016, 53, 366-376.	1.5	32
1858	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. New England Journal of Medicine, 2016, 374, 454-468.	13.9	227
1859	Heterogeneity in Women's Adherence and Its Role in Optimal Breast Cancer Screening Policies. Management Science, 2016, 62, 1339-1362.	2.4	56
1860	The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prevention Research, 2016, 9, 379-384.	0.7	19
1861	Understanding inherited genetic risk of adult glioma – a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.0	62
1862	Epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.0	15
1863	Correlates of misperception of breast cancer risk among Korean-American Women. Women and Health, 2016, 56, 634-649.	0.4	4
1864	Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. Journal of the National Cancer Institute, 2016, 108, djv365.	3.0	28
1865	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 842-851.	0.6	7
1866	Molecular epidemiology, and possible real-world applications in breast cancer. Breast Cancer, 2016, 23, 33-38.	1.3	23
1867	Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families. Breast Cancer, 2017, 24, 238-244.	1.3	17
1868	A multi-wavelength, laser-based optical spectroscopy device for breast density and breast cancer risk pre-screening. Journal of Biophotonics, 2017, 10, 565-576.	1.1	19
1869	Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer. Journal of Epidemiology, 2017, 27, 98-106.	1.1	8
1870	An empirically derived dietary pattern associated with breast cancer risk is validated in a nested case-control cohort from a randomized primary prevention trial. Clinical Nutrition ESPEN, 2017, 17, 8-17.	0.5	10
1871	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of Clinical Oncology, 2017, 35, 743-750.	0.8	58
1872	Effects of a web-based intervention on women's breast health behaviors. Translational Behavioral Medicine, 2017, 7, 309-319.	1.2	15
1873	Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 938-944.	1.1	28
1874	Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. American Journal of Roentgenology, 2017, 208, 248-255.	1.0	15

#	Article	IF	Citations
1875	Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. Breast, 2017, 32, 93-97.	0.9	8
1876	Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer. Radiology, 2017, 283, 361-370.	3.6	242
1877	Screening Mammography: Patient Perceptions and Preferences Regarding Communication of Estimated Breast Cancer Risk. American Journal of Roentgenology, 2017, 208, 1163-1170.	1.0	16
1878	Incorporating cancer risk information into general practice: a qualitative study using focus groups with health professionals. British Journal of General Practice, 2017, 67, e218-e226.	0.7	18
1879	The Smoking Mind: A Psycho-Cognitive Perspective. Beitrage Zur Tabakforschung International/ Contributions To Tobacco Research, 2017, 27, 33-41.	0.3	0
1880	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Proceedings of SPIE, 2017, 10134, .	0.8	0
1881	Comparison of Breast Cancer Risk Predictive Models and Screening Strategies for Chinese Women. Journal of Women's Health, 2017, 26, 294-302.	1.5	5
1882	Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clinical Cancer Research, 2017, 23, 4181-4189.	3.2	26
1883	Improving Breast Cancer Screening Adherence Among Hospitalized Women. Journal of Women's Health, 2017, 26, 1094-1098.	1.5	12
1884	Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Research, 2017, 19, 34.	2.2	64
1886	Breast Cancer Risk Assessment Models and High-Risk Screening. Radiologic Clinics of North America, 2017, 55, 457-474.	0.9	25
1887	Radiomic modeling of BI-RADS density categories. Proceedings of SPIE, 2017, , .	0.8	0
1888	Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case–control study in the EPIC Florence cohort. Breast Cancer Research and Treatment, 2017, 164, 467-473.	1.1	18
1889	Contributions of risk preference, time orientation and perceptions to breast cancer screening regularity. Social Science and Medicine, 2017, 185, 147-157.	1.8	19
1890	Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Research and Treatment, 2017, 164, 263-284.	1.1	130
1891	In utero exposure to atrazine analytes and early menarche in the Avon Longitudinal Study of Parents and Children Cohort. Environmental Research, 2017, 156, 420-425.	3.7	23
1892	Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecologic Oncology, 2017, 146, 205-214.	0.6	16
1893	An exploratory study of patients' views about being at high-risk for breast cancer and risk management beliefs and intentions, before and after risk counselling: Preliminary evidence of the influence of beliefs on post-counselling prevention intentions. Patient Education and Counseling, 2017, 100, 575-582.	1.0	7

#	Article	IF	Citations
1894	Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma <i>In Situ</i>. Cancer Prevention Research, 2017, 10, 434-441.	0.7	35
1895	Assessing Breast Cancer Risk Estimates Based on the Gail Model and Its Predictors in Qatari Women. Journal of Primary Care and Community Health, 2017, 8, 180-187.	1.0	19
1896	Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. Journal of Veterinary Internal Medicine, 2017, 31, 970-978.	0.6	18
1897	Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Research and Treatment, 2017, 165, 285-291.	1.1	14
1898	Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). International Journal of Epidemiology, 2017, 46, 1740-1741g.	0.9	88
1899	Genomic Medicine in Primary Care. , 2017, , 1-18.		1
1900	Editorial: Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. Journal of the National Cancer Institute, 2017, 109, .	3.0	2
1901	A Comprehensive Model of Colorectal Cancer by Risk Factor Status and Subsite Using Data From the Nursesâ€™ Health Study. American Journal of Epidemiology, 2017, 185, 224-237.	1.6	39
1902	Using an Internet-Based Breast Cancer Risk Assessment Tool to Improve Social-Cognitive Precursors of Physical Activity. Medical Decision Making, 2017, 37, 657-669.	1.2	11
1903	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. Journal of the National Cancer Institute, 2017, 109, djw290.	3.0	171
1904	Cancer Screening and Early Detection in the 21 st Century. Seminars in Oncology Nursing, 2017, 33, 121-128.	0.7	141
1905	Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease. International Journal of Cancer, 2017, 141, 1078-1090.	2.3	32
1906	What Does â€œPrecision Medicineâ€•Have to Say About Prevention?. Epidemiology, 2017, 28, 479-483.	1.2	8
1907	A clinical model for identifying the short-term risk of breast cancer. Breast Cancer Research, 2017, 19, 29.	2.2	79
1908	Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1102.	3.4	14
1909	Timing the Use of Breast Cancer Risk Information in Biopsy Decisionâ€Making. Production and Operations Management, 2017, 26, 1333-1358.	2.1	11
1910	Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. Journal of the National Cancer Institute, 2017, 109, djw215.	3.0	53
1911	Cancer Prevention in the Era of Precision Oncology. Clinical Pharmacology and Therapeutics, 2017, 101, 575-577.	2.3	7

#	ARTICLE	IF	CITATIONS
1912	Risk Factors That Increase Risk of Estrogen Receptorâ€"Positive and â€"Negative Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw276.	3.0	55
1913	Comparison of approaches for incorporating new information into existing risk prediction models. Statistics in Medicine, 2017, 36, 1134-1156.	0.8	11
1914	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	0.7	61
1915	Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies. Journal of the National Cancer Institute, 2017, 109, .	3.0	10
1916	Evaluation of Cancer Risk in Epidemiologic Studies with Genetic and Molecular Data. , 2017, , 297-313.		0
1917	Contemporary Evaluation of Breast Cancer Screening. , 2017, , 331-342.		0
1919	Breast Cancer Risk Prediction Using Electronic Health Records. , 2017, , .		10
1920	Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. Oncologist, 2017, 22, 1431-1443.	1.9	39
1921	State of the evidence 2017: an update on the connection between breast cancer and the environment. Environmental Health, 2017, 16, 94.	1.7	147
1922	How the growth rate of host cells affects cancer risk in a deterministic way. Chaos, 2017, 27, 093101.	1.0	4
1923	Shrink: A Breast Cancer Risk Assessment Model Based on Medical Social Network. , 2017, , .		5
1924	Maximizing Value Through Innovations in Radiologist-Driven Communications in Breast Imaging. American Journal of Roentgenology, 2017, 209, 1001-1005.	1.0	6
1925	Preventive therapy for cancer. Lancet Oncology, The, 2017, 18, e472-e482.	5.1	81
1926	Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Research and Treatment, 2017, 166, 603-612.	1.1	22
1928	Asymptotic distribution of â^†AUC, NRIs, and IDI based on theory of Uâ€statistics. Statistics in Medicine, 2017, 36, 3334-3360.	0.8	20
1929	Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Research and Treatment, 2017, 165, 193-200.	1.1	155
1930	Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. Menopause, 2017, 24, 1145-1153.	0.8	26
1931	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Research and Treatment, 2017, 166, 145-156.	1.1	1

#	Article	IF	Citations
1932	Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk. Breast Cancer Research and Treatment, 2017, 165, 215-223.	1.1	7
1933	Preventing invasive breast cancer using endocrine therapy. Breast, 2017, 34, S47-S54.	0.9	14
1934	Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s. BMC Medical Informatics and Decision Making, 2017, 17, 29.	1.5	21
1935	Automatic Estimation of Volumetric Breast Density Using Artificial Neural Network-Based Calibration of Full-Field Digital Mammography: Feasibility on Japanese Women With and Without Breast Cancer. Journal of Digital Imaging, 2017, 30, 215-227.	1.6	12
1936	A model for individualized risk prediction of contralateral breast cancer. Breast Cancer Research and Treatment, 2017, 161, 153-160.	1.1	38
1939	Breast cancer risk assessment by Gail Model in women of Baghdad. Alexandria Journal of Medicine, 2017, 53, 183-186.	0.4	9
1940	Robust dynamic risk prediction with longitudinal studies. Statistical Theory and Related Fields, 2017, 1, 159-170.	0.2	0
1941	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. Oncology Letters, 2017, 14, 4384-4390.	0.8	2
1942	The Preventive Intervention of Hereditary Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 41-57.	0.8	19
1943	Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age. Breast Cancer Research, 2017, 19, 81.	2.2	66
1944	Risk Prediction Models for Post-Stroke Dementia. Geriatrics (Switzerland), 2017, 2, 19.	0.6	7
1945	A stillbirth calculator: Development and internal validation of a clinical prediction model to quantify stillbirth risk. PLoS ONE, 2017, 12, e0173461.	1.1	21
1946	Simulation modeling for stratified breast cancer screening â€" a systematic review of cost and quality of life assumptions. BMC Health Services Research, 2017, 17, 802.	0.9	6
1948	Nasopharyngeal carcinoma risk prediction *via* salivary detection of host and Epstein-Barr virus genetic variants. Oncotarget, 2017, 8, 95066-95074.	0.8	13
1950	The future is now: Technology's impact on the practice of genetic counseling. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 15-23.	0.7	35
1951	Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening. Journal of the National Cancer Institute, 2018, 110, 994-1002.	3.0	46
1952	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of QuÃ©bec (Canada). BMJ Open, 2018, 8, e016662.	0.8	9
1953	Effect of interventions incorporating personalised cancer risk information on intentions and behaviour: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2018, 8, e017717.	0.8	26

#	ARTICLE	IF	CITATIONS
1954	Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology, 2018, 154, 2152-2164.e19.	0.6	226
1955	Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 636-643.	1.1	16
1956	Risk factors for breast cancer in a cohort of mammographic screening program: a nested case–control study within the <scp>FR</scp>iCaM study. Cancer Medicine, 2018, 7, 2145-2152.	1.3	25
1957	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. Current Surgery Reports, 2018, 6, 1.	0.4	2
1958	An efficient risk estimator with external information under additive hazards model. Acta Mathematicae Applicatae Sinica, 2018, 34, 35-50.	0.4	1
1959	Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density. JAMA Oncology, 2018, 4, e180174.	3.4	148
1960	Psychological Features of Breast Cancer in Mexican Women I: Personality Traits and Stress Symptoms. Advances in Neuroimmune Biology, 2018, 7, 3-15.	0.7	2
1961	Precision Therapy of Head and Neck Squamous Cell Carcinoma. Journal of Dental Research, 2018, 97, 614-621.	2.5	44
1962	Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Familial Cancer, 2018, 17, 495-505.	0.9	17
1963	Factors Associated with False Positive Results on Screening Mammography in a Population of Predominantly Hispanic Women. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 446-453.	1.1	17
1964	Optimizing performance of BreastScreen Norway using value of information in graphical models. Statistics in Medicine, 2018, 37, 1531-1549.	0.8	1
1965	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology, 2018, 4, 476.	3.4	109
1966	The impact of patient age on breast cancer risk prediction models. Breast Journal, 2018, 24, 592-598.	0.4	8
1967	Improving estimation and prediction in linear regression incorporating external information from an established reduced model. Statistics in Medicine, 2018, 37, 1515-1530.	0.8	19
1968	Personalised screening: is this the way forward?. Clinical Radiology, 2018, 73, 327-333.	0.5	18
1969	Primary Prevention of Breast Cancer. , 2018, , 219-236.e3.		2
1970	Clinical Management of the Patient at Increased or High Risk. , 2018, , 1004-1010.e2.		0
1971	Hereditary Breast Cancer Genetics and Risk Prediction Techniques. , 2018, , 43-56.		0

#	Article	IF	Citations
1972	Predicting risk for adverse health events using random forest. Journal of Applied Statistics, 2018, 45, 2279-2294.	0.6	21
1973	Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis. Breast Cancer Research, 2018, 20, 18.	2.2	66
1975	Implications of false‑positive results for future cancer screenings. Cancer, 2018, 124, 2390-2398.	2.0	19
1976	Breast-density assessment with hand-held ultrasound: A novel biomarker to assess breast cancer risk and to tailor screening?. European Radiology, 2018, 28, 3165-3175.	2.3	24
1977	How Do We Approach Benign Proliferative Lesions?. Current Oncology Reports, 2018, 20, 34.	1.8	9
1978	Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention?. Breast, 2018, 39, 24-32.	0.9	30
1979	Calculating Probability in Sex Offender Risk Assessment. International Journal of Offender Therapy and Comparative Criminology, 2018, 62, 1262-1280.	0.8	4
1980	Calibration of medical diagnostic classifier scores to the probability of disease. Statistical Methods in Medical Research, 2018, 27, 1394-1409.	0.7	14
1981	Examining Mammography Use by Breast Cancer Risk, Race, Nativity, and Socioeconomic Status. Journal of Immigrant and Minority Health, 2018, 20, 59-65.	0.8	29
1982	Informing Women and Their Physicians about Recommendations for Adjunct Breast MRI Screening: A Cohort Study. Health Communication, 2018, 33, 489-495.	1.8	7
1983	A model to predict risk of postpartum infection after Caesarean delivery*. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 2409-2417.	0.7	7
1984	The Importance of Family History in Breast Cancer Patients in Primary Care Setting: a Cross-sectional Study. Journal of Cancer Education, 2018, 33, 602-609.	0.6	0
1985	Adaptive decision-making of breast cancer mammography screening: A heuristic-based regression model. Omega, 2018, 76, 70-84.	3.6	14
1986	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clinical Breast Cancer, 2018, 18, e205-e218.	1.1	5
1987	Risk-Reducing Mastectomy and Breast Reconstruction. Clinics in Plastic Surgery, 2018, 45, 129-136.	0.7	7
1988	Kernel machine score test for pathway analysis in the presence of semi-competing risks. Statistical Methods in Medical Research, 2018, 27, 1099-1114.	0.7	2
1989	Predictive accuracy of combined genetic and environmental risk scores. Genetic Epidemiology, 2018, 42, 4-19.	0.6	32
1990	Prediction of breast cancer risk using a machine learning approach embedded with a locality preserving projection algorithm. Physics in Medicine and Biology, 2018, 63, 035020.	1.6	70

#	ARTICLE	IF	CITATIONS
1991	A new near-term breast cancer risk prediction scheme based on the quantitative analysis of ipsilateral view mammograms. Computer Methods and Programs in Biomedicine, 2018, 155, 29-38.	2.6	7
1992	Progress of statistical analysis in biomedical research through the historical review of the development of the Framingham score. Irish Journal of Medical Science, 2018, 187, 639-645.	0.8	1
1993	Utilization of breast cancer screening with magnetic resonance imaging in community practice. Journal of General Internal Medicine, 2018, 33, 275-283.	1.3	28
1994	On Estimation of the Hazard Function From Population-Based Case–Control Studies. Journal of the American Statistical Association, 2018, 113, 560-570.	1.8	4
1995	Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause, 2018, 25, 11-20.	0.8	164
1996	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	0.8	22
1997	Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky055.	1.4	16
1998	Classification of Breast Cancer Risk Factors Using Several Resampling Approaches. , 2018, , .		10
1999	Towards Digital Cancer Genetic Counseling. , 2018, , .		3
2000	Rule Discovery from Breast Cancer Risk Factors using Association Rule Mining. , 2018, , .		5
2001	Trailing the Path to Preventive Oncology. Advances in Cancer Prevention, 2018, 03, .	0.2	0
2002	Are you dense? The implications and imaging of the dense breast. South African Journal of Radiology, 2018, 22, 1356.	0.1	0
2004	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. The Cochrane Library, 2018, , .	1.5	1
2005	The father–daughter relationship in the wake of maternal death from breast cancer. Palliative and Supportive Care, 2018, 16, 741-748.	0.6	2
2006	Cancer Survivor Health Needs for Women. Primary Care - Clinics in Office Practice, 2018, 45, 659-676.	0.7	3
2007	2 History of Magnetic Resonance Imaging in Breast Cancer Screening. , 2018, , .		0
2008	Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women. Ethnicity and Health, 2018, 26, 1-24.	1.5	13
2009	Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women. Breast Cancer Research, 2018, 20, 155.	2.2	22

#	ARTICLE	IF	CITATIONS
2010	Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. Breast Cancer Research, 2018, 20, 147.	2.2	24
2011	Validation of a genetic risk score for Arkansas women of color. PLoS ONE, 2018, 13, e0204834.	1.1	12
2012	Density and tailored breast cancer screening: practice and prediction â€" an overview. Acta Radiologica Open, 2018, 7, 205846011879121.	0.3	8
2013	Mammographic Breast Density and Its Effects on Imaging. , 2018, , 9-16.		0
2014	Psychological Features of Breast Cancer in Mexican Women II: The Psychological Network. Advances in Neuroimmune Biology, 2018, 7, 91-105.	0.7	1
2015	Nipple-sparing mastectomy in women at high risk of developing breast cancer. Gland Surgery, 2018, 7, 325-336.	0.5	5
2016	Atypical Breast Proliferative Lesions and Benign Breast Disease. , 2018, , .		0
2017	Views of Low-Income Women of Color at Increased Risk for Breast Cancer. Narrative Inquiry in Bioethics, 2018, 8, 53-66.	0.0	7
2018	The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus. Current Cardiology Reports, 2018, 20, 126.	1.3	1
2019	To Screen or Not to Screen Adults 45-49 Years of Age: That is the Question. American Journal of Gastroenterology, 2018, 113, 1750-1753.	0.2	26
2020	Reasonable patient care under uncertainty. Health Economics (United Kingdom), 2018, 27, 1397-1421.	0.8	22
2021	A feasibility study of breast cancer genetic risk assessment in a federally qualified health center. Cancer, 2018, 124, 3733-3741.	2.0	17
2022	A suggested framework for conducting esophageal cancer screening in China. Journal of Digestive Diseases, 2018, 19, 722-729.	0.7	12
2023	Review of non-clinical risk models to aid prevention of breast cancer. Cancer Causes and Control, 2018, 29, 967-986.	0.8	15
2024	Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. Cancer Research, 2018, 78, 6011-6021.	0.4	67
2025	Breast Cancer Incidence and Risk Reduction in the Hispanic Population. Cureus, 2018, 10, e2235.	0.2	36
2026	Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested caseâ€"control study. PLoS Medicine, 2018, 15, e1002644.	3.9	91
2027	Breast Cancer Screening and Optimizing Recommendations. Seminars in Roentgenology, 2018, 53, 280-293.	0.2	2

#	Article	IF	Citations
2028	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagnostic and Prognostic Research, 2018, 2, .	0.8	5
2029	Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Research and Treatment, 2018, 171, 435-442.	1.1	73
2030	Social factors matter in cancer risk and survivorship. Cancer Causes and Control, 2018, 29, 611-618.	0.8	68
2031	A randomized controlled trial of a supportive expressive group intervention for women with a family history of breast cancer. Psycho-Oncology, 2018, 27, 2645-2653.	1.0	10
2032	Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer, 2018, 124, 3319-3328.	2.0	7
2033	Exploration of Racial Differences in Reproductive Factors for Breast Cancer among Women aged 55-74. Journal of Cancer, 2018, 9, 469-478.	1.2	0
2034	Occurrence of Occult Malignancies in Reduction Mammoplasties. Frontiers in Surgery, 2018, 5, 17.	0.6	8
2035	Case Report and Review of Adolescent Atypical Ductal Hyperplasia and Juvenile Fibroadenoma: How Do We Assess and Manage Future Risk?. Clinical Breast Cancer, 2018, 18, e751-e754.	1.1	1
2036	The current application of the Royston-Parmar model for prognostic modeling in health research: a scoping review. Diagnostic and Prognostic Research, 2018, 2, 4.	0.8	23
2037	Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease. Breast Cancer Research, 2018, 20, 91.	2.2	10
2039	CE: Breast Cancer Screening: A Review of Current Guidelines. American Journal of Nursing, 2018, 118, 34-41.	0.2	18
2040	Mammography Screening 2.0 â€" How Can Risk-Adapted Screening be Implemented in Clinical Practice?. Geburtshilfe Und Frauenheilkunde, 2018, 78, 506-511.	0.8	4
2041	Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools. Journal of Women's Health, 2019, 28, 114-116.	1.5	10
2042	Re-evaluating if observation continues to be the best management of idiopathic granulomatous mastitis. Surgery, 2019, 166, 1176-1180.	1.0	41
2043	Barriers and facilitators to implementing cancer prevention clinical decision support in primary care: a qualitative study. BMC Health Services Research, 2019, 19, 534.	0.9	29
2044	Patterns of Breast Imaging Use Among Women with a Personal History of Breast Cancer. Journal of General Internal Medicine, 2019, 34, 2098-2106.	1.3	7
2045	Dynamic risk prediction for diabetes using biomarker change measurements. BMC Medical Research Methodology, 2019, 19, 175.	1.4	8
2046	Recent development in lung risk prediction model and its characteristic. Journal of Physics: Conference Series, 2019, 1150, 012011.	0.3	1

#	ARTICLE	IF	CITATIONS
2047	Breast Cancer Susceptibility—Towards Individualised Risk Prediction. Current Genetic Medicine Reports, 2019, 7, 124-135.	1.9	4
2048	Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire. Genetics and Molecular Biology, 2019, 42, 232-237.	0.6	12
2050	Screening of populations at high risk for breast cancer. Journal of Surgical Oncology, 2019, 120, 820-830.	0.8	10
2051	Synthetic data method to incorporate external information into a current study. Canadian Journal of Statistics, 2019, 47, 580-603.	0.6	12
2052	Interactive decision support for esophageal adenocarcinoma screening and surveillance. BMC Gastroenterology, 2019, 19, 109.	0.8	4
2053	Risk estimation, anxiety, and breast cancer worry in women at risk for breast cancer: A single‐arm trial of personalized risk communication. Psycho-Oncology, 2019, 28, 2226-2232.	1.0	15
2054	Challenges with quality of race and ethnicity data in observational databases. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 730-736.	2.2	116
2055	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectrum, 2019, 3, pkz066.	1.4	8
2056	Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. Cancer, 2019, 125, 4407-4416.	2.0	19
2057	Medication Use to Reduce Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 857.	3.8	132
2058	Medication Use for the Risk Reduction of Primary Breast Cancer in Women. JAMA - Journal of the American Medical Association, 2019, 322, 868.	3.8	81
2059	Breast Cancer Risk Prediction Models: Challenges in Clinical Application. , 2019, 23, 256-259.		0
2060	A Multi-Center Competing Risks Model and Its Absolute Risk Calculation Approach. International Journal of Environmental Research and Public Health, 2019, 16, 3435.	1.2	1
2061	Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians. Preventive Medicine, 2019, 129, 105834.	1.6	22
2062	Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Research and Treatment, 2019, 175, 229-237.	1.1	7
2063	Guidelines-Based Cancer Risk Assessment. Seminars in Oncology Nursing, 2019, 35, 34-46.	0.7	5
2064	Excision recommended in high-risk patients: Revisiting the diagnosis of papilloma on core biopsy in the context of patient risk. Breast Journal, 2019, 25, 232-236.	0.4	15
2065	Interprofessional work in early detection of breast cancer: An integrative review. Radiography, 2019, 25, 170-177.	1.1	4

#	ARTICLE	IF	CITATIONS
2066	Predicting Breast Cancer by Applying Deep Learning to Linked Health Records and Mammograms. Radiology, 2019, 292, 331-342.	3.6	115
2067	Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models. Breast Cancer Research, 2019, 21, 75.	2.2	73
2068	Female family members lack understanding of indeterminate negative BRCA1/2 test results shared by probands. Journal of Genetic Counseling, 2019, 28, 950-961.	0.9	5
2069	A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging, 2019, 1, 99-106.	0.5	39
2070	Breast Cancer Risk Assessment and Genetic Testing. , 2019, , 367-382.		0
2071	A systematic review and quality assessment of individualised breast cancer risk prediction models. British Journal of Cancer, 2019, 121, 76-85.	2.9	89
2072	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 61-74.	1.8	41
2073	A Deep Learning Mammography-based Model for Improved Breast Cancer Risk Prediction. Radiology, 2019, 292, 60-66.	3.6	401
2074	Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population. Cancer Genetics, 2019, 235-236, 72-76.	0.2	18
2075	Comparing the Various Breast Cancer Screening Guidelines. Journal for Nurse Practitioners, 2019, 15, 574-578.	0.4	0
2076	Comparison of Questionnaire-Based Breast Cancer Prediction Models in the Nurses' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1187-1194.	1.1	12
2077	Establishing Cohorts to Generate the Evidence Base to Reduce the Burden of Breast Cancer in Sub-Saharan Africa: Results From a Feasibility Study in Kenya. Journal of Global Oncology, 2019, 5, 1-10.	0.5	1
2078	Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI. American Journal of Roentgenology, 2019, 212, 1412-1418.	1.0	15
2079	Factors associated with intentions for breast cancer risk management: Does risk group matter?. Psycho-Oncology, 2019, 28, 1119-1126.	1.0	5
2080	Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer. Journal of Personalized Medicine, 2019, 9, 15.	1.1	21
2081	Applying the Hippocratic Oath in breast cancer-The case for promoting prevention. Breast Journal, 2019, 25, 187-189.	0.4	0
2082	Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms. Breast, 2019, 46, 48-51.	0.9	8
2083	Implementing a Population-Based Breast Cancer Risk Assessment Program. Clinical Breast Cancer, 2019, 19, 246-253.e2.	1.1	9

#	Article	IF	Citations
2084	Utilization of a breast cancer risk assessment tool by internal medicine residents in a primary care clinic: impact of an educational program. BMC Cancer, 2019, 19, 228.	1.1	13
2086	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Research and Treatment, 2019, 176, 141-148.	1.1	56
2087	Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Research, 2019, 21, 48.	2.2	52
2088	Deep Learning Model to Assess Cancer Risk on the Basis of a Breast MR Image Alone. American Journal of Roentgenology, 2019, 213, 227-233.	1.0	21
2089	Ultrasound for Breast Cancer Screening in High-Risk Women: Results From a Population-Based Cancer Screening Program in China. Frontiers in Oncology, 2019, 9, 286.	1.3	18
2090	Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Research and Treatment, 2019, 175, 519-523.	1.1	55
2091	Modeling risk assessment for breast cancer in symptomatic women: a Saudi Arabian study . Cancer Management and Research, 2019, Volume 11, 1125-1132.	0.9	3
2092	The Impact of a Risk-Based Breast Cancer Screening Decision Aid on Initiation of Mammography Among Younger Women: Report of a Randomized Trial. MDM Policy and Practice, 2019, 4, 238146831881288.	0.5	16
2093	Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model. BMC Cancer, 2019, 19, 128.	1.1	12
2094	Imbalances in cellular immunological parameters in blood predetermine tumor onset in a natural mouse model of breast cancer. Cancer Immunology, Immunotherapy, 2019, 68, 721-729.	2.0	2
2096	10-year performance of four models of breast cancer risk: a validation study. Lancet Oncology, The, 2019, 20, 504-517.	5.1	116
2098	Combined effect of modifiable and non-modifiable risk factors for colorectal cancer risk in a pooled analysis of 11 population-based studies. BMJ Open Gastroenterology, 2019, 6, e000339.	1.1	28
2099	Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. Cancer Prevention Research, 2019, 12, 801-808.	0.7	6
2100	Detection of early breast cancer beyond mammographic screening: a promising biomarker panel. Biomarkers in Medicine, 2019, 13, 1107-1117.	0.6	11
2101	Cancer cases detected in the prevention and control service of a private cancer clinic in Peru. Infectious Agents and Cancer, 2019, 14, 44.	1.2	2
2102	Breast cancer risk assessment: Evaluation of screening tools for genetics referral. Journal of the American Association of Nurse Practitioners, 2019, 31, 562-572.	0.5	1
2103	Use of detailed family history data to improve risk prediction,with application to breast cancer screening. PLoS ONE, 2019, 14, e0226407.	1.1	3
2104	Predicting breast cancer risk using personal health data and machine learning models. PLoS ONE, 2019, 14, e0226765.	1.1	61

#	ARTICLE	IF	CITATIONS
2105	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 452-459.	1.1	31
2106	High-Intensity Interval Training Is Feasible in Women at High Risk for Breast Cancer. Medicine and Science in Sports and Exercise, 2019, 51, 2193-2200.	0.2	6
2107	Predictive Capacity of Risk Models in Liver Transplantation. Transplantation Direct, 2019, 5, e457.	0.8	18
2108	Development of a comprehensive health-risk prediction tool for postmenopausal women. Menopause, 2019, 26, 1385-1394.	0.8	7
2109	A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China . Cancer Management and Research, 2019, Volume 11, 10029-10039.	0.9	8
2110	<p>Risk Assessment for Breast Cancer Development and Its Clinical Impact on Screening Performance in Iranian Women</p>. Cancer Management and Research, 2019, Volume 11, 10073-10082.	0.9	3
2111	Assessment of Quantitative Magnetic Resonance Imaging Background Parenchymal Enhancement Parameters to Improve Determination of Individual Breast Cancer Risk. Journal of Computer Assisted Tomography, 2019, 43, 85-92.	0.5	11
2112	An Intervention Tool to Increase Patient–Physician Discussion of Lifestyle Risk Factors for Breast Cancer. Journal of Women's Health, 2019, 28, 1468-1475.	1.5	5
2113	Rural–Urban Residence and Stage at Breast Cancer Diagnosis Among Postmenopausal Women: The Women's Health Initiative. Journal of Women's Health, 2019, 28, 276-283.	1.5	14
2114	Performance of Single-Nucleotide Polymorphisms in Breast Cancer Risk Prediction Models: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 506-521.	1.1	15
2115	Risk Stratification for Screening Mammography: Benefits and Harms. American Journal of Roentgenology, 2019, 212, 250-258.	1.0	15
2116	Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development, 2019, , .	0.2	4
2117	Performance validation of the ALPPS risk model. Hpb, 2019, 21, 711-721.	0.1	14
2118	Estimating the receiver operating characteristic curve in matched case control studies. Statistics in Medicine, 2019, 38, 437-451.	0.8	8
2119	Informing a Risk Prediction Model for Binary Outcomes with External Coefficient Information. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 121-139.	0.5	17
2120	Estimating the risk of PTSD in recent trauma survivors: results of the International Consortium to Predict PTSD (ICPP). World Psychiatry, 2019, 18, 77-87.	4.8	126
2121	Beyond Breast Density: Radiomic Phenotypes Enhance Assessment of Breast Cancer Risk. Radiology, 2019, 290, 50-51.	3.6	10
2122	Assessing the medical workforces perceived barriers to the prescription of risk‐reducing medication for women at high‐risk of breast cancer. Breast Journal, 2019, 25, 34-40.	0.4	1

#	Article	IF	Citations
2123	Developing and validating the Personal Risk of Oncogenic Human Papillomavirus infection score in US Women. Family Practice, 2019, 36, 395-401.	0.8	1
2124	Exploring Explanatory Models of Risk in Breast Cancer Risk Counseling Discussions. Cancer Nursing, 2019, 42, 3-11.	0.7	12
2125	Prenatal diethylstilbestrol exposure and cancer risk in women. Environmental and Molecular Mutagenesis, 2019, 60, 395-403.	0.9	27
2126	Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. Journal of Community Genetics, 2019, 10, 61-71.	0.5	7
2127	BCRAM: A Social-Network-Inspired Breast Cancer Risk Assessment Model. IEEE Transactions on Industrial Informatics, 2019, 15, 366-376.	7.2	20
2128	Perception of Breast Cancer Risk in Over 11,000 Patients During Routine Mammography Exam. Journal of Cancer Education, 2020, 35, 782-787.	0.6	5
2129	Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification. Journal of the National Cancer Institute, 2020, 112, 278-285.	3.0	61
2130	The lure of incredible certitude. Economics and Philosophy, 2020, 36, 216-245.	0.3	16
2131	Assessment and management of B3 breast lesions with atypia: a focused review. Climacteric, 2020, 23, 17-23.	1.1	3
2132	Infertility and mortality. American Journal of Obstetrics and Gynecology, 2020, 222, 251.e1-251.e10.	0.7	29
2133	Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. Journal of the National Cancer Institute, 2020, 112, 489-497.	3.0	59
2134	Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2020, 27, 627-629.	0.7	3
2135	Choosing Breast Cancer Risk Models: Importance of Independent Validation. Journal of the National Cancer Institute, 2020, 112, 433-435.	3.0	12
2136	Machine learning approach for breast cancer prognosis prediction. , 2020, , 41-68.		7
2137	Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. British Journal of Dermatology, 2020, 182, 1262-1268.	1.4	12
2138	Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk. Journal of Surgical Research, 2020, 245, 153-162.	0.8	1
2139	Effect of interventions including provision of personalised cancer risk information on accuracy of risk perception and psychological responses: A systematic review and meta-analysis. Patient Education and Counseling, 2020, 103, 83-95.	1.0	12
2140	A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International Journal of Cancer, 2020, 146, 2122-2129.	2.3	38

#	Article	IF	Citations
2141	Estimating the decision curve and its precision from three study designs. Biometrical Journal, 2020, 62, 764-776.	0.6	5
2142	Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome. American Journal of Surgery, 2020, 219, 430-433.	0.9	3
2143	Deep learning modeling using normal mammograms for predicting breast cancer risk. Medical Physics, 2020, 47, 110-118.	1.6	71
2144	Individual and joint performance of DNA methylation profiles, genetic risk score and environmental risk scores for predicting breast cancer risk. Molecular Oncology, 2020, 14, 42-53.	2.1	13
2145	Risk-based breast cancer screening strategies in women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 3-17.	1.4	48
2146	Data Sharing for the Public Good. Journal of the National Cancer Institute, 2020, 112, 867-868.	3.0	0
2147	Screening and Early Detection. , 2020, , 375-398.e7.		1
2148	Censored linear regression in the presence or absence of auxiliary survival information. Biometrics, 2020, 76, 734-745.	0.8	6
2149	Breast cancer prevention in high-risk women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 18-31.	1.4	98
2150	Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. Cancer Medicine, 2020, 9, 816-823.	1.3	6
2151	Radiologic Technologist and Radiologist Knowledge Gaps about Breast Density Revealed by an Online Continuing Education Course. Journal of Breast Imaging, 2020, 2, 315-329.	0.5	2
2152	Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hereditary Cancer in Clinical Practice, 2020, 18, 20.	0.6	3
2153	Predicting the risk of esophageal high-grade lesions in opportunistic screening. Gastrointestinal Endoscopy, 2020, 92, 1136-1137.	0.5	1
2154	Breast cancer risk assessment and management programs: A practical guide. Breast Journal, 2020, 26, 1556-1564.	0.4	7
2155	Utilization of Complementary Alternative Medicine, Diet, and Exercise Among Women at High Risk for Developing Breast Cancer. Integrative Cancer Therapies, 2020, 19, 153473542092261.	0.8	1
2156	Utilization of health information technology among cancer genetic counselors. Molecular Genetics & Genomic Medicine, 2020, 8, e1315.	0.6	14
2157	Family health history's place in genomic medicine. , 2020, , 29-48.		0
2158	A preliminary risk prediction model for cannabis use disorder. Preventive Medicine Reports, 2020, 20, 101228.	0.8	9

#	Article	IF	Citations
2159	Breast cancer risk assessment and early diagnosis using Principal Component Analysis and support vector machine techniques. Informatics in Medicine Unlocked, 2020, 21, 100459.	1.9	4
2160	At the intersection of precision medicine and population health: an implementation-effectiveness study of family health history based systematic risk assessment in primary care. BMC Health Services Research, 2020, 20, 1015.	0.9	13
2161	Menopausal Hormone Therapy and Long-term Breast Cancer Risk. JAMA - Journal of the American Medical Association, 2020, 324, 347.	3.8	4
2162	Whole Breast Sound Speed Measurement from US Tomography Correlates Strongly with Volumetric Breast Density from Mammography. Journal of Breast Imaging, 2020, 2, 443-451.	0.5	4
2163	Differences in breast cancer risk after benign breast disease by type of screening diagnosis. Breast, 2020, 54, 343-348.	0.9	12
2164	Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities. Npj Digital Medicine, 2020, 3, 99.	5.7	106
2166	Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial. Cancers, 2020, 12, 2526.	1.7	3
2167	Breast Cancer Risk Perception and Mammography Screening Behavior of Women in Northeast Brazil. Women S Health Reports, 2020, 1, 150-158.	0.4	6
2168	Analysis of breast cancer data: a comparative study on different feature selection techniques. , 2020, , .		3
2169	Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology, 2020, 297, 327-333.	3.6	40
2170	Inference about time-dependent prognostic accuracy measures in the presence of competing risks. BMC Medical Research Methodology, 2020, 20, 219.	1.4	4
2171	The association between cigarette smoking, cancer screening, and cancer stage: a prospective study of the womenâ€™s health initiative observational cohort. BMJ Open, 2020, 10, e037945.	0.8	15
2172	New Approach for Risk Estimation Algorithms of BRCA1/2 Negativeness Detection with Modelling Supervised Machine Learning Techniques. Disease Markers, 2020, 2020, 1-7.	0.6	0
2173	The accuracy of breast cancer risk self-assessment does not correlate with knowledge about breast cancer and knowledge and attitudes towards primary chemoprevention. Preventive Medicine Reports, 2020, 20, 101229.	0.8	5
2174	Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2389-2394.	1.1	16
2175	Incidence and Clinicopathological Features of Breast Cancer in the Northern Emirates: Experience from Sharjah Breast Care Center . International Journal of Women's Health, 2020, Volume 12, 893-899.	1.1	7
2176	Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights. Cells, 2020, 9, 1091.	1.8	38
2177	Assessing breast cancer risk within the general screening population: developing a breast cancer risk model to identify higher risk women at mammographic screening. European Radiology, 2020, 30, 5417-5426.	2.3	10

#	Article	IF	Citations
2178	Assessment of the risk of developing breast cancer using the Gail model in Asian females: A systematic review. Heliyon, 2020, 6, e03794.	1.4	13
2179	Precision health through prediction modelling: factors to consider before implementing a prediction model in clinical practice. Journal of Primary Health Care, 2020, 12, 3.	0.2	9
2180	The Increasing Complexity of Preventive Services. Journal of Women's Health, 2020, 29, 748-749.	1.5	0
2181	Adult height after gonadotropinâ€releasing hormone agonist treatment in girls with early puberty: A metaâ€analysis. Clinical Endocrinology, 2020, 93, 135-145.	1.2	6
2182	Reply to BC Johnston and GH Guyatt. American Journal of Clinical Nutrition, 2020, 111, 1108-1109.	2.2	2
2183	Impact of adding breast density to breast cancer risk models: A systematic review. European Journal of Radiology, 2020, 127, 109019.	1.2	33
2184	Validation of two US breast cancer risk prediction models in German women. Cancer Causes and Control, 2020, 31, 525-536.	0.8	5
2185	The joy and duty of a marginal teratologist. Birth Defects Research, 2020, 112, 918-928.	0.8	0
2186	Key steps for effective breast cancer prevention. Nature Reviews Cancer, 2020, 20, 417-436.	12.8	386
2187	Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Womenâ€™s Health Initiative. Cancer, 2020, 126, 3638-3647.	2.0	48
2188	Generalized mean residual life models for case-cohort and nested case-control studies. Lifetime Data Analysis, 2020, 26, 789-819.	0.4	4
2189	Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer. Npj Breast Cancer, 2020, 6, 24.	2.3	10
2190	Breast Cancer Risk Assessment. Mayo Clinic Proceedings, 2020, 95, 1268-1275.	1.4	12
2191	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
2192	Practical implementation of frailty models in Mendelian risk prediction. Genetic Epidemiology, 2020, 44, 564-578.	0.6	2
2193	Risk Stratification Strategies for Colorectal Cancer Screening. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 423-440.	0.6	2
2194	The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health, 2020, 20, 876.	1.2	4
2195	Estimation of Absolute Risk of Colorectal Cancer Based on Healthy Lifestyle, Genetic Risk, and Colonoscopy Status in a Population-Based Study. Gastroenterology, 2020, 159, 129-138.e9.	0.6	67

#	ARTICLE	IF	CITATIONS
2196	Breast cancer risk, worry, and anxiety: Effect on patient perceptions of false-positive screening results. Breast, 2020, 50, 104-112.	0.9	13
2197	Association between selenium intake and breast cancer risk: results from the Women's Health Initiative. Breast Cancer Research and Treatment, 2020, 183, 217-226.	1.1	16
2198	Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial. Menopause, 2020, 27, 693-700.	0.8	15
2199	A Complex Systems Model of Breast Cancer Etiology: The Paradigm II Conceptual Model. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1720-1730.	1.1	11
2200	Factors to Consider in Developing Breast Cancer Risk Models to Implement into Clinical Care. Current Epidemiology Reports, 2020, 7, 113-116.	1.1	2
2201	Pre-implementation adaptation of primary care cancer prevention clinical decision support in a predominantly rural healthcare system. BMC Medical Informatics and Decision Making, 2020, 20, 117.	1.5	9
2202	iCARE: An R package to build, validate and apply absolute risk models. PLoS ONE, 2020, 15, e0228198.	1.1	61
2204	The Menstrual Cycle and Risk of Breast Cancer: A Review. Frontiers in Oncology, 2020, 10, 21.	1.3	33
2205	Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions. Cancers, 2020, 12, 508.	1.7	36
2206	The Application of Gail Model to Predict the Risk of Developing Breast Cancer among Jordanian Women. Journal of Oncology, 2020, 2020, 1-6.	0.6	4
2207	Inclusion of Endogenous Plasma Dehydroepiandrosterone Sulfate and Mammographic Density in Risk Prediction Models for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 574-581.	1.1	6
2208	A unified approach for synthesizing population-level covariate effect information in semiparametric estimation with survival data. Statistics in Medicine, 2020, 39, 1573-1590.	0.8	10
2209	Breast cancer risk prediction models and subsequent tumor characteristics. Breast Cancer, 2020, 27, 662-669.	1.3	3
2210	Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer. Human Molecular Genetics, 2020, 29, 662-673.	1.4	13
2211	Breast cancer risk reduction: Notable achievements and remaining challenges. Breast Journal, 2020, 26, 86-91.	0.4	3
2212	Radial Profile Analysis of Epithelial Polarity in Breast Acini: A Tool for Primary (Breast) Cancer Prevention. Frontiers in Medicine, 2019, 6, 314.	1.2	5
2213	Translate but validate: necessary steps in improving the use and utility of cancer risk models. Cancer Causes and Control, 2020, 31, 537-540.	0.8	1
2214	Personalized risk prediction for breast cancer pre-screening using artificial intelligence and thermal radiomics. Artificial Intelligence in Medicine, 2020, 105, 101854.	3.8	38

#	ARTICLE	IF	CITATIONS
2215	An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 87-89.	0.9	26
2216	Validating Breast Cancer Risk Prediction Models in the Korean Cancer Prevention Study-II Biobank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1271-1277.	1.1	6
2217	Effect of a Mammography Screening Decision Aid for Women 75 Years and Older. JAMA Internal Medicine, 2020, 180, 831.	2.6	40
2218	ASMBS position statement on the relationship between obesity and cancer, and the role of bariatric surgery: risk, timing of treatment, effects on disease biology, and qualification for surgery. Surgery for Obesity and Related Diseases, 2020, 16, 713-724.	1.0	14
2219	Predicting the risk of depression among adolescents in Nepal using a model developed in Brazil: the IDEA Project. European Child and Adolescent Psychiatry, 2021, 30, 213-223.	2.8	22
2220	Impact of Age, Race, and Socioeconomic Status on Women's Perceptions and Preferences Regarding Communication of Estimated Breast Cancer Risk. Academic Radiology, 2021, 28, 655-663.	1.3	4
2221	Germline testing for homologous recombination repair genesâ€"opportunities and challenges. Genes Chromosomes and Cancer, 2021, 60, 332-343.	1.5	7
2222	Additive value of exposure parameters for breast cancer diagnosis in digital mammography. European Radiology, 2021, 31, 2539-2547.	2.3	2
2223	Derivation and validation of a predictive model for advanced colorectal neoplasia in asymptomatic adults. Gut, 2021, 70, 1155-1161.	6.1	12
2224	Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment. Annals of Internal Medicine, 2021, 174, 408-412.	2.0	13
2225	Applications of Artificial Intelligence in Breast Imaging. Radiologic Clinics of North America, 2021, 59, 139-148.	0.9	29
2226	Potential of using mammography screening appointments to identify high-risk women: cross sectional survey results from the national health interview survey. Breast Cancer Research and Treatment, 2021, 186, 229-235.	1.1	2
2227	Empirical evaluation of sub-cohort sampling designs for risk prediction modeling. Journal of Applied Statistics, 2021, 48, 1374-1401.	0.6	4
2228	Breast cancer screening in women at high risk of hereditary breast cancer: an Australian experience. ANZ Journal of Surgery, 2021, 91, 685-690.	0.3	2
2229	The Steroid Metabolome and Breast Cancer Risk in Women with a Family History of Breast Cancer: The Novel Role of Adrenal Androgens and Glucocorticoids. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 89-96.	1.1	8
2230	Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community. JCO Oncology Practice, 2021, 17, e217-e225.	1.4	9
2231	Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A populationâ€"based cohort study. International Journal of Cancer, 2021, 148, 1351-1359.	2.3	4
2233	High-Risk Patients for Gynaecological Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 49-63.	0.1	0

#	Article	IF	Citations
2234	Deep Learning-Based Artificial Intelligence for Mammography. Korean Journal of Radiology, 2021, 22, 1225.	1.5	37
2235	Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. JNCI Cancer Spectrum, 2021, 5, pkaa114.	1.4	4
2236	Management Strategies for Women at an Inherited High Risk of Breast Cancer. , 2021, , 53-56.		0
2237	A streamlined model for use in clinical breast cancer risk assessment maintains predictive power and is further improved with inclusion of a polygenic risk score. PLoS ONE, 2021, 16, e0245375.	1.1	6
2238	Association between Breast Cancer Screening Intention and Behavior in the Context of Screening Cessation in Older Women. Medical Decision Making, 2021, 41, 240-244.	1.2	4
2239	Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. MHealth, 2021, 7, 0-0.	0.9	3
2240	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2021, 30, 342-360.	0.9	18
2241	Assessing the clinical utility of genetic risk scores for targeted cancer screening. Journal of Translational Medicine, 2021, 19, 41.	1.8	5
2242	Personalized Screening for Breast Cancer: Rationale, Present Practices, and Future Directions. Annals of Surgical Oncology, 2021, 28, 4306-4317.	0.7	30
2243	Present Options in the Prevention of Breast Cancer. , 2021, , 117-127.		0
2244	Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation. BMC Cancer, 2021, 21, 194.	1.1	6
2245	Relation of Quantitative Histologic and Radiologic Breast Tissue Composition Metrics With Invasive Breast Cancer Risk. JNCI Cancer Spectrum, 2021, 5, pkab015.	1.4	7
2246	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. Journal of Breast Imaging, 2021, 3, 144-155.	0.5	47
2247	Synthesizing external aggregated information in the presence of population heterogeneity: A penalized empirical likelihood approach. Biometrics, 2022, 78, 679-690.	0.8	12
2248	Reply. Journal of Vascular Surgery, 2021, 73, 1113-1114.	0.6	0
2249	Accuracy of self-perceived risk perception of breast cancer development in Iranian women. BMC Women's Health, 2021, 21, 93.	0.8	3
2250	Facilities of a comprehensive examination in the diagnosis of benign breast diseases and breast cancer. Gynecology, 2021, 23, 48-54.	0.1	0
2251	Design and rationale of an intervention to improve cancer prevention using clinical decision support and shared decision making: A clinic-randomized trial. Contemporary Clinical Trials, 2021, 102, 106271.	0.8	10

#	ARTICLE	IF	CITATIONS
2252	Artificial Intelligence and Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 251-279.	0.5	71
2253	Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS ONE, 2021, 16, e0248930.	1.1	7
2254	Estimating the Breast Cancer Burden in Germany and Implications for Risk-based Screening. Cancer Prevention Research, 2021, 14, 627-634.	0.7	1
2255	The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease. Npj Breast Cancer, 2021, 7, 23.	2.3	5
2256	Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study. Breast Cancer Research and Treatment, 2021, 188, 749-758.	1.1	3
2258	Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort. BMJ Open, 2021, 11, e045078.	0.8	4
2259	Risk Projection for Time-to-Event Outcome Leveraging Summary Statistics With Source Individual-Level Data. Journal of the American Statistical Association, 0, , 1-13.	1.8	4
2260	Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients. Mayo Clinic Proceedings, 2021, 96, 1033-1040.	1.4	7
2261	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. BMC Cancer, 2021, 21, 637.	1.1	15
2262	Distribution of Estimated Lifetime Breast Cancer Risk Among Women Undergoing Screening Mammography. American Journal of Roentgenology, 2021, 217, 48-55.	1.0	8
2263	A systematic review of decision aids for mammography screening: Focus on outcomes and characteristics. International Journal of Medical Informatics, 2021, 149, 104406.	1.6	10
2265	Development and external validation of a breast cancer absolute risk prediction model in Chinese population. Breast Cancer Research, 2021, 23, 62.	2.2	6
2266	Mammographic microcalcifications and risk of breast cancer. British Journal of Cancer, 2021, 125, 759-765.	2.9	32
2268	Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. Npj Breast Cancer, 2021, 7, 78.	2.3	12
2270	Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese Medical Journal, 2021, 134, 1655-1657.	0.9	3
2271	Endocrine prevention of breast cancer. Molecular and Cellular Endocrinology, 2021, 530, 111284.	1.6	8
2272	Low-Fat Dietary Modification and Risk of Ductal Carcinoma In Situ of the Breast in the Women's Health Initiative Dietary Modification Trial. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1753-1756.	1.1	2
2273	Association of Family History with the Development of Breast Cancer: A Cohort Study of 129,374 Women in KoGES Data. International Journal of Environmental Research and Public Health, 2021, 18, 6409.	1.2	5

#	Article	IF	Citations
2274	Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States. Journal of Genetic Counseling, 2021, 30, 1737-1747.	0.9	2
2275	A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. JNCI Cancer Spectrum, 2021, 5, pkab072.	1.4	12
2276	Burden of Risk Factors for Cervical Cancer Among Women Living in East Africa: An Analysis of the Latest Demographic Health Surveys Conducted Between 2014 and 2017. JCO Global Oncology, 2021, 7, 1116-1128.	0.8	5
2277	Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer. Breast Cancer Research and Treatment, 2021, 189, 533-539.	1.1	6
2278	Management of Cardiovascular Risk in Perimenopausal Women with Diabetes. Diabetes and Metabolism Journal, 2021, 45, 492-501.	1.8	8
2279	Dose†dependent effects of aerobic exercise on clinically relevant biomarkers among healthy women at high genetic risk for breast cancer: A secondary analysis of a randomized controlled study. Cancer Reports, 2021, , e1497.	0.6	3
2280	A Personal Breast Cancer Risk Stratification Model Using Common Variants and Environmental Risk Factors in Japanese Females. Cancers, 2021, 13, 3796.	1.7	4
2281	Primary Care Providers Underutilize Breast Screening MRI for High-Risk Women. Current Problems in Diagnostic Radiology, 2021, 50, 489-494.	0.6	4
2282	Capturing the Rest: Inpatient Mammography for Nonadherent Hospitalized Women. American Journal of Preventive Medicine, 2021, 61, 709-715.	1.6	3
2283	A meta-inference framework to integrate multiple external models into a current study. Biostatistics, 2023, 24, 406-424.	0.9	7
2284	Performance of the IBIS/Tyrer†Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. Cancer, 2021, 127, 3742-3750.	2.0	21
2285	Re†calibrating pure risk integrating individual data from two†phase studies with external summary statistics. Biometrics, 2022, 78, 1515-1529.	0.8	2
2286	Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers, 2021, 13, 4150.	1.7	21
2287	Effects by educational attainment of a mammography screening patient decision aid for women aged 75 years and older. Cancer, 2021, 127, 4455-4463.	2.0	3
2288	Increasing referral of at†risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer, 2021, , .	2.0	5
2289	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	1.0	0
2290	Breast Density Awareness and Knowledge in a Mammography Screening Cohort of Predominantly Hispanic Women: Does Breast Density Notification Matter?. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1913-1920.	1.1	10
2291	Blood DNA methylation profiles improve breast cancer prediction. Molecular Oncology, 2022, 16, 42-53.	2.1	19

#	Article	IF	Citations
2293	Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. Journal of Clinical Oncology, 2021, 39, 3012-3021.	0.8	9
2294	Predicting the risk of cancer in adults using supervised machine learning: a scoping review. BMJ Open, 2021, 11, e047755.	0.8	13
2295	Determination of thresholds of risk in women at average risk of breast cancer to personalize the organized screening program. Scientific Reports, 2021, 11, 19104.	1.6	3
2296	Breast diseases. , 2022, , 289-322.e3.		1
2297	Public Records. , 2021, , 6413-6417.		0
2298	Estimating Individualized Absolute Risk for Esophageal Squamous Cell Carcinoma: A Population-Based Study in High-Risk Areas of China. Frontiers in Oncology, 2020, 10, 598603.	1.3	16
2299	Toward robust mammography-based models for breast cancer risk. Science Translational Medicine, 2021, 13, .	5.8	100
2300	Breast cancer â€" diagnostic and therapeutic approach with an emphasis on pregnancy. Ginecologia Ro, 2021, 3, 16.	0.0	0
2301	Genetic cancer risk assessment. Cancer, 1999, 86, 1663-1672.	2.0	5
2302	Genetic cancer risk assessment. Putting it all together. Cancer, 1999, 86, 2483-92.	2.0	23
2305	The relationship between age and incidence of breast cancer population and screening program data. Cancer, 1992, 69, 1896-1903.	2.0	22
2306	The effect of dietary fat and fiber on serum estrogen concentrations in premenopausal women under controlled dietary conditions. Cancer, 1994, 74, 1125-1131.	2.0	88
2307	Lung Cancer Susceptibility and Risk Assessment Models. , 0, , 33-60.		1
2308	Genetic Counseling for Inherited Cancer Syndromes. , 2004, , 30-60.		1
2309	Challenges in Monitoring the Breast Cancer Prevention Trial. , 2006, , 118-135.		4
2310	Benigne und maligne Tumoren der Mamma. , 2006, , 689-731.		1
2311	Benign and Malignant Diseases of the Breast. , 2008, , 2005-2035.		1
2312	Breast Cancer Prevention. Cancer Treatment and Research, 2008, 141, 149-164.	0.2	27

#	ARTICLE	IF	CITATIONS
2313	Prevention of Breast Cancer Using SERMs. Advances in Experimental Medicine and Biology, 2008, 630, 232-236.	0.8	8
2314	Risk Factors. , 2010, , 3-22.		5
2315	Breast Cancer Chemoprevention. , 2010, , 43-59.		2
2316	The insulin-like growth factor-1 ligand in breast cancer management. Cancer Metastasis - Biology and Treatment, 2007, , 203-217.	0.1	1
2317	Fertility Communication and High-Risk Patients. , 2014, , 61-72.		2
2318	Statistical Models for Screening: Planning Public Health Programs. Cancer Treatment and Research, 2002, 113, 19-36.	0.2	3
2319	Daughters of Breast Cancer Patients. , 1998, , 603-619.		3
2320	Psychological distress associated with genetic breast cancer risk. , 1996, , 282-289.		7
2321	Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs. , 2005, , 213-237.		5
2322	Counteracting Estrogen as Breast Cancer Prevention. , 2005, , 249-264.		4
2323	Lifestyle, Genes, and Cancer. Methods in Molecular Biology, 2009, 472, 25-56.	0.4	35
2324	Epigenetic Epidemiology for Cancer Risk: Harnessing Germline Epigenetic Variation. Methods in Molecular Biology, 2012, 863, 439-465.	0.4	17
2326	Genomic Cancer Risk Assessment. , 2020, , 187-207.		1
2327	Exploring Breast Cancer Prediction for Cuban Women. Advances in Intelligent Systems and Computing, 2020, , 480-489.	0.5	3
2328	A Revisit on Correlation between TabÃ¡r and Birads Based Risk Assessment Schemes with Full Field Digital Mammography. Lecture Notes in Computer Science, 2014, , 327-333.	1.0	1
2329	Breast Cancer Epidemiology. , 2016, , 125-137.		6
2330	Endocrine Therapy in Clinical Practice. Cancer Drug Discovery and Development, 2019, , 215-240.	0.2	1
2331	Rates, Risks, Measures of Association and Impact. , 2005, , 89-156.		4

#	Article	IF	Citations
2332	Pronto: A Non-monotonic Probabilistic Description Logic Reasoner. , 2008, , 822-826.		25
2333	Optimization and Evaluation of Reasoning in Probabilistic Description Logic: Towards a Systematic Approach. Lecture Notes in Computer Science, 2008, , 213-228.	1.0	22
2334	The New Paradigm in Breast Cancer Prevention. , 2004, , 379-438.		2
2336	A Phantom Study for Assessing the Effect of Different Digital Detectors on Mammographic Texture Features. Lecture Notes in Computer Science, 2012, , 604-610.	1.0	5
2338	Tamoxifenâ€™s Impact as a Preventive Agent in Clinical Practice and an Update on the STAR Trial. Recent Results in Cancer Research, 2003, 163, 87-95.	1.8	13
2339	Benign and Malignant Diseases of the Breast. , 2001, , 1699-1732.		2
2340	Identification of the Woman at Risk for Breast Cancer: Problem Solved?. Recent Results in Cancer Research, 1999, 151, 85-95.	1.8	11
2341	Familial Breast Cancer. Recent Results in Cancer Research, 1996, 140, 5-16.	1.8	13
2342	Design and Current Status of the NSABP Breast Cancer Prevention Trial. Recent Results in Cancer Research, 1996, 140, 309-317.	1.8	7
2343	Who Develops Breast Cancer?. , 1995, , 3-9.		2
2344	Counseling the High-Risk Woman. , 1995, , 69-80.		2
2345	Translational Research in Oncology. , 2020, , 261-311.		3
2346	The Role of Genomics in Enabling Prospective Health Care. , 2009, , 378-385.		5
2347	Cancer Prevention, Screening, and Early Detection. , 2008, , 361-395.		3
2349	Epidemiology of Lung Cancer. , 2010, , 1098-1115.		339
2350	Primary Prevention of Breast Cancer. , 2009, , 349-369.		1
2351	Clinical Management of the Patient at Increased or High Risk. , 2009, , 1381-1392.		1
2352	The Breast. , 2010, , 1065-1095.		20

#	ARTICLE	IF	CITATIONS
2353	Gail Model Improves the Diagnostic Performance of the Fifth Edition of Ultrasound BI-RADS for Predicting Breast Cancer: A Multicenter Prospective Study. Academic Radiology, 2022, 29, S1-S7.	1.3	8
2355	MR IMAGING IN SCREENING WOMEN AT INCREASED RISK FOR BREAST CANCER. Magnetic Resonance Imaging Clinics of North America, 2001, 9, 357-372.	0.6	21
2357	Genetic testing: psychological aspects and implications. Journal of Consulting and Clinical Psychology, 2002, 70, 784-97.	1.6	132
2358	A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. Health Psychology, 1996, 15, 75-83.	1.3	70
2359	Stress and genetic testing for disease risk. Health Psychology, 1997, 16, 8-19.	1.3	63
2360	Physical symptoms, distress, and breast cancer risk perceptions in women with benign breast problems. Health Psychology, 1998, 17, 371-5.	1.3	19
2361	Breast cancer: Psychosocial factors influencing risk perception, screening, diagnosis, and treatment.. , 1997, , 295-314.		6
2362	Issues in Bilateral Prophylactic Mastectomy. Cancer Practice, 2001, 9, 6-10.	0.8	1
2363	CaDet, a Computer-Based Clinical Decision Support System for Early Cancer Detection. Cancer Detection and Prevention, 1999, 23, 78-87.	2.1	5
2364	Color Data v2: a user-friendly, open-access database with hereditary cancer and hereditary cardiovascular conditions datasets. Database: the Journal of Biological Databases and Curation, 2020, 2020, .	1.4	5
2365	Risk Comprehension and Judgments of Statistical Evidentiary Appeals: When a Picture is Not Worth a Thousand Words. Human Communication Research, 2005, 31, 423-452.	1.9	21
2366	Risk for Subsequent Development of Breast Cancer. American Journal of Surgical Pathology, 2003, 27, 271-274.	2.1	11
2367	Inherited susceptibility to breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology, 1998, 10, 3-8.	0.9	5
2368	The family history component of cancer genetic risk counseling. Cancer Nursing, 1999, 22, 96-102.	0.7	10
2369	Breast Cancer Risk Analysis and Counseling. Clinical Obstetrics and Gynecology, 1996, 39, 851-859.	0.6	5
2370	Does This Patient Have Breast Cancer? The Screening Clinical Breast Examination: Should It Be Done? How?. Obstetrical and Gynecological Survey, 2000, 55, 432-433.	0.2	3
2371	Prognosis Based Definition of Resectability in Pancreatic Cancer. Annals of Surgery, 2022, 275, 175-181.	2.1	46
2372	Breast Cancer: Risk Assessment and Prevention. Southern Medical Journal, 2010, 103, 333-338.	0.3	13

#	ARTICLE	IF	CITATIONS
2374	Quantifying predictive capability of electronic health records for the most harmful breast cancer. , 2018, 10577, .		5
2375	CANCER STEM CELLS: Redefining the Paradigm of Cancer Treatment Strategies. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 140-148.	3.4	59
2376	Fortnightly Review: Familial breast cancer. BMJ: British Medical Journal, 1994, 308, 183-187.	2.4	71
2377	Why should primary care physicians know about breast cancer genetics?. Western Journal of Medicine, 2001, 175, 168-173.	0.3	7
2378	Simplified Breast Risk Tool Integrating Questionnaire Risk Factors, Mammographic Density, and Polygenic Risk Score: Development and Validation. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 600-607.	1.1	14
2379	Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue. Cancer Prevention Research, 2021, 14, 1-4.	0.7	3
2380	Frequency or Probability? A Qualitative Study of Risk Communication Formats Used in Health Care. , 0, .		6
2381	Risk Factors and Health Promotion in Families of Patients With Breast Cancer. Clinical Journal of Oncology Nursing, 2002, 6, 83-87.	0.3	4
2382	Addressing the Support Needs of Women at High Risk for Breast Cancer: Evidence-Based Care by Advanced Practice Nurses. Oncology Nursing Forum, 2002, 29, E77-E84.	0.5	32
2383	Selective Estrogen Receptor Modulation. , 2002, , 271-285.		4
2384	BRCA-1, BRCA-2 and Hereditary Breast Cancer. , 2002, , 555-624.		6
2385	A Model of Perceived Risk for Colorectal Cancer Among Japanese Americans. Journal of Cancer Education, 2004, 19, 251-257.	0.6	4
2386	Recruiting Research Participants at Community Education Sites. Journal of Cancer Education, 2005, 20, 235-239.	0.6	13
2387	Risk Models for Breast Cancer and Their Validation. Statistical Science, 2020, 35, 14-30.	1.6	37
2388	Developing Genetic Epidemiological Models to Predict Risk for Nasopharyngeal Carcinoma in High-Risk Population of China. PLoS ONE, 2013, 8, e56128.	1.1	21
2389	Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLoS ONE, 2013, 8, e57475.	1.1	75
2390	Korean Risk Assessment Model for Breast Cancer Risk Prediction. PLoS ONE, 2013, 8, e76736.	1.1	44
2391	A Self-Report Risk Index to Predict Occurrence of Dementia in Three Independent Cohorts of Older Adults: The ANU-ADRI. PLoS ONE, 2014, 9, e86141.	1.1	121

#	ARTICLE	IF	CITATIONS
2392	Alternative Performance Measures for Prediction Models. PLoS ONE, 2014, 9, e91249.	1.1	36
2393	Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients. PLoS ONE, 2016, 11, e0160966.	1.1	7
2394	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS ONE, 2017, 12, e0168601.	1.1	16
2395	Potential Mechanisms behind Physical Exercise vs. Epigenetic Regulation for Preventing Breast Cancer. Journal of Cancer Prevention & Current Research, 2017, 8, .	0.1	1
2396	Polymorphism in CYP17, GSTM1 and the progesterone receptor genes and its relationship with mammographic density. Brazilian Journal of Medical and Biological Research, 2009, 42, 323-329.	0.7	15
2398	Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist. Oncologist, 1998, 3, 403-412.	1.9	12
2399	The Incidence Rate of Breast Cancer in Suleimani Governorate in 2006: Preliminary Study. Journal of Zankoy Sulaimani - Part A, 2009, 12, 59-65.	0.1	1
2400	Development and Validation of a Primary Care-Based Family Health History and Decision Support Program (MeTree). North Carolina Medical Journal, 2013, 74, 287-296.	0.1	50
2401	Towards a more precise and individualized assessment of breast cancer risk. Aging, 2019, 11, 1305-1316.	1.4	9
2402	The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population. Oncotarget, 2016, 7, 75457-75467.	0.8	12
2403	Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling. Oncotarget, 2016, 7, 86457-86468.	0.8	21
2404	Quantitative assessment of background parenchymal enhancement in breast magnetic resonance images predicts the risk of breast cancer. Oncotarget, 2017, 8, 10620-10627.	0.8	28
2405	Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget, 2017, 8, 112170-112183.	0.8	30
2406	A way forward for cancer prevention therapy: personalized risk assessment. Oncotarget, 2019, 10, 6898-6912.	0.8	2
2407	Individual- and county-level determinants of high breast cancer incidence rates. Translational Cancer Research, 2019, 8, S323-S333.	0.4	4
2408	The search for cancer risk factors: when can we stop looking?. American Journal of Public Health, 2001, 91, 360-364.	1.5	35
2409	Flu Shots, Mammogram, and the Perception of Probabilities. SSRN Electronic Journal, 0, , .	0.4	6
2410	Using Intensive Longitudinal Data Collected via Mobile Phone to Detect Imminent Lapse in Smokers Undergoing a Scheduled Quit Attempt. Journal of Medical Internet Research, 2016, 18, e275.	2.1	55

#	ARTICLE	IF	CITATIONS
2411	A Personalized Automated Messaging System to Improve Adherence to Prostate Cancer Screening: Research Protocol. JMIR Research Protocols, 2012, 1, e20.	0.5	8
2412	Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. JMIR Research Protocols, 2017, 6, e184.	0.5	30
2413	Bridging the Data Gap in Breast Cancer Risk Assessment to Enable Widespread Clinical Implementation across the Multiethnic Landscape of the US. Journal of Cancer Treatment & Diagnosis, 2018, 2, 1-6.	0.9	5
2414	Gail Model Underestimates Breast Cancer Risk in Thai Population. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2385-2389.	0.5	10
2415	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research, 2016, 4, 1-210.	0.4	75
2416	The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Current Oncology, 2007, 14, 89-96.	0.9	37
2417	Role of Imaging in Breast Cancer Detection. AAOHN Journal, 2010, 58, 131-134.	0.5	1
2418	Discussing breast cancer and hormone replacement therapy with women.. Cleveland Clinic Journal of Medicine, 2002, 69, 838-838.	0.6	4
2419	Trends in breast cancer screening and diagnosis. Cleveland Clinic Journal of Medicine, 2008, 75, S2-S9.	0.6	30
2420	How to spot heritable breast cancer: A primary care physician's guide. Cleveland Clinic Journal of Medicine, 2014, 81, 31-40.	0.6	3
2421	Is there a time limit for systemic menopausal hormone therapy?. Cleveland Clinic Journal of Medicine, 2016, 83, 605-612.	0.6	6
2422	Risk Assessment and Pharmacogenetics in Molecular and Genomic Epidemiology. Journal of Preventive Medicine and Public Health, 2009, 42, 371.	0.7	5
2423	Breast cancer in the young: role of the geneticist. Journal of Thoracic Disease, 2013, 5 Suppl 1, S19-26.	0.6	6
2424	Credible ecological inference for medical decisions with personalized risk assessment. Quantitative Economics, 2018, 9, 541-569.	0.9	18
2425	New Technologies in Personalized Decision Support to Enhance Patient Choice. Advances in Bioinformatics and Biomedical Engineering Book Series, 2012, , 220-235.	0.2	1
2426	Breast Cancer Risk Prediction in Korean Women: Review and Perspectives on Personalized Breast Cancer Screening. Journal of Breast Cancer, 2020, 23, 331.	0.8	5
2427	Estimating Relative Risk of Breast Cancer in Korean Women Using Computer Program. Journal of Korean Breast Cancer Society, 2004, 7, 294.	0.1	2
2428	Lifetime and 5 years risk of breast cancer and attributable risk factor according to Gail model in Iranian women. Journal of Pharmacy and Bioallied Sciences, 2015, 7, 207.	0.2	7

#	ARTICLE	IF	CITATIONS
2429	Assessment of common risk factors and validation of the Gail model for breast cancer: A hospital-based study from Western India. Tzu Chi Medical Journal, 2020, 32, 362.	0.4	1
2430	Association between Health Behaviors and a Family History of Cancer among Korean Women. Cancer Research and Treatment, 2016, 48, 806-814.	1.3	8
2431	Cohort Study of Risk Factors for Breast Cancer in Post Menopausal Women. Epidemiology and Health, 2013, 35, e2013003.	0.8	25
2432	An Evaluation of FaHRAS Computer Programmesâ€™ Utility in Family History Triage of Breast Cancer. Advances in Breast Cancer Research, 2014, 03, 17-21.	0.1	4
2433	Applying the Lorenz curve to disease risk to optimize health benefits under cost constraints. Statistics and Its Interface, 2009, 2, 117-121.	0.2	17
2434	Shift work and cancer â€“ considerations on rationale, mechanisms, and epidemiology. Scandinavian Journal of Work, Environment and Health, 2010, 36, 163-179.	1.7	199
2435	Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: A systematic review. World Journal of Clinical Oncology, 2020, 12, 217-242.	0.9	10
2436	Volumetric Breast Ultrasound as a Screening Modality in Mammographically Dense Breasts. ISRN Radiology, 2013, 2013, 1-7.	1.2	5
2437	Psychological Impact of Health Risk Appraisal of Korean Women at Different Levels of Breast Cancer Risk: Neglected Aspect of the Web-based Cancer Risk Assessment Tool. Asian Pacific Journal of Cancer Prevention, 2012, 13, 437-441.	0.5	3
2438	Compliance with Screening Recommendations According to Breast Cancer Risk Levels in Izmir, Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 1737-1742.	0.5	10
2439	Development and Validation of a Breast Cancer Risk Prediction Model for Thai Women: A Cross-Sectional Study. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6811-6817.	0.5	14
2440	Risk of Malignancy Associated with a Maternal Family History of Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2039-2044.	0.5	8
2441	Breast Cancer Risk Assessment Using the Gail Model: a Turkish Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 303-306.	0.5	20
2442	Depression and the Risk of Breast Cancer: A Meta-Analysis of Cohort Studies. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3233-3239.	0.5	16
2443	Cancer Risk Models: Translating Family History into Clinical Management. Annals of Internal Medicine, 2007, 147, 515.	2.0	5
2444	Characteristics Associated with Participation in ENGAGED 2 â€“ A Web-based Breast Cancer Risk Communication and Decision Support Trial. , 2020, 24, 1-4.		4
2445	Profile of Breast Diseases in Post Pubertal Women Assessed By Clinical Breast Examination â€“ A Community Based Study in Rural Pondicherry. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, PC07-11.	0.8	4
2446	Locoregional and Locally Advanced Breast Cancer. UNIPA Springer Series, 2021, , 429-466.	0.1	0

#	ARTICLE	IF	CITATIONS
2447	Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer. Cancer Biology and Medicine, 2021, , 1-13.	1.4	1
2449	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. British Journal of Cancer, 2021, 125, 1712-1717.	2.9	4
2450	Patient Perceptions of Using Clinical Decision Support for Cancer Screening and Prevention: â€œI wouldnâ€™t have thought about getting screened without it.â€• Journal of Patient-centered Research and Reviews, 2021, 8, 297-306.	0.6	3
2451	Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models. Cancers, 2021, 13, 5194.	1.7	7
2452	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. The Cochrane Library, 2021, 2021, CD013091.	1.5	4
2453	The current status of risk-stratified breast screening. British Journal of Cancer, 2022, 126, 533-550.	2.9	47
2454	Improving the Accuracy of Screening Dense Breasted Women for Breast Cancer By Combining Clinically Based Risk Assessment Models with Ultrasound Imaging. Academic Radiology, 2022, 29, S8-S9.	1.3	1
2455	Tamoxifen and Other Antiestrogens in Prevention and Therapy of Breast Cancer. , 2000, , 79-99.		0
2457	Hematology/Oncology. , 2001, , 177-207.		0
2458	Maligne Tumoren der Mamma. , 2001, , 713-754.		0
2459	SERMs in postmenopausal Womenâ€™s health. , 2002, , 279-295.		1
2461	Menopause Therapy. , 2002, , 299-312.		0
2462	Risk Assessment & Genetic Testing. , 2002, 107, 29-59.		2
2463	SERMs and Breast Cancer Prevention. , 2002, , 267-278.		0
2464	Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer. , 2002, , 303-308.		0
2466	Managing healthy women at risk of breast cancer. Australian Prescriber, 2002, 25, 139-141.	0.5	0
2467	Early Breast Cancer. , 2003, , 331-342.		0
2469	Biostatistics. , 2004, , 29-56.		0

#	ARTICLE	IF	CITATIONS
2471	Risk Assessment in Benign Breast Disease. , 2004, , 138-145.		0
2472	Assessing Genetic Risk of Cancer. , 2004, , 1-30.		0
2473	Aromatase Inhibitors as Chemopreventives of Breast Cancer. , 2004, , 231-243.		0
2476	Prostate Cancer Prevention. , 2005, , 185-203.		1
2477	Breast Cancer after Childhood Cancer. Annals of Internal Medicine, 2005, 142, 472.	2.0	0
2479	Fighting Breast Cancer: A Call for a New Paradigm. , 2005, 9, 73-6.		0
2480	QuimioprevenciÃ³n del cÃ¡ncer de mama. Oncologia, 2006, 29, .	0.0	1
2481	Cancer Chemoprevention. , 2006, , 1318-1340.		1
2482	Breast Diseases. , 2007, , 327-357.		1
2483	The Genetic Epidemiology of Hereditary Breast Cancer. , 2007, , 1-17.		0
2484	Primary Prevention of Breast Cancer, Screening for Early Detection of Breast Cancer, and Diagnostic Evaluation of Clinical and Mammographic Breast Abnormalities. , 2008, , 27-55.		2
2485	A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. , 2008, , 391-398.		0
2486	Breast Disorders. , 2008, , 213-249.		0
2489	Models of Absolute Risk. , 2008, , 259-274.		0
2490	Risk Management of Hereditary Breast Cancer. , 2008, , 93-105.		0
2491	Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Cancer Treatment and Research, 2009, 147, 1-29.	0.2	1
2492	Strategies of Hormonal Prevention. Cancer Treatment and Research, 2009, 147, 1-35.	0.2	0
2493	Flow- Injection Spectrophotometric Determination of some Sulpha Drugs via Oxidative Coupling with 4-Amino-N, N-diethylaniline. Application to Various Samples. Journal of Zankoy Sulaimani - Part A, 2009, 12, 67-76.	0.1	0

#	ARTICLE	IF	CITATIONS
2494	Breast-Cancer Prevention with Antiestrogens. , 2009, , 213-231.		0
2495	Recent Progress in Breast Cancer Research. , 2009, , 385-408.		2
2496	Breast Cancer Stem Cells. , 2009, , 167-192.		0
2497	Identifying and Managing the High-Risk Patient. , 2009, , 101-122.		0
2498	Surgical Management of Inherited Susceptibility to Breast Cancer. , 2010, , 61-78.		0
2499	Chemoprevention of Breast Cancer. , 2010, , 569-583.		0
2500	High Risk Indicators: Microscopic Lesions, Personal and Family History, Assessment, and Management. , 2010, , 39-60.		0
2501	Identification and Management of Women at High Familial Risk for Breast Cancer. , 2010, , 135-145.		0
2502	Breast Disorders and Breast Cancer Screening. , 2010, , 1206-1211.e1.		0
2503	Computer Aided Risk Estimation of Breast Cancer. Advances in Bioinformatics and Biomedical Engineering Book Series, 2010, , 204-214.	0.2	0
2505	Chemoprevention. , 2011, , 209-226.		0
2506	Obtaining and Using Genetic Information. , 2011, , 1-21.		0
2507	Hereditary Breast Cancer Syndromes. , 2011, , 51-104.		0
2509	Brustdrüse. , 2011, , 171-203.		0
2510	5 Breast Imaging. , 2011, , 61-88.		0
2511	Mammogram Interpretation. , 2011, , 24-62.		0
2512	Epidemiology of Breast Cancer. , 2011, , 25-55.		3
2513	Magnetic Resonance Imaging (MRI) in the Screening of High-Risk Patients and in the Detection and Diagnosis of Early Breast Cancer. , 2011, , 45-55.		1

#	Article	IF	Citations
2514	Measures of Health Status, Functioning, and Use of Health Services. , 2012, , 217-267.		0
2515	Development of an Individual Prevention Tool: The Breast Cancer Risk Profile. , 2012, , 219-230.		0
2516	Foods and Nutrients for Secondary Prevention: Risk Classification with Artificial Intelligence. , 2012, , 161-177.		0
2517	Breast Cancer Risk Assessment Using the OncoVueÂ® Model. SIS Journal, 0, , .	0.0	0
2518	Addressing Statistical Requirements and Practical Limitations in Development of Biomarker Panels and Prognostic Models. Internal Medicine: Open Access, 2012, 02, .	0.0	0
2519	How to Optimize Population Screening Programs for Breast Cancer Using Mathematical Models. , 0, , .		0
2520	Integrating Prevention and Screening for Lung Cancer into Clinical Practice. Statistics in the Health Sciences, 2013, , 349-381.	0.2	0
2521	Identifying Women at High Risk of Breast Cancer: Understanding the Risk Models. , 2013, , 1-28.		0
2523	The impact of information given to patientsâ€™ families: Breast cancer risk notification. Analise Psicologica, 2012, 20, 27-34.	0.2	0
2525	Chemoprevention: Cinderella Waiting for the Ball. Milestones in Drug Therapy, 2013, , 115-134.	0.1	1
2526	Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer. , 2013, , 206-227.		1
2527	Individualization of Decision Making Regarding Mammographic Screening for Breast Cancer in Women 40-49 y.o. with First Degree Relative with Breast Cancer. International Journal of User-Driven Healthcare, 2013, 3, 49-63.	0.1	0
2530	Estimating Improvement in Prediction with Matched Case-Control Designs. Lecture Notes in Statistics, 2013, , 143-177.	0.1	0
2531	Evaluation of Quality of Life of Breast Cancer Patient Next-of-kin in Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2771-2776.	0.5	4
2532	High Risk Lesions. , 2014, , 249-267.		0
2534	Breast Cancer Prevention. , 2014, , 445-489.		1
2535	The Bioepidemiology of Multiple Primary Cancers. Medical Radiology, 2014, , 227-239.	0.0	0
2536	Risk Assessment in Benign Breast Lesions. , 2014, , 269-287.		0

#	ARTICLE	IF	CITATIONS
2537	Designing the Chemoprevention Trials of Tomorrow: Applying Lessons Learned from Past Definitive Trials. Methods in Pharmacology and Toxicology, 2014, , 265-284.	0.1	0
2539	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1
2540	Rates, Risks, Measures of Association andÂImpact. , 2014, , 123-185.		0
2541	The genetics of breast cancer, risk-reducing surgery and prevention. , 2014, , 127-145.		0
2542	Breast Cancer Risk Assessment and Level of Knowledge in Women With Low Levels of Education. The Journal of Kartal Training and Research Hospital, 2014, 25, 181-186.	0.0	5
2543	Le dÃ©pistage organisÃ© du cancer du sein. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 369-386.	0.0	0
2544	CORRELATION OF RISK FACTORS WITH HPE GRADING IN BREAST CANCER. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 2687-2692.	0.1	0
2545	Risk of breast cancer in the Nurses' Health Study: applying the Gail model. JAMA - Journal of the American Medical Association, 1993, 270, 2925-2926.	3.8	1
2546	Special Issues Concerning Postmenopausal Hormone Replacement Therapy and Breast Cancer. CPOBGYN Clinical Perspectives in Obstetrics and Gynecology, 1994, , 398-409.	0.1	0
2547	Trial of Tamoxifen Therapy for Protection. , 1995, , 91-101.		0
2550	Hormonal strategies for the prevention of breast cancer. Cancer Treatment and Research, 1998, 94, 135-157.	0.2	0
2551	Computerized Analysis of Digitized Mammograms of Women with Low Breast Cancer Risk and of BRCA1/BRCA2 Gene-Mutation Carriers. Computational Imaging and Vision, 1998, , 419-422.	0.6	1
2552	Genetic Counseling and Genetic Testing for Cancer Risk Assessment. Clinical Obstetrics and Gynecology, 1998, 41, 141-156.	0.6	2
2553	The Lifetime Risk of Developing Prostate Cancer in White and Black Men. Journal of Urology, 1998, , 1578-1579.	0.2	15
2554	Chemoprevention and Heritable Cancer Risk. , 1999, , 135-152.		0
2555	Components of a Genetic Cancer Risk Clinic. , 1999, , 1-26.		0
2556	Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer. , 1999, , 283-311.		1
2557	Modeling Risk of Breast Cancer and Decisions about Genetic Testing. Lecture Notes in Statistics, 1999, , 133-203.	0.1	3

#	ARTICLE	IF	CITATIONS
2558	Estimating Individualized Risk of Breast Cancer. , 1999, , 39-53.		0
2559	Testing for Breast Cancer Risk in the Ashkenazim. , 1999, , 65-80.		0
2561	Breast Cancer Genetics and Risk Assessment. , 2015, , 1-21.		0
2562	Genetically Based Breast Cancer: Risk Assessment, Counseling, and Testing. , 2015, , 137-159.		0
2563	Early Breast Cancers. , 2015, , 61-112.		0
2564	Mapping the Risk of Breast Cancer to Exposure from Traffic- Related Air Pollution Using Land-Use Regression in Vancouver, B.C. ISEE Conference Abstracts, 2014, 2014, 2719.	0.0	0
2565	A Nearest Neighbor Approach to Build a Readable Risk Score for Breast Cancer. Annals of Information Systems, 2015, , 249-269.	0.5	0
2566	Refining and Validating a Two-stage and Web-based Cancer Risk Assessment Tool for Village Doctors in China. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10683-10690.	0.5	0
2567	Breast Chapter. Pediatric Oncology, 2015, , 325-337.	0.5	0
2568	Utilization of the Breast Cancer Risk Assessment Tool in the Identification and Screening of Women at Increased Risk of Breast Cancer. Journal of Women's Health Care, 2015, 04, .	0.2	0
2569	Cancer Chemoprevention. , 2015, , 809-824.e4.		0
2570	Epidemiology, Risk Factors, and Prevention. , 2016, , 57-87.		1
2571	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2016, , 1-25.		0
2572	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
2574	Inhibition of Depurinating Estrogen-DNA Adduct Formation in the Prevention of Breast and Other Cancers. , 2016, , 113-145.		0
2575	Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. , 2016, , 83-101.		0
2576	Public Records. , 2016, , 1-5.		0
2577	Regularized Neural Network to Identify Potential Breast Cancer: A Bayesian Approach. Journal of Modern Applied Statistical Methods, 2016, 15, 563-579.	0.2	0

#	ARTICLE	IF	CITATIONS
2579	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2017, , 613-637.		0
2580	Association between alcohol consumption and breast cancer development: a case-control study. Revista Brasileira De Mastologia, 2017, 27, 220-224.	0.0	0
2581	Breast Cancer Risk Prediction in Women with Atypical Breast Lesions. , 2018, , 103-113.		1
2582	Morphological and Molecular Approaches to Breast Cancer Risk Assessment. , 2018, , 81-91.		0
2583	Sensitivities of the Gail, NSABP and NCI Risk Analysis Models for Turkish Women for Breast Cancer Risk Assessment. Ankara Medical Journal, 0, , .	0.1	0
2585	Breast Imaging. , 2019, , 189-222.		0
2586	Estimating Risk of Breast Cancer Occurrences at Different Ages: Application of Survival Techniques. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3033-3038.	0.5	1
2587	Risk models for breast cancer. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2019, 15, 503-510.	0.2	0
2589	Commentary on Terry et al., 10-Year Performance of Four Models of Breast Cancer Risk: A Validation Study. Lancet Oncol. 2019;20(4):504-17. Med One, 2019, , .	1.5	1
2590	Breast Cancer Risk Assessment Model Based on sl-SDAE. Communications in Computer and Information Science, 2019, , 417-430.	0.4	0
2591	Breast Cancer Prevention. , 2019, , 543-606.		0
2592	Epidemiology, Risk Factors, and Prevention. , 2019, , 39-61.		1
2593	Identifying High-Risk Female Patients. , 2019, , 185-190.		0
2594	Analysis of mammographic density as a predictor for breast cancer occurrence. , 2019, , .		0
2596	Assessment of the Gail Model in Estimating the Risk of Breast Cancer: Effect of Cancer Worry and Risk in Healthy Women. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1765-1771.	0.5	6
2599	The Mastologist and the Patient with Mammary Siliconomas. , 2020, , 173-183.		0
2601	Lifestyle Changes and Prevention: Unique Issues for Young Women. , 2020, , 177-195.		0
2602	Taking Care of Yourself and Your Risk for Breast Cancer (CUIDARSE): A Randomized Controlled Trial of a Health Communication Intervention for Latinas. Health Education and Behavior, 2020, 47, 569-580.	1.3	5

#	Article	IF	Citations
2605	Robust Estimation of Breast Cancer Incidence Risk in Presence of Incomplete or Inaccurate Information. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2307-2313.	0.5	2
2607	Breast cancer risk stratification for mammographic screening: A nation‑wide screening cohort of 24,431 women in Singapore. Cancer Medicine, 2021, 10, 8182-8191.	1.3	6
2608	Can Endocrine Therapy Reduce the Risk of Breast Cancer in South African Women?. Wits Journal of Clinical Medicine, 2020, 2, 39.	0.0	0
2609	Feasibility and acceptability of personalised breast cancer screening (DECIDO study): protocol of a single-arm proof-of-concept trial. BMJ Open, 2020, 10, e044597.	0.8	10
2611	Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. Journal of the National Cancer Institute, 2021, 113, 660-661.	3.0	2
2613	Postmenopausal hormone therapy and its association with breast cancer. Journal of Mid-Life Health, 2020, 11, 187.	0.4	2
2614	Development and validation of composite risk score to assess risks of major noncommunicable diseases in Northern Indian populations: A research protocol. International Journal of Noncommunicable Diseases, 2020, 5, 207.	0.4	0
2615	Calculating, Using and Improving Individual Breast Cancer Risk Estimates. , 2020, , 309-324.		1
2617	Case Histories of Significant Medical Advances: Tamoxifen. SSRN Electronic Journal, 0, , .	0.4	1
2618	Predicting Breast Cancer via Supervised Machine Learning Methods on Class Imbalanced Data. International Journal of Advanced Computer Science and Applications, 2020, 11, .	0.5	10
2619	External validation of a mammographic texture marker for breast cancer risk in a case–control study. Journal of Medical Imaging, 2020, 7, 1.	0.8	3
2622	A Review of Breast Cancer Risk Factors in Adolescents and Young Adults. Cancers, 2021, 13, 5552.	1.7	7
2624	Data Mining and Analysis of Lung Cancer. , 0, , 118-144.		0
2628	Genetic Screening and Counseling for High-Risk Populations. , 2006, , 341-357.		0
2632	SERMs and the Breast. , 0, , 239-270.		0
2633	The Role of SERMs in the Management of Postmenopausal Women. , 0, , 333-349.		0
2634	Breast Cancer Risk in Women with Abnormal Cytology in Nipple Aspirate Fluid. , 2008, , 203-216.		0
2635	Models of Absolute Risk. , 2005, , 137-140.		0

#	ARTICLE	IF	CITATIONS
2636	Ductal Lavage. , 2005, , 239-247.		0
2638	Operative ÃœBerlegungen beim FamiliÃ´ren Mammakarzinom. , 0, , 93-106.		1
2639	Prevention of Breast Cancer. , 2006, , 63-94.		0
2640	Risikoberechnungen in Familien. , 2007, , 279-326.		0
2641	Estimating Individual Cancer Risks in the UK National Breast Screening Programme: A Feasibility Study. Lecture Notes in Computer Science, 2008, , 469-476.	1.0	2
2642	Role of Screening: Guidelines and Recommendations. , 2021, , 15-21.		0
2644	Screening strategy modification based on personalized breast cancer risk stratification and its implementation in the national guidelines â€" pilot study. Zdravstveno Varstvo, 2020, 59, 211-218.	0.6	3
2645	Understanding risk and lessons for clinical risk communication about treatment preferences. Quality and Safety in Health Care, 2001, 10, i9-i13.	2.5	59
2646	Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Cmaj, 2001, 164, 1681-90.	0.9	28
2647	Risks and benefits of hormone replacement therapy: the evidence speaks. Cmaj, 2003, 168, 1001-10.	0.9	19
2648	Assessing and managing breast cancer risk: clinical tools for advising patients. MedGenMed: Medscape General Medicine, 2004, 6, 8.	0.2	2
2649	Management of women at increased risk for breast cancer: preliminary results from a new program. Cmaj, 1997, 157, 1235-42.	0.9	10
2650	Genes and generalists: why we need professionals with added competencies. Western Journal of Medicine, 1999, 171, 375-9.	0.3	8
2651	Computer support for genetic advice in primary care. British Journal of General Practice, 1999, 49, 572-5.	0.7	7
2652	The Canadian National Breast Screening Study: a clinician's perspective. Cmaj, 1992, 147, 1437-9.	0.9	0
2653	Can tamoxifen prevent breast cancer?. Cmaj, 1993, 148, 141-4.	0.9	1
2654	Women's views on chemoprevention of breast cancer: qualitative study. Canadian Family Physician, 2006, 52, 624-5.	0.1	41
2655	Recruitment of African American and white postmenopausal women into clinical trials: the beneficial effects of soy trial experience. Ethnicity and Disease, 2006, 16, 938-42.	1.0	12

#	Article	IF	Citations
2656	Gene-environment interaction and public health. American Journal of Human Genetics, 1995, 56, 821-3.	2.6	22
2657	Setting up a breast cancer family history clinic. Annals of the Royal College of Surgeons of England, 1999, 81, 393-8.	0.3	0
2658	Recruiting diverse patients to a breast cancer risk communication trial--waiting rooms can improve access. Journal of the National Medical Association, 2007, 99, 917-22.	0.6	9
2659	Breast cancer risk assessment in socioeconomically disadvantaged urban communities. Journal of the National Medical Association, 2007, 99, 752-6.	0.6	1
2660	BRCA phenocopies or ascertainment bias?. Journal of Medical Genetics, 2007, 44, e86; author reply e88.	1.5	8
2661	Cancer risk assessment. Journal of the National Medical Association, 1997, 89, 21-6.	0.6	2
2662	Colorectal cancer risk perceptions and screening intentions in a minority population. Journal of the National Medical Association, 2000, 92, 492-500.	0.6	48
2663	ChMP: A collaborative medical history portal. AMIA ... Annual Symposium proceedings, 2008, , 859-63.	0.2	2
2664	Identification and extraction of family history information from clinical reports. AMIA ... Annual Symposium proceedings, 2008, , 247-51.	0.2	25
2667	Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 332-49.	0.4	13
2668	Knowledge, attitudes, and practices surrounding breast cancer and screening in female teachers of buraidah, saudi arabia. International Journal of Health Sciences, 2007, 1, 61-71.	0.4	47
2669	Can breast cancer be prevented?. Ochsner Journal, 2000, 2, 10-3.	0.5	0
2670	Recent advances in the systemic therapy of breast cancer. Ochsner Journal, 2000, 2, 24-32.	0.5	1
2671	Smooth isotonic regression: a new method to calibrate predictive models. AMIA Summits on Translational Science Proceedings, 2011, 2011, 16-20.	0.4	8
2672	Modeling the risk of esophageal squamous cell carcinoma and squamous dysplasia in a high risk area in Iran. Archives of Iranian Medicine, 2012, 15, 18-21.	0.2	29
2673	Genetic variants improve breast cancer risk prediction on mammograms. AMIA ... Annual Symposium proceedings, 2013, 2013, 876-85.	0.2	11
2675	University of Hawai'i Cancer Center connection: The vital role of cancer registries in the recruitment of an understudied minority population into a breast cancer study: Breast Cancer Risk Model for the Pacific. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2014, 73, 335-40.	0.4	3
2676	The construct of breast cancer risk perception: need for a better risk communication?. Facts, Views & Vision in ObGyn, 2009, 1, 122-9.	0.5	9

#	Article	IF	Citations
2677	Breast cancer screening: Evidence of the effect of adjunct ultrasound screening in women with unilateral mammography-negative dense breasts. Journal of Research in Medical Sciences, 2015, 20, 228-32.	0.4	4
2678	Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2016, 16, 1-30.	3.0	3
2679	Development and validation of a primary care-based family health history and decision support program (MeTree). North Carolina Medical Journal, 2013, 74, 287-96.	0.1	55
2680	A Risk Assessment Comparison of Breast Cancer and Factors Affected to Risk Perception of Women in Turkey: A Cross-sectional Study. Iranian Journal of Public Health, 2017, 46, 308-317.	0.3	10
2681	Using Machine Learning Algorithms to Predict Risk for Development of Calciphylaxis in Patients with Chronic Kidney Disease. AMIA Summits on Translational Science Proceedings, 2018, 2017, 139-146.	0.4	5
2682	Improving breast cancer risk prediction by using demographic risk factors, abnormality features on mammograms and genetic variants. AMIA ... Annual Symposium proceedings, 2018, 2018, 1253-1262.	0.2	0
2683	Evaluating the Impact of Uncertainty on Risk Prediction: Towards More Robust Prediction Models. AMIA ... Annual Symposium proceedings, 2018, 2018, 1461-1470.	0.2	2
2684	Machine Learning Assisted Discovery of Novel Predictive Lab Tests Using Electronic Health Record Data. AMIA Summits on Translational Science Proceedings, 2019, 2019, 572-581.	0.4	2
2685	Developing a community-based breast cancer risk prediction tool for resource-poor settings. Journal of Education and Health Promotion, 2019, 8, 106.	0.3	0
2686	Adherence of Internet-Based Cancer Risk Assessment Tools to Best Practices in Risk Communication: Content Analysis. Journal of Medical Internet Research, 2021, 23, e23318.	2.1	1
2687	Discriminatory Accuracy of the Gail Model for Breast Cancer Risk Assessment among Iranian Women. Iranian Journal of Public Health, 2020, 49, 2205-2213.	0.3	0
2688	Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study. Journal of Medical Internet Research, 2022, 24, e29124.	2.1	0
2689	Determination of Significant Pretreatment Factors that Predict Survival in Indonesian Subjects with Breast Cancer. Open Access Macedonian Journal of Medical Sciences, 2020, 9, 1458-1461.	0.1	0
2690	The evolving role of the Women's Health Specialist in cancer prevention and survivorship. Menopause, 2021, Publish Ahead of Print, 104-113.	0.8	0
2691	Image retrieval—based parenchymal analysis for breast cancer risk assessment. Medical Physics, 2021, , .	1.6	2
2692	Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population. Frontiers in Oncology, 2021, 11, 740227.	1.3	3
2693	Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. Breast Cancer Research and Treatment, 2022, 192, 375-383.	1.1	5
2695	The Value of Tyrer-Cuzick Versus Gail Risk Modeling in Predicting Benefit from Screening MRI in Breast Cancer. The Journal of Breast Health, 2022, 18, 79-84.	0.4	1

#	Article	IF	Citations
2696	Discriminatory Accuracy of the Gail Model for Breast Cancer Risk Assessment among Iranian Women. Iranian Journal of Public Health, 2020, 49, 2205-2213.	0.3	3
2697	Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. Journal of the National Cancer Institute, 2022, 114, 676-685.	3.0	18
2698	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. Journal of the National Cancer Institute, 2022, , .	3.0	15
2699	The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ. Npj Breast Cancer, 2022, 8, 6.	2.3	13
2700	Optimizing risk-based breast cancer screening policies with reinforcement learning. Nature Medicine, 2022, 28, 136-143.	15.2	34
2701	Affect regulation as a moderator of intentions for breast cancer chemoprevention. Journal of Behavioral Medicine, 2022, , 1.	1.1	0
2702	An Advanced Machine Learning Method for Simultaneous Breast Cancer Risk Prediction and Risk Factors' Significance Ranking in Chinese Population. SSRN Electronic Journal, 0, , .	0.4	0
2703	Interval Cancer Detection Using a Neural Network and Breast Density in Women with Negative Screening Mammograms. Radiology, 2022, 303, 269-275.	3.6	26
2704	Hereditary Breast and Ovarian Cancer. Obstetrics and Gynecology Clinics of North America, 2022, 49, 117-147.	0.7	3
2705	A Low-Glucose Eating Pattern Improves Biomarkers of Postmenopausal Breast Cancer Risk: An Exploratory Secondary Analysis of a Randomized Feasibility Trial. Nutrients, 2021, 13, 4508.	1.7	5
2706	Background Parenchymal Enhancement in Contrast-enhanced Spectral Mammography: A Retrospective Analysis and a Pictorial Review of Clinical Cases. In Vivo, 2022, 36, 853-858.	0.6	1
2707	Conceptual design of the dual X-ray absorptiometry health informatics prediction system for osteoporosis care. Health Informatics Journal, 2022, 28, 146045822110664.	1.1	2
2709	The relationship between night shift work and breast cancer incidence: A systematic review and meta-analysis of observational studies. Open Medicine (Poland), 2022, 17, 712-731.	0.6	5
2710	Simple Linear Cancer Risk Prediction Models With Novel Features Outperform Complex Approaches. JCO Clinical Cancer Informatics, 2022, 6, e2100166.	1.0	2
2711	Clinical Decision Support with or without Shared Decision Making to Improve Preventive Cancer Care: A Cluster-Randomized Trial. Medical Decision Making, 2022, 42, 808-821.	1.2	4
2713	Learning accurate personalized survival models for predicting hospital discharge and mortality of COVID-19 patients. Scientific Reports, 2022, 12, 4472.	1.6	3
2714	Prediction of hereditary cancers using neural networks. Annals of Applied Statistics, 2022, 16, .	0.5	0
2715	Field cancerization in breast cancer. Journal of Pathology, 2022, 257, 561-574.	2.1	16

#	ARTICLE	IF	CITATIONS
2716	BREAst screening Tailored for HEr (BREATHE)â€"A study protocol on personalised risk-based breast cancer screening programme. PLoS ONE, 2022, 17, e0265965.	1.1	11
2717	Breast cancer risk evaluation for the primary care physician. Cleveland Clinic Journal of Medicine, 2022, 89, 139-146.	0.6	3
2718	Effect of inpatient breast cancer education and risk assessment on mammography utilization among hospitalized women post discharge. Hospital Practice (1995), 2022, 50, 132-137.	0.5	0
2719	Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. BMJ Open, 2022, 12, e050828.	0.8	4
2720	The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness. Cancer Medicine, 2022, 11, 2896-2905.	1.3	4
2721	Interaction of leisureâ€time physical activity with body mass index on the risk of obesityâ€related cancers: A pooled study. International Journal of Cancer, 2022, , .	2.3	4
2722	A Female Career in Research. Annual Review of Nutrition, 2022, 42, .	4.3	0
2723	The effect of the use of the Gail model on breast cancer diagnosis in BIRADs 4a cases. Turkish Journal of Surgery, 2021, 37, 394-399.	0.1	0
2724	Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes. Cancers, 2022, 14, 45.	1.7	11
2725	Mammography screening and mortality by risk status in the California teachers study. BMC Cancer, 2021, 21, 1341.	1.1	4
2726	Assessment of breast cancer risk among Iraqi women in 2019. BMC Women's Health, 2021, 21, 412.	0.8	6
2727	Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genetics in Medicine, 2022, 24, 1485-1494.	1.1	23
2732	Computer Aided Risk Estimation of Breast Cancer. , 0, , 314-324.		0
2733	Genetic Counseling for Hereditary Tumors. , 0, , 467-485.		0
2735	Diet-Driven Inflammation and Insulinemia and Risk of Interval Breast Cancer. Nutrition and Cancer, 2022, , 1-15.	0.9	1
2736	Accuracy of cancer-risk assessment in primary care practice. Journal of Cancer Education, 2001, 16, 193-8.	0.6	8
2737	A concept model for individual surveillance in genetic cancer care. Journal of Cancer Education, 2002, 17, 78-82.	0.6	0
2738	Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Medicine, 2022, 20, 150.	2.3	9

#	ARTICLE	IF	CITATIONS
2739	Breast carcinogenesis: can the examination of ductal fluid enhance our understanding?. Oncology Nursing Forum, 2005, 32, 33-9.	0.5	1
2740	Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clinica Belgica, 2011, 66, 283-92.	0.5	17
2742	Goodness-of-Fit Two-Phase Sampling Designs for Time-to-Event Outcomes. SSRN Electronic Journal, 0, , .	0.4	0
2744	A Bayesian learning model to predict the risk for cannabis use disorder. Drug and Alcohol Dependence, 2022, 236, 109476.	1.6	5
2745	Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer. Npj Breast Cancer, 2022, 8, 59.	2.3	4
2746	Analyzing cohort studies with intervalâ€censored data: A new modelâ€based linear rankâ€type test. Statistics in Medicine, 2022, , .	0.8	0
2747	CBCRisk-Black: a personalized contralateral breast cancer risk prediction model for black women. Breast Cancer Research and Treatment, 2022, 194, 179-186.	1.1	2
2748	Breast-specific gamma imaging. , 0, , 34-36.		0
2749	Mammographic Breast Density, Benign Breast Disease, and Subsequent Breast Cancer Risk in 3.9 Million Korean Women. Radiology, 2022, 304, 534-541.	3.6	10
2750	Statistical methods for Mendelian models with multiple genes and cancers. Genetic Epidemiology, 2022, 46, 395-414.	0.6	3
2751	Gail model and fifth edition of ultrasound BIâ€RADS help predict axillary lymph node metastasis in breast cancerâ€"A multicenter prospective study. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	0
2752	Increased Prevalence of Breast and All-cause Cancer in Female Orthopaedic Surgeons. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 2022, 6, .	0.4	7
2753	Risk assessment and prediction for lung cancer among Hong Kong Chinese men. BMC Cancer, 2022, 22, .	1.1	4
2754	Factors Associated with Screening Mammogram Uptake among Women Attending an Urban University Primary Care Clinic in Malaysia. International Journal of Environmental Research and Public Health, 2022, 19, 6103.	1.2	2
2759	Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction. Plastic and Reconstructive Surgery, 0, Publish Ahead of Print, .	0.7	1
2760	Improving identification of symptomatic cancer at primary care clinics: A predictive modeling analysis in Botswana.. International Journal of Cancer, 0, , .	2.3	0
2761	Optimal breast cancer risk reduction policies tailored to personal risk level. Health Care Management Science, 0, , .	1.5	0
2762	Metabolic Links to Socioeconomic Stresses Uniquely Affecting Ancestry in Normal Breast Tissue at Risk for Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	3

#	Article	IF	Citations
2763	Tools for Contralateral Prophylactic Mastectomy Decision Making. Journal of Clinical Oncology, 2022, 40, 3653-3659.	0.8	5
2764	Incorporating family history of disease improves polygenic risk scores in diverse populations. Cell Genomics, 2022, 2, 100152.	3.0	17
2765	Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations. Breast Cancer Research and Treatment, 2022, 194, 673-682.	1.1	1
2766	Multistate models for the natural history of cancer progression. British Journal of Cancer, 2022, 127, 1279-1288.	2.9	3
2767	What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 723-732.	1.1	71
2768	Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk. Clinical Cancer Research, 2005, 11, 166-172.	3.2	147
2769	Deep learning of longitudinal mammogram examinations for breast cancer risk prediction. Pattern Recognition, 2022, 132, 108919.	5.1	7
2770	Radiomics in photon-counting dedicated breast CT: potential of texture analysis for breast density classification. European Radiology Experimental, 2022, 6, .	1.7	2
2771	The Impact of 51 Risk Factors on Life Expectancy in Canada: Findings from a New Risk Prediction Model Based on Data from the Global Burden of Disease Study. International Journal of Environmental Research and Public Health, 2022, 19, 8958.	1.2	1
2772	Risk prediction models for breast cancer: a systematic review. BMJ Open, 2022, 12, e055398.	0.8	3
2773	Breast Differentiation and Its Implication in Cancer Prevention. Clinical Cancer Research, 2005, 11, 931s-936s.	3.2	128
2774	The False Dawn of Polygenic Risk Scores for Human Disease Prediction. Journal of Personalized Medicine, 2022, 12, 1266.	1.1	6
2775	Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study. BMC Cancer, 2022, 22, .	1.1	2
2776	Broad clinical manifestations of polygenic risk for coronary artery disease in the Women's Health Initiative. Communications Medicine, 2022, 2, .	1.9	1
2777	How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research. British Journal of Cancer, 2022, 127, 1916-1924.	2.9	5
2778	A risk calculator to predict suicide attempts among individuals with<scp>early‐onset</scp>bipolar disorder. Bipolar Disorders, 2022, 24, 749-757.	1.1	5
2779	Feasibility and Acceptability of Personalized Breast Cancer Screening (DECIDO Study): A Single-Arm Proof-of-Concept Trial. International Journal of Environmental Research and Public Health, 2022, 19, 10426.	1.2	5
2780	Breast imaging and deep learning: past, present, and future. Advances in Magnetic Resonance Technology and Applications, 2022, , 589-609.	0.0	0

#	Article	IF	Citations
2781	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
2782	Risk-Based Breast Cancer Prognosis Using Minimal Patient Characteristics. , 2022, , .		0
2783	Bilateral Analysis Boosts the Performance of Mammography-based Deep Learning Models in Breast Cancer Risk Prediction. , 2022, , .		0
2784	Associations of Biomarker-Calibrated Healthy Eating Index-2010 Scores with Chronic Disease Risk and Their Dependency on Energy Intake and Body Mass Index in Postmenopausal Women. Journal of Nutrition, 2022, 152, 2808-2817.	1.3	0
2785	Modified Brier score for evaluating prediction accuracy for binary outcomes. Statistical Methods in Medical Research, 2022, 31, 2287-2296.	0.7	8
2786	Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2022, 34, 983-992.	0.8	1
2787	Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives. Cancers, 2022, 14, 4218.	1.7	25
2788	Prototype to estimate breast cancer suspicion in a hospital of the Mexican public health system. , 2022, , .		0
2789	Individual risk prediction: Comparing random forests with Cox proportionalâ€hazards model by a simulation study. Biometrical Journal, 2023, 65, .	0.6	5
2790	Early Detection of Breast Cancer Using CNN. Advances in Intelligent Systems and Computing, 2023, , 577-587.	0.5	0
2791	Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for Taiwan. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 2208-2218.	1.1	1
2792	The Landmark Seriesâ€"Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women. Annals of Surgical Oncology, 2023, 30, 58-67.	0.7	10
2793	Brain MRI and clinical exam findings in women with multiple gadolinium-based contrast agent (GBCA) exposures due to screening breast MRIs. Clinical Imaging, 2022, 92, 57-62.	0.8	0
2794	Impact and Assessment of Breast Density. Medical Radiology, 2022, , 419-434.	0.0	0
2795	External Validation of a Mammography-Derived AI-Based Risk Model in a U.S. Breast Cancer Screening Cohort of White and Black Women. Cancers, 2022, 14, 4803.	1.7	3
2799	Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 98-104.	1.1	2
2803	Genetics of Breast Cancer. Surgical Clinics of North America, 2022, , .	0.5	5
2804	Interaction between blood pressure and genetic risk score for bladder cancer, and risk of urothelial carcinoma in men. Scientific Reports, 2022, 12, .	1.6	4

#	Article	IF	Citations
2806	Contralateral Prophylactic Mastectomy in Average Risk Women: Who Can Choose This Wisely?. Annals of Surgical Oncology, 0, , .	0.7	0
2807	Breast diseases. , 2023, , 311-344.e7.		0
2809	AutoScore-Ordinal: an interpretable machine learning framework for generating scoring models for ordinal outcomes. BMC Medical Research Methodology, 2022, 22, .	1.4	2
2810	Challenges and Changes of the Breast Cancer Screening Paradigm. Journal of Magnetic Resonance Imaging, 2023, 57, 706-726.	1.9	2
2812	Conceptualizing eating disorder recovery research: Current perspectives and future research directions. Journal of Eating Disorders, 2022, 10, .	1.3	2
2813	Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?. Cancer Communications, 2023, 43, 75-86.	3.7	26
2814	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. Journal of Cancer Research and Clinical Oncology, 2023, 149, 721-735.	1.2	5
2815	The Need for Information and Support among First-degree Relatives of Patients with Breast Cancer What Do We Know?. BezmiÃ¢lem Science, 2022, 10, 683-690.	0.1	0
2816	Personalized breast cancer onset prediction from lifestyle and health history information. PLoS ONE, 2022, 17, e0279174.	1.1	1
2817	Prediction of breast cancer risk among women of the Mariana Islands: the BRISK retrospective caseâ€"control study. BMJ Open, 2022, 12, e061205.	0.8	0
2818	Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort. Breast Cancer Research, 2022, 24, .	2.2	3
2819	The co-development of personalised 10-year breast cancer risk communications: a â€˜think-aloudâ€™ study. BMC Cancer, 2022, 22, .	1.1	6
2820	Obesity and metabolic dysfunction correlate with background parenchymal enhancement in premenopausal women. Obesity, 2023, 31, 479-486.	1.5	2
2821	Validation of a genetic-enhanced risk prediction model for colorectal cancer in a large community-based cohort. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0
2822	Effect of an Educational Intervention on Womenâ€™s Health Care Provider Knowledge Gaps About Breast Cancer Risk Model Use and High-risk Screening Recommendations. Journal of Breast Imaging, 2023, 5, 30-39.	0.5	5
2823	Estimation of Breast Density from Human Mammograms using U-Nets. , 2022, , .		2
2825	A Machine Learning based Approach for Breast Cancer Prediction. , 2022, , .		0
2826	A model for predicting both breast cancer risk and non-breast cancer death among womenâ€‰>â€‰55Âyears old. Breast Cancer Research, 2023, 25, .	2.2	1

#	Article	IF	Citations
2827	Epidemiologisches Wissen, persönliche Erfahrungen und Entscheidungsfindung â€" Ãœberlegungen zum Konzept der Ã„rzte-Patienten-Beziehung. , 2023, , 125-138.		0
2828	Proactive breast cancer risk assessment in primary care: a review based on the principles of screening. British Journal of Cancer, 2023, 128, 1636-1646.	2.9	7
2829	Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. , 2022, , 2617-2635.		0
2830	Optimising the delivery of breast cancer risk assessment for women aged 30â€"39â€°years: A qualitative study of womenâ€™s views. Women's Health, 2023, 19, 174550572311603.	0.7	2
2831	Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast Cancer Research and Treatment, 2023, 198, 335-347.	1.1	4
2832	Combining Breast Cancer Risk Prediction Models. Cancers, 2023, 15, 1090.	1.7	2
2833	The Genetic and Immunologic Landscape Underlying the Risk of Malignant Progression in Laryngeal Dysplasia. Cancers, 2023, 15, 1117.	1.7	0
2834	Hereditary Cancer Syndromes. , 2023, , .		0
2835	Breast Cancer Risk Assessment Models and Multi-Cancer Early Detection Tests. , 2023, , 29-43.		0
2836	Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population. Cancer Prevention Research, 2023, 16, 281-291.	0.7	1
2837	An Improved Training Algorithm Based on Ensemble Penalized Cox Regression for Predicting Absolute Cancer Risk. China CDC Weekly, 2023, 5, 206-212.	1.0	0
2838	Genetic Risk Scores and Missing Heritability in Ovarian Cancer. Genes, 2023, 14, 762.	1.0	1
2839	Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Medical Weekly, 2023, 153, 40055.	0.8	0
2840	Genetic Factors in the Screening and Imaging for Breast Cancer. Korean Journal of Radiology, 0, 24, .	1.5	2
2842	Implementing the National Dense Breast Reporting Standard, Expanding Supplemental Screening Using Current Guidelines, and the Proposed Find It Early Act. Journal of Breast Imaging, 2023, 5, 712-723.	0.5	8
2843	Editorial: Sex steroid hormones: effects on breast cancer risk and etiology. Frontiers in Endocrinology, 0, 14, .	1.5	0
2875	Quizzing the Quizzes: Improving Cancer Risk Factor Analysis Quizzes. , 2023, , .		0
2896	Hereditary Breast Cancer. Risk- Assessment, Screening and Risk- Reduction Strategies. , 2023, , 79-110.		1

#	Article	IF	Citations
2904	An Ontology forÂBreast Cancer Screening. Lecture Notes in Computer Science, 2023, , 5-14.	1.0	1
2909	Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection. Cancer Treatment and Research, 2023, , 63-88.	0.2	0
2916	A Comprehensive Review on Artificial Intelligence-Driven Radiomics for Early Cancer Detection and Intelligent Medical Supply Chain. Advances in Logistics, Operations, and Management Science Book Series, 2024, , 226-254.	0.3	0